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 N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors that serve 
crucial signaling and neurotrophic functions throughout the central nervous system.  Both 
hyperfunction and hypofunction of NMDARs are associated with neurological and 
neuropsychiatric conditions. Thus, both positive and negative pharmacological NMDAR 
modulators are of clinical interest as treatments.  Understanding drug mechanisms could lead to 
more rational drug design. Memantine and ketamine are NMDAR open channel blockers that 
exhibit similar pharmacodynamics at NMDARs but have different clinical uses. Memantine 
improves cognitive decline during Alzheimer’s disease. Ketamine is an anesthetic and analgesic 
with psychotomimetic effects, but it is also a rapid acting and long-lived antidepressant. How 
these mechanistically similar blockers mediate different effects on behavior is unclear, but we 
hypothesized that unappreciated differences in their pharmacodynamics may contribute.  This 
thesis investigated effects of memantine and ketamine during pathological (excitotoxic) and 
physiological activity in vitro, where pharmacokinetic effects could largely be ignored. We 
focused on non-steady state conditions that mimic synaptic transmission. I found that synaptic 
NMDAR activation is responsible for hypoxic excitotoxic cell death and revealed that 
memantine, a putative selective extrasynaptic receptor blocker, acquires its selectivity as a result 
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of tonic agonist presentation rather than from affinity for specific populations. Further 
investigation into the similar synaptic pharmacodynamics of memantine and ketamine revealed a 
subtle difference in their response to voltage perturbations that was unmasked during 
physiological activity by increasing the open probability of the channel or by very strong 
activity. This suggests that regional differences in activity or channel open probability in vivo 
may control the efficacy of these blockers and partially explain their clinical differences. To 
further explore properties of ketamine relevant to its antidepressant action, I examined how its 
pharmacodynamics compares to its major metabolite, norketamine, and to chemical biology 
analogues of ketamine that show promise in tracking alternative targets for ketamine.  In all, 
these studies reveal mechanistic insights into the pharmacodynamics of two NMDAR channel 
blockers that may partly explain their clinical effects.  
 
  
 
 
 
 
 
 
 
 
 
 
1 
 
Chapter 1 
“Introduction” 
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Synaptic Transmission 
 Neural function and cognition relies on rapid, efficient, and malleable communication 
between neurons throughout the brain. This process is mediated by chemicals called 
“neurotransmitters” released at the synapse, a small space between neuronal axon terminals and 
dendritic spines or shafts. In the presynaptic terminal, neurotransmitters are packaged into 
vesicles that fuse to the membrane and release their contents into the synaptic cleft in response to 
an action potential propagating down the axon.  These neurotransmitters then bind to either 
metabotropic or ionotropic receptors on the postsynaptic membrane. Ionotropic receptors 
respond to ligand binding by gating ion channels, which directly leads to depolarization or 
hyperpolarization of the postsynaptic cell. Metabotropic receptors trigger internal signal 
transduction pathways that also lead to an increase or decrease in cellular activity. There are 
three primary ionotropic receptors that respond to the excitatory neurotransmitter, glutamate, and 
they are named for their specific agonists: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptors (AMPARs), kainate acid receptors (KARs), and N-methyl-D-aspartate receptors 
(NMDARs). My thesis is centered on NMDARs which are necessary for critical high level 
cognitive functions including learning and memory. The level of their activity must be tightly 
regulated since both hyperfunction and hypofunction can lead to excitotoxicity, a form of 
neuronal death which may contribute in pathological states like stroke, Alzheimer’s disease, 
Parkinson’s disease and many others.  
 Since NMDAR hyperfunction and hypofunction underlie many neurological and 
neuropsychiatric disorders, relevant treatments often involve modulation of NMDAR activity. 
Understanding the actions of both positive and negative modulators is critical for rational drug 
design. Memantine and ketamine are two pharmacologically similar NMDAR open channel 
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blockers. Memantine is primarily used to treat cognitive decline during Alzheimer’s disease, 
while ketamine is a known anesthetic with psychotomimetic properties that has recently emerged 
as a rapid acting and long-lived antidepressant. How these mechanistically similar blockers have 
such different behavioral profiles is unclear but we hypothesized that unappreciated 
pharmacodynamic differences may contribute.  
 This dissertation investigates NMDAR modulation by memantine and ketamine during 
physiological and pathophysiological events in vitro. The first section (Chapter 2) focuses on 
neuroprotection by memantine during excitotoxicity in cell culture. I reveal that synaptic 
NMDARs play a primary role in hypoxic excitotoxic cell death and show that memantine 
“selectivity” for receptor populations is accounted for by different agonist presentations common 
at different receptor populations. The second section (Chapter 3-4) turns to pharmacodynamic 
properties of memantine and ketamine, particularly during non-steady state conditions. Data in 
this section reveals the importance of the NMDAR channel open probability and network 
activity in differentiating the drugs during physiological activity. The third section (Chapter 5) 
focuses on ketamine’s role as an antidepressant. Since its antidepressant qualities persist long 
after its metabolism and clearance in vivo, it is likely that it elicits long-term synaptic changes. 
To investigate how ketamine metabolism may contribute to its antidepressant effects, I compared 
its pharmacodynamics to norketamine, the primary metabolite of ketamine in vivo. In addition, I 
characterized novel chemical biology tools that may be useful to track alternative intracellular 
targets for ketamine.  
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NMDA Receptors-Structure and Expression  
NMDARs are obligatory heterotetramers formed by a combination of four splicing 
variants of GluN1, four separate GluN2 subunits (NR2A-D), and in some cases two GluN3 
variants (A-B) (Monyer et al., 1992b; Monyer et al., 1994). Most NMDARs are comprised of 
two obligatory GluN1 subunits coupled with a homomeric or heteromeric pair of modulatory 
GluN2 subunits. These constitute glutamate and glycine/D-serine sensitive receptors. Some 
receptors are formed with GluN3 subunits, in lieu of GluN2, resulting in strictly glycine sensitive 
excitatory receptors, important in prenatal development (Pachernegg et al., 2012). GluN2 
subunits, which contain the glutamate binding site, all have different glutamate affinity, single 
channel conductance, open probability and desensitization profiles (Stern et al., 1992; Krupp et 
al., 1998; Rossi et al., 2002; Erreger et al., 2007; Traynelis et al., 2010). My experiments were 
conducted in dissociated hippocampal neurons, which contain only GluN1/GluN2A and 
GluN1/GluN2B receptors (Monyer et al., 1994).  
Figure 1.1 depicts a representative GluN2A containing NMDAR.  GluN2A and 2B 
containing receptors have three unique characteristics that combine to dictate their 
biological/neurological role and contribute to their toxicity. First, they require two different 
agonists to activate: glutamate and glycine/D-serine, which have binding sites on GluN2 subunits 
and GluN1 subunits respectively (Figure 1.1A).  Until recently, the glycine/D-serine site was 
presumed to be saturated with glycine in vivo, but recent evidence suggests that D-serine may 
supersede it at least at the synapse (Papouin et al., 2012). Second, they experience prominent, 
voltage dependent, Mg
2+ 
block (Kuner and Schoepfer, 1996). Due to these traits, they are often 
called “coincidence detectors” because they require simultaneous agonist binding and membrane 
depolarization to relieve magnesium block in order to conduct. Magnesium ions and many 
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channel blockers, including memantine and ketamine, all bind relatively near the “selectivity 
filter” or Q/R/N residue of the NMDAR (Ferrer-Montiel et al., 1995; Kuner and Schoepfer, 
1996; Chen and Lipton, 2005; Limapichat et al., 2013). The Q/R/N residue is found in all 
glutamate receptors, and it dictates the ion conductance of the channel (Figure 1.1B). NMDARs 
contain an asparagine residue (N) at this location, which makes them more permeable to calcium 
than most AMPARs or KARs (Huettner, 2014). In addition, receptors containing GluN2A/B 
subunits are most permeable to calcium, relative to the other NMDAR subtypes (Burnashev et 
al., 1992). This allows NMDARs, particularly those containing GluN2A or GluN2B subunits, to 
regulate internal processes necessary for synaptic plasticity and cell survival. Conversely, 
abnormal activation of some or all of these receptors can trigger cell death pathways.  
 Another unique property of NMDARs that will become important to conclusions drawn 
in later chapters is their low open probability (Po). Most ionotropic receptors operate with a Po 
around 1 when all available sites are bound by agonist, particularly glycine and AMPA receptors 
(Silver et al., 1996; Chen et al., 1999). In contrast, NMDAR open probability in the whole cell 
configuration is around 0.04 and does not vary significantly between synaptic or extrasynaptic 
receptor populations, leading to a only a fraction of receptors opening during synaptic events 
(Rosenmund et al., 1995). This low efficacy, in the presence of saturating agonist, gives them 
dynamic range for modulation by positive and negative effectors. Channel blockers, like 
memantine and ketamine, require the receptor to open in order to access their binding site 
(MacDonald et al., 1991; Chen and Lipton, 1997). For these modulators, receptor open 
probability becomes a critical variable to determine blocker effects in vitro and in vivo. This will 
be explored in Chapters 3 and 4. 
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Excitotoxicity 
 Excitotoxicity is neuronal death triggered by the neurotransmitter glutamate, or its 
excitatory analogues acting on excitatory receptors, usually ionotropic glutamate receptors.  It 
was first observed in the retina (Lucas and Newhouse, 1957) but has since been characterized 
throughout the brain (Olney, 1969; Olney and Sharpe, 1969). It was named “excitotoxicity” by 
John Olney when he realized it was a common property across all neurons (Rothman and Olney, 
1987).  NMDAR hyperfunction leads to classical excitotoxic cell death, but hypofunction of 
NMDARs on inhibitory neurons can also trigger rampant network excitability and excitotoxicity 
in intact circuits (Olney and Ishimaru, 1999). In addition, hypofunction of NMDARs can lead to 
Figure 1.1 Schematic of NMDA Receptor: A. Diagram indicating the necessary two GluN1 
subunits alternating with the two GluN2 residues (GluN2A in diagram). The relative locations of 
three domains: amino terminal domain (ATD), ligand binding domain (LBD), and the C-terminus 
are indicated. The glutamate and glycine/D-serine binding sites are located in the LBD of GluN2 
and GluN1 subunits respectively. Note: drawing is not to scale. Some rearrangement of the 
subunits between ATD and LBD is expected (Lee et al., 2014). B. Transmembrane domain (TMD) 
diagrammed in more detail. Each subunit has four sections that comprise the TMD (M1-4). Shown 
here are the two sections that directly line the channel pore: M3 and M2, which briefly reenters the 
channel and contains the Q/R/N residue (N in NMDARs), necessary for ion selectivity (Huettner, 
2014; Lee et al., 2014). Permeant ions (at resting membrane potential without Mg
2+
 channel block) 
are indicated with arrows. Mg
2+
 channel block at resting membrane potentials is illustrated. Many 
channel blockers also bind near the selectivity filter. 
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cell autonomous apoptotic cell death, particularly during development (Olney, 2003). This thesis 
will focus on classical excitotoxicity mediated by NMDAR hyperfunction, although 
hypofunction may contribute to some neurodegenerative diseases (Newcomer et al., 2000). 
Excitotoxicity is distinguished from other forms of cell death such as apoptosis or 
necrosis because it depends on excitatory transmitters and activation of excitatory ionotropic or 
metabotropic receptors. It is morphologically characterized by intracellular vacuolization that 
can occur before or after organelle swelling and chromatin clumping and fragmentation (Olney 
and Ishimaru, 1999; Olney, 2003). Excitotoxicity has two stages: the acute stage dependent 
largely on cation influx and cellular swelling, and delayed Ca
2+
 dependent death.  The delayed 
stage is characterized by release of lactate dehydrogenase (LDH), a metabolic marker for cell 
death (Olney and Ishimaru, 1999). Late stage cell death compromises cell membranes, leading to 
nuclear/chromatin staining by normally impermeable markers such as Trypan Blue or propidium 
iodide (PI). In later chapters, these tools are used to assess cell death following excitotoxic 
insults.  
Since abnormal activation of excitatory receptors underlies excitotoxicity (Sattler and 
Tymianski, 2001) characterizing these receptors and generating targeted therapeutics to dampen 
their activity has largely defined research into excitotoxicity. The primary ionotropic receptors 
responsible for excitotoxicity, particularly during the delayed stage, are NMDA receptors, due to 
their high affinity for glutamate and permissiveness to calcium influx (Rothman and Olney, 
1987). However, as described earlier, NMDA receptors are vital for normal neuronal function 
(Olney et al., 1989; Ikonomidou et al., 1999). What defines a “neuroprotective” NMDA receptor 
from a “toxic” one? This question has been addressed by two primary hypotheses. 
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 The first hypothesis, championed by early generations of investigators, suggests that all 
NMDA receptors have the capacity for death. It is the overall level of activation that determines 
cell fate. In this scheme, NMDA receptor activity exists on a bell curve: hyper-activation and 
hypofunction lead to cell death (Figure 1.2A) (Rothman and Olney, 1987; Olney et al., 1989; 
Choi and Rothman, 1990).  This simple scheme ignores the complexity involved in the NMDAR 
system, including receptor trafficking and location, and receptor subtype and identity. Later 
hypotheses posited instead that certain populations of NMDARs were uniquely poised to mediate 
cell death. Specifically, one hypothesis, termed the “location” hypothesis or “toxic extrasynaptic 
receptor” hypothesis suggests that surface location (synaptic or extrasynaptic) dictates the 
neurotoxic potential of NMDA receptors (Figure 1.2B). In the most extreme version of this 
hypothesis, synaptic NMDA receptors are entirely neuroprotective and extrasynaptic receptors 
are entirely neurotoxic, regardless of their level of activity (Hardingham et al., 2002; 
Hardingham and Bading, 2003; Papadia et al., 2005; Papadia et al., 2008; Hardingham and 
Bading, 2010).  
      
Figure 1.2 Competing hypotheses defining NMDAR contribution to excitotoxicity. A. 
Classical excitotoxicity assumes all NMDARs are capable of causing excitotoxicity when 
activated in excess. Hyperfunction and hypofunction can both lead to cell death (Olney., 
2003). B. Location hypothesis suggests instead that extrasynaptic receptor over activation is 
entirely responsible for cell death (red line). Synaptic receptor activation (blue line), even at 
high levels, is always protective (Hardingham and Bading, 2010).  
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 Giles Hardingham and colleagues first proposed the “location” hypothesis in 2002 
(Hardingham et al., 2002). They showed that synaptic NMDAR activation, even at excessive 
levels, up-regulates pro-survival transcriptional factors, particularly cAMP response element 
binding protein (CREB). Conversely, extrasynaptic receptors, isolated by selective synaptic 
receptor block with the use-dependent antagonist dizocilpine (MK-801), down regulate CREB. 
Excessive synaptic stimulation, conducted through trains of action potentials, resulted in little 
neuronal death, measured by mitochondrial membrane potential and LDH production. Selective 
extrasynaptic activity caused robust neuronal damage by these measures. The authors concluded 
that synaptic receptors, even if excessively stimulated, are entirely neuroprotective; extrasynaptic 
receptors are entirely responsible for cell death in excitotoxic conditions. Additional studies 
showed that this toxic/nontoxic dichotomy was developmentally regulated and strengthened the 
link between synaptic receptors and neuroprotection (Hardingham and Bading, 2002; Papadia et 
al., 2008). The “toxic extrasynaptic hypothesis” was rapidly accepted in the literature and applied 
to neurodegenerative diseases such as Alzheimer’s disease and Huntington’s disease (Okamoto 
et al., 2009; Bordji et al., 2010).  
 The “toxic extrasynaptic NMDA receptor” hypothesis received a further boost when 
another study showed that memantine, a clinically used open channel blocker of the NMDAR, 
may be selective for extrasynaptic receptors (Xia et al., 2010). The authors found that low 
concentrations of memantine (1 μM) strongly blocked extrasynaptic receptors during tonic 
application of glutamate, but had minimal effects on synaptic EPSCs in hippocampal autapses 
(self-synapses formed by solitary neurons). This work was seen as conclusive evidence that 
memantine was “selective” for extrasynaptic NMDA receptors. Subsequently, memantine was 
used as a “selective extrasynaptic receptor antagonist” to delineate differences between synaptic 
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and extrasynaptic receptor signaling in a variety of pathological conditions, including Huntington 
disease and Alzheimer’s disease, in vivo (Lipton, 2005; Okamoto et al., 2009; Bordji et al., 
2010).  The “extrasynaptic receptor hypothesis” was therefore supported by two legs: a 
dichotomy between synaptic and extrasynaptic activation and signaling, and a clinically useful 
selective extrasynaptic receptor antagonist.  
The groundwork studies for the location hypothesis concentrated on exogenous 
excitotoxic insults mediated by bulk application of glutamate. These insults may bias 
extrasynaptic activation due to powerful glutamate uptake systems that would shield the synapse 
from the exogenous glutamate (Bergles and Jahr, 1998; Mennerick et al., 1999). Another 
common experimental model to mimic the oxygen deprivation during a stroke or ischemic insult 
in vivo is hypoxia or oxygen-glucose deprivation (OGD), applied to dissociated cell culture.  
Since these insults are metabolic, the source of excitotoxic glutamate release is endogenous and 
may be neuronal or glial in nature through, respectively, elevated synaptic release or reversal of 
the glial glutamate uptake system (Rothman, 1983; Rothman, 1984; Rossi et al., 2000). Whether 
the location hypothesis pertains to endogenous insults is unclear.  
The majority of papers describing the “location hypothesis” relied on the loss of calcium 
imaging during synaptic activity to prove complete synaptic block.  However, calcium imaging 
cannot fully distinguish between calcium influxes from the extracellular medium from calcium 
released from intracellular stores. Further, it may not have the sensitivity to resolve minute fluxes 
in calcium, triggered by a few receptors.  Recent studies have shown that synaptic NMDARs 
comprise nearly 70% of all surface receptors (Tovar and Westbrook, 2002; Harris and Pettit, 
2007). Additional modifiers that were used during synaptic receptor block, like 4-amino-pyridine 
(4-AP), may also have lead to increased quantal content and spillover (Hardingham et al., 2002). 
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These modifications may have limited the specificity of synaptic receptor block. 
Electrophysiological methods which focus on NMDAR activation can provide a much needed 
check on the validity of the synaptic receptor block described by earlier papers (Hardingham et 
al., 2002).  
The use of memantine as a selective extrasynaptic antagonist also has limitations. 
Memantine is a use-dependent blocker and may stand a better chance to block receptors when 
glutamate accumulates and tonically activates receptors compared to transient activation of 
synaptic receptors.  At the same time, memantine block could drastically slow as receptors open 
less frequently in low agonist conditions, which dominate in extrasynaptic regions (Chen et al., 
1992; Chen and Lipton, 1997). In contrast, high synaptic glutamate approaching 1 mM 
(Clements et al., 1992) may actually favor stronger block even during a briefer time frame. Thus, 
it is still unclear whether memantine’s selectivity is due to a genuine higher affinity for 
extrasynaptic over synaptic receptors or whether it is an artifact of the different types of agonist 
presentation typical for the two regions: phasic vs. tonic. If the selectivity is context dependent, 
during excitotoxic conditions where tonic/prolonged glutamate activates synaptic NMDA 
receptors, memantine may in fact act at synaptic NMDARs.   
 The first aim of my thesis addresses the role synaptic NMDA receptors play in 
endogenous excitotoxic insults and explores the specificity of memantine for extrasynaptic 
receptors in the face of phasic vs. tonic agonist presentation. Investigation into this question is 
detailed in chapter 2. I will show that, when excitotoxic glutamate release is endogenous, cell 
death is caused by excessive synaptic, not extrasynaptic, receptor activation. I will further show 
that memantine shows little selectivity for extrasynaptic receptors when agonist presentation is 
held constant at the two populations.  
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Pharmacological Agents: the actions of memantine and ketamine  
Memantine is not the only open channel blocker of the NMDAR with clinical relevance. 
Here, I will describe similarities and differences between memantine and ketamine, a similar 
channel blocker with clinical usefulness, and outline the rationale for the studies pursued in 
chapters 3 and 4 of this thesis.  
                  Due to their critical role in cognitive and behavioral function, it is not surprising that 
NMDA receptors are the target for many therapeutic treatments of psychiatric and neurological 
disorders. Both memantine and ketamine are clinically used open channel blockers of the 
NMDAR. Their structures are depicted in Figure 1.3. Memantine is an antiepileptic (Chojnacka-
Wojcik et al., 1983; Meldrum et al., 1986; Parsons et al., 1995) and neuroprotectant against 
ischemic injury in animal models (Chen et al., 1998). It is moderately effective at treating 
moderate to severe cognitive decline in Alzheimer’s disease (Olivares et al., 2012). It has little to 
no psychotomimetic or addictive qualities and only has limited actions as an antidepressant. 
Ketamine is clinically used as an anesthetic and analgesic, and has been recently discovered to 
have rapid antidepressant actions (Berman et al., 2000; Zarate et al., 2006a; Marland et al., 
2013). Unlike memantine, ketamine produces strong psychotomimetic symptoms soon after 
administration which limits its clinical utility (Krystal et al., 1994).   
                   
Figure 1.3 Structures of memantine and ketamine.  
13 
 
  The differences between memantine and ketamine in vivo are surprising only when 
compared to their striking similarities at the NMDAR. Both are considered “trapped” open 
channel blockers since they require the channel to open to access their binding site, but can 
remain bound to the receptor even after channel closure and agonist removal (MacDonald et al., 
1991; Chen et al., 1992; Blanpied et al., 1997). Figure 1.4 depicts the kinetic scheme of such a 
blocker. Note how the blocker cannot associate/dissociate from the channel unless it is in the 
open configuration. This renders memantine and ketamine dependent on bound agonist to 
unblock the receptor. Several lines of evidence suggest that their primary binding site is within 
the channel. Memantine is occluded by magnesium pre-application and both memantine and 
ketamine have higher IC50 concentrations in the presence of magnesium at NR2A/NR2B 
containing channels (Chen et al., 1992; Kotermanski and Johnson, 2009). Mutational analyses 
reveal that memantine’s binding site is close to the selectivity filter on the M2 transmembrane 
loop (see Figure 1.1). Specifically, the ammonium group interacts with the Q/R/N-site 
asparagine (N1-N616) in the NR1 subunit, with its methyl groups stabilizing binding by 
interacting with alanine residues located nearby on the GluN2 subunit (N2-A645 and N2-A646) 
(Chen and Lipton, 2005; Limapichat et al., 2013). Likewise, the phencyclidine (PCP) binding 
site which overlaps with ketamine binding also resides on the M2 region of the transmembrane 
section on GluN1 (N1-W593) (Ferrer-Montiel et al., 1995). Both drugs are strongly voltage 
dependent and have reduced block at positive potentials (Parsons et al., 1995; Gilling et al., 
2009).  Finally, many channel blockers including ketamine are strongly influenced by the 
direction of ion flow through the channel (Mennerick et al., 1998; Dravid et al., 2007). All of 
these lines of evidence suggest that each blocker at least partly interacts with a binding site inside 
the channel pore.  
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In addition to similar mechanisms of block the drugs also display similar IC50 
concentrations and similar blocking kinetics, although memantine is slightly faster to dissociate 
(Gilling et al., 2009). It is the speed of blocker dissociation (or koff) that underlies Stuart Lipton’s 
main argument for differences between these drugs. Lipton argues that the severity of a drug’s 
neurological effects inversely correlates with its koff. Thus, open channel blockers like MK-801 
which are extremely slow to dissociate cause severe side-effects in vivo (unconsciousness and 
coma). Drugs with a faster but still not ideal koff, like PCP or ketamine, lead to dissociation, 
psychotomimetic hallucinations and other cognitive disturbances. Memantine, Lipton argues, has 
the ideal rate of offset: allowing it to quickly escape from the channel during agonist application 
and minimizing its complications in vivo (Lipton, 2005).  
 Another explanation argues that pharmacokinetic differences between the drugs dictate 
their neurological differences. Ketamine’s half-life is about 2 hours, compared to 60-80 hours for 
memantine (Wieber et al., 1975; Sonkusare et al., 2005; Liu et al., 2008). Ketamine is also 
administered differently, typically intraveneously, not orally. Ketamine’s rapid administration 
and half life could lead to concentration spikes in the CNS and comparatively higher NMDAR 
block. This would suggest that titrating memantine or ketamine administration to match each 
Figure 1.4 Kinetic scheme of a “trapped” channel blocker. Blocker (B) can only 
associate/dissociate from the channel when it is in the open state (A2R* to A2R*B transition) and 
can remain bound as channel closes and agonist dissociates (RB) Legend: A: Agonist. R: Receptor. 
B: Blocker. Open configuration is depicted with an asterisk (A2R* or A2R*B).  
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other should eliminate these differences. However, a study that titrated ketamine administration 
to minimize concentration spikes showed that psychotomimetic properties were unchanged 
(Krystal et al., 1994). To directly address this, a recent study administered memantine and 
ketamine to rodents and assessed exploratory behavior and spatial working memory at different 
time points (15 or 45 minutes) post-injection. They found no effect of delay between 
administration and testing on behavioral outcomes for both memantine and ketamine 
(Kotermanski et al., 2013). 
 While differences in steady-state actions or pharmacokinetics may contribute to some 
aspects of memantine and ketamine behavioral effects, these explanations ignore a fundamental 
property of the nervous system: its dynamic nature. Previous work with memantine and ketamine 
had largely focused on their actions during steady-state agonist presentation or membrane 
voltage. In contrast, neurons in vivo typically do not experience steady agonist presentation. 
Instead, synaptic release of glutamate is rapid and transient. Likewise, membrane voltage and 
depolarization is rarely constant and sustained. Postsynaptic receptor activation and ion influx 
leads to transient voltage perturbations.  How such perturbations affect NMDAR open channel 
blockers has not been investigated. Finally, how will open channel blockers, which depend on 
channel gating to function, interact with a receptor with exceptionally low open probability? Will 
a “trapped” blocker be able to appreciably escape the channel when opening is infrequent and 
transient? 
 The second aim of my thesis investigates the synaptic pharmacodynamics of memantine 
and ketamine, and the important role that receptor open probability plays in differentiating these 
drugs in vitro.  Investigation into this question is detailed in chapter 3. I found that the low basal 
open probability of the NMDAR masks pharmacodynamic differences between memantine and 
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ketamine during network activity in vitro. This led to a subsequent question: can positive 
allosteric modulation alter NMDAR channel block by memantine and ketamine and differentiate 
them during physiological activity?  
Endogenous positive and negative allosteric modulators of the NMDAR  
Open channel blockers, which are sensitive to receptor open probability, do not work in a 
vacuum. They must interact with the NMDAR just as it is acted upon by external agents. This 
means that in addition to being subject to variations in voltage and agonist presentation, 
memantine and ketamine must also interact with endogenous compounds that either increase or 
decrease receptor efficacy in vivo.   The NMDA receptors are sensitive to a number of natural 
and synthetic modulators. Some negative allosteric modulators include: protons, Zn
2+
, 
intracellular Ca
2+
, and some neurosteroids (Clark et al., 1990; Tang et al., 1990; Erreger and 
Traynelis, 2008; Amico-Ruvio et al., 2011). While the receptor experiences positive modulation 
less frequently, two positive modulators are pregnenolone sulfate and 24-S-hydroxycholesterol, 
which was recently described by our group.   
Pregnenolone sulfate (PS) is a neurosteroid that potentiates NMDAR responses with an 
EC50 ~ 40 μM (Wu et al., 1991). It increases channel open probability without affecting the 
potency of either glutamate or glycine (Bowlby, 1993). However, increased desensitization 
during PS application may mask its potentiation and reduce its usefulness over long application 
protocols (Horak et al., 2004). Additionally, PS potently reduces GABA current, and also has 
small inhibitory effects on AMPA and glycine receptors (Bowlby, 1993; Shen et al., 2000). It 
also can potentiate presynaptic release in some neuronal circuits (Zamudio-Bulcock and 
Valenzuela, 2011).  Thus, it is a useful tool to assess how receptor potentiation might have on 
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pharmacodynamic properties of NMDAR open channel blockers, but it is ineffective as a tool to 
assess the same potentiation during network studies, when a variety of affected receptors will 
contribute to pharmacological effects. 
Like PS, 24-S hydroxycholesterol (24S-HC) is a cholesterol metabolite, although unlike 
PS it is the product of a single enzymatic conversion. It is an oxysterol that is most abundant in 
the brain because of its primary role in cholesterol clearance (Lund et al., 2003). It is synthesized 
by cholesterol 24-hydroxylase and crosses the blood-brain barrier to allow for further hepatic 
metabolism and bodily clearance.  Despite the high cholesterol content in myelin, 24S-HC 
production, measured by expression of cholesterol 24-hydroxylase (CYP46A1), is featured 
primarily in the grey matter with peak expression in the retina, hippocampus and cerebellum 
(Lund et al., 1999; Lein et al., 2007). Recent studies have shown that it is a potent and selective 
positive allosteric modulator (PAM) of the NMDAR (Paul et al., 2013; Linsenbardt et al., 2014). 
Our group has identified a number of synthetic analogs with similar allosteric effects to 24S-HC.  
These analogues occlude the actions of 24S-HC but not the effects of PS, suggesting an 
‘oxysterol site’ and a separate ‘PS site’ of allosteric modulation (Paul et al., 2013; Linsenbardt et 
al., 2014). One such analog is SGE-201 which has improved potency and enhanced water 
solubility, increasing its experimental tractability in culture.  
 Earlier studies investigated the relevance of channel open probability (Po) in dictating, 
specifically, the potency of channel blockers like memantine and ketamine. These studies 
manipulated agonist concentration to alter Po, but each arrived at different conclusions in favor 
of (Chen et al., 1992) or against (Gilling et al., 2007) IC50 alteration by changes in open 
probability.  The fundamental problem with this approach is that at very low agonist 
concentrations (low open probability), channel block slows so profoundly it can prevent accurate 
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measurement of equilibrium block (Gilling et al., 2007).  Further, manipulating agonist 
concentration is difficult in networks of active neurons when synaptic release dictates agonist 
presentation. How positive modulation affects the actions of memantine and ketamine in 
networks was unknown.  
 The third aim of this thesis addresses two questions. How positive modulation, by PS or 
SGE-201 affects the pharmacodynamic properties of open channel blockers and whether 
differences between memantine and ketamine in network assays can be “unmasked” by addition 
of a selective NMDAR potentiator. Investigation into these questions is detailed in Chapter 4. I 
found that positive allosteric modulators (PAMs) did not affect steady-state voltage dependence 
or potency of channel blockers, but did accelerate pharmacodynamic properties at the synapse. 
This leads to a differentiation between memantine and ketamine pharmacodynamics in network 
activity and their ability to protect against mild excitotoxic insults.  
Ketamine and its Metabolites: Querying with Chemical Biology 
 While ketamine has traditionally been used as an anesthetic and analgesic, it has recently 
shown rapid antidepressant actions, even among a patient population unresponsive to traditional 
therapies (Zarate et al., 2006a). Unlike anesthesia and analgesia, antidepressant benefits persist 
long after ketamine clears from the system – in many cases up to a few weeks. This suggests that 
ketamine activates downstream signaling pathways, including transcription and translation, to 
induce long term changes in neuronal circuitry.  
 Reduction in glutamate signaling brought about by ketamine block leads to several 
downstream pathways considered critical for synaptogenesis and synaptic plasticity. Transient 
NMDAR blockade triggers downstream activation of mammalian target of rapamycin (mTOR) 
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and activation of eukaryotic elongation factor 2 (eEF2), which promotes expression of synaptic 
proteins like GluA1 (primary AMPA receptor subunit) and postsynaptic density protein-95 
(PSD95). This in turn leads to increased spine formation and synaptogenesis (Li et al., 2010). 
Alternatively, reduction in spontaneous NMDA signaling can lead to rapid BDNF production 
and release, again promoting synaptogenesis (Autry et al., 2011). The consequence of these 
changes is improved neuronal circuitry and synaptic efficiency.  
 Investigations into ketamine’s antidepressant mechanism have heretofore exclusively 
focused on ketamine.  However, ketamine experiences rapid metabolic processing in vivo. 
Shortly after administration, ketamine is rapidly metabolized into the neuroactive compound, 
norketamine (Cohen and Trevor, 1974). Unlike ketamine which rapidly clears from the body (t1/2
 
= 2-3 h), norketamine persists much longer (t1/2 = 11 h) (Wieber et al., 1975). Like ketamine, 
norketamine antagonizes NMDAR responses, but its pharmacology has not been extensively 
investigated (Ebert et al., 1997; Dravid et al., 2007). Although norketamine has anesthetic 
actions in rodents, and can contribute to ketamine induced anesthesia in humans, it does not 
contribute to the psychotomimetic symptoms (Leung and Baillie, 1986; Olofsen et al., 2012).  
After ketamine administration, norketamine’s plasma levels increase and persist long after 
psychotomimetic effects dissipate (Zarate et al., 2012). Bolstering the theory that norketamine 
can contribute to the antidepressant effect, norketamine and ketamine plasma levels correlate to 
prefrontal cortex theta modulations, a predictor of antidepressant efficacy (Horacek et al., 2010). 
Nevertheless, it has not been shown that norketamine alone has antidepressant activity, nor is its 
activity at NMDAR fully characterized.  
 Most investigators assume the behavioral effects of ketamine are mediated by a classical 
locus of activity at surface NMDA receptors. However, a novel hypothesis suggests instead that 
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ketamine may permeate the membrane, bind to nascent NMDARs, and trigger important 
downstream pathways necessary for synaptogenesis (Lester et al., 2012). If ketamine 
accumulates intracellularly, there may be other unknown intracellular targets for ketamine that 
could be exploited for therapies. However, ascertaining these targets is difficult with 
electrophysiological techniques alone.  
 One strategy that could aid in this investigation and has been employed in the context of 
other receptors, namely GABAA receptors, is bioorthogonal click chemistry and photolabeling. 
Copper catalyzed Huisgen cycloaddition allows the covalent linkage of an alkyne containing 
molecule to an azide-conjugated molecule (Lutz and Zarafshani, 2008). Since alkyne and azide 
linkages are not found in vivo, the labeled molecules can be unambiguously identified as the 
exogenous analogue. Since a number of azide-linked fluorophores are available, it is possible 
that attaching an alkyne group to the norketamine/ketamine structure could yield a functional 
molecule that would be useful in tracking intracellular ketamine accumulation.  
 The fourth aim of my thesis addressed two issues. How does norketamine pharmacology 
and pharmacodynamics compare to ketamine? Is the intracellular ketamine hypothesis viable 
and can clear intracellular targets be ascertained? Investigation into these questions is detailed 
in Chapter 5. I found subtle pharmacodynamic differences between ketamine and norketamine 
that are consistent with their different behavioral outcomes. Additionally, I characterized a 
norketamine molecule containing an alkyne chain and found it retains many properties of the 
parent molecules (ketamine and norketamine), was behaviorally relevant and could be used to 
track intracellular accumulation.  
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Summary 
Effective NMDAR modulation is critical for normal neuronal function and is accomplished 
through endogenous and exogenous means. The goal of this thesis is to describe how two 
clinically useful agents, memantine and ketamine, modulate the NMDAR. We found that subtle 
pharmacodynamic differences between these blockers can be revealed through sufficiently high 
receptor activity or receptor potentiation. This observation provides a possible link from 
apparently similar actions in vitro to their behavioral differences. Throughout the thesis, the 
critical role of NMDAR activity in causing excitotoxicity is featured and related to channel 
modulation. The data presented in this thesis strengthens current understanding of NMDAR 
pharmacology and toxicity and may prove useful to generate effective therapeutics.  
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ABSTRACT 
Excessive NMDA receptor activation and excitotoxicity underlies pathology in many 
neuropsychiatric and neurological disorders, including hypoxia/ischemia.  Thus, the development 
of effective therapeutics for these disorders demands a complete understanding of NMDA 
receptor (NMDAR) activation during excitotoxic insults.  The extrasynaptic NMDAR hypothesis 
posits that synaptic NMDARs are neurotrophic/neuroprotective and extrasynaptic NMDARs are 
neurotoxic.  In part, the extrasynaptic hypothesis is built on observed selectivity for extrasynaptic 
receptors of a neuroprotective use-dependent NMDAR channel blocker, memantine.  We found 
that a neuroprotective concentration of memantine shows little selectivity for extrasynaptic 
NMDARs when all receptors are tonically activated by exogenous glutamate.  This led us to test 
the extrasynaptic NMDAR hypothesis using metabolic challenge, where the source of 
excitotoxic glutamate buildup may be largely synaptic.  Three independent approaches suggest 
strongly that synaptic receptors participate prominently in hypoxic excitotoxicity.  First, block of 
glutamate transporters with a non-substrate antagonist exacerbated rather than prevented 
damage, consistent with a primarily synaptic source of glutamate.  Second, selective preblock of 
synaptic NMDARs with a slowly reversible, use-dependent antagonist protected nearly fully 
against prolonged hypoxic insult.  Third, glutamate pyruvate transaminase (GPT), which 
degrades ambient but not synaptic glutamate, did not protect against hypoxia but protected 
against exogenous glutamate damage.  Together, these results suggest that synaptic NMDARs 
can mediate excitotoxicity, particularly when the glutamate source is synaptic and when synaptic 
receptor contributions are rigorously defined.  Moreover, the results suggest that in some 
situations therapeutically targeting extrasynaptic receptors may be inappropriate.  
 
 
32 
 
INTRODUCTION 
Excitotoxicity is an important contributor to many neurodegenerative diseases and 
neuropsychiatric disorders.  Excitotoxicity is initiated in part through excessive NMDA receptor 
(NMDAR) activation (Rothman and Olney, 1987).  However, NMDAR antagonists have 
deleterious side effects due to the critical role NMDARs play in normal synaptic signaling and 
plasticity (Olney et al., 1989; Ikonomidou et al., 1999).  Thus, there is a need for therapeutics to 
balance preservation of normal function with neuroprotection.  One hypothesis, the extrasynaptic 
NMDAR toxicity hypothesis (Hardingham et al., 2002; Lipton, 2007; Hardingham and Bading, 
2010), is attractive in this regard because extrasynaptic receptors could be therapeutically 
targeted without compromising normal synaptic function.  This hypothesis posits that 
extrasynaptic NMDARs selectively trigger cell death pathways while synaptic receptors trigger 
trophic pathways.  However, the breadth of the extrasynaptic hypothesis in models of 
excitotoxicity has not been fully tested. 
 
Accumulating evidence suggests that extrasynaptic NMDARs play a unique role in cell death.  
Extrasynaptic receptors may become activated when excessive levels of glutamate spill out of 
the synapse during prolonged depolarization.  Another source of extrasynaptic glutamate during 
depolarizing insults is the reverse operation of glutamate transporters (Jabaudon et al., 2000; 
Rossi et al., 2000).  These factors could conspire to initiate signaling cascades uniquely activated 
by extrasynaptic receptors and that overwhelm trophic effects of synaptic receptor activation 
(Hardingham et al., 2002; Soriano et al., 2006; Papadia et al., 2008; Dick and Bading, 2010).  
Support for the extrasynaptic receptor hypothesis comes from neuroprotective effects of a drug, 
memantine, which may selectively target extrasynaptic receptors (Leveille et al., 2008; Okamoto 
et al., 2009; Xia et al., 2010).  However, memantine’s selectivity has not been evaluated under 
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conditions of excessive receptor stimulation that may occur during excitotoxic insults.  Other 
studies supporting the extrasynaptic hypothesis have employed exogenous excitotoxic agonists, 
which may be prevented from reaching synaptic receptors by glial glutamate uptake (Sattler et 
al., 2000; Sinor et al., 2000) and therefore provide a somewhat artificial excitotoxic stimulus.  
Whether the extrasynaptic hypothesis applies to insults involving endogenous glutamate, such as 
metabolic challenge, remains uncertain.   
 
Here we specifically characterized memantine’s selectivity for receptor populations during 
excitotoxic paradigms and directly investigated the role synaptic receptors play in hypoxia-
induced excitotoxic insults.  We demonstrate that memantine blocks synaptic receptors when 
activated equivalently to extrasynaptic receptors.  Furthermore, our findings suggest that 
memantine’s protection may result from blocking excessively activated synaptic receptors.  We 
demonstrate that synaptic receptors appear to account for virtually all the MK-801-sensitive cell 
death caused by hypoxia.  Our findings argue for a tempered view of the extrasynaptic receptor 
hypothesis. 
  
34 
 
MATERIALS AND METHODS 
Cell cultures 
Hippocampal cultures were prepared as either mass cultures or microcultures (as indicated in 
Figure legends) from postnatal day 1-3 rat pups anesthetized with isoflurane, under protocols 
consistent with NIH guidelines and approved by the Washington University Animal Studies 
Committee.  Protocols were adapted from earlier descriptions (Huettner and Baughman, 1986; 
Bekkers et al., 1990; Tong and Jahr, 1994; Mennerick et al., 1995).  Hippocampal slices (500 m 
thickness) were digested with 1 mg ml
-1
 papain in oxygenated Leibovitz L-15 medium 
(Invitrogen, Gaithersburg, MD, USA).  Tissue was mechanically triturated in modified Eagle's 
medium (Invitrogen) containing 5% horse serum, 5% fetal calf serum, 17 mM D-glucose, 400 
M glutamine, 50 U ml-1 penicillin and 50 μg ml-1 streptomycin.  Cells were seeded in modified 
Eagle's medium at a density of ~650 cells mm
-2 
as mass cultures (onto 25 mm cover glasses 
coated with 5 mg ml
-1
 collagen or 0.1 mg ml
-1
 poly-D-lysine with 1 mg ml
-1
 laminin) or 100 cells 
mm
-2
 as "microisland" cultures (onto 35 mm plastic culture dishes coated with collagen 
microdroplets on a layer of 0.15% agarose).  Cultures were incubated at 37° C in a humidified 
chamber with 5%CO2/95% air.  Cytosine arabinoside (6.7 μM) was added 3-4 days after plating 
to inhibit glial proliferation.  The following day, half of the culture medium was replaced
 
with 
Neurobasal medium (Invitrogen) plus B27 supplement (Invitrogen).   
 
Hypoxia Exposure 
DIV 14-15 mass cultures were subjected to hypoxia in a commercially available chamber 
(Billups-Rothenberg Company) humidified and saturated with 95% nitrogen and 5% CO2 at 37° 
C for the specified amount of time (2.5 h).  The gas exchange followed the specifications of the 
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chamber manufacturer (flow of 20 L per minute for four minutes to achieve 100% gas 
exchange).  After the insult, we removed cells from the chamber and incubated them under 
standard culture conditions until the cell death assay (24 h later).  Procedures for controls 
included all media changes and incubation times relevant to the insult conditions.  For 
experiments in which exogenous glutamate exposure was used in place of hypoxia, medium was 
exchanged with conditioned Neurobasal medium from sibling cultures, 50 µM glutamate was 
added, and cultures were incubated for 2.5 h at 37° C.  The concentration of glutamate was 
chosen to approximate the death observed during the same period (2.5 h) of hypoxia.  The 
cultures were then returned to their original medium for 24 h until the cell death assay was 
performed.  For experiments in which glutamate pyruvate transaminase (GPT) was used, 
medium was replaced with conditioned medium prepared with GPT (5 U ml
-1
, Roche) and 2 mM 
pyruvate (Sigma).  The neurons were then exposed to hypoxia or 50 µM glutamate.  Following 
2.5 h, cultures were returned to their original medium for 24 h until the cell death assay was 
performed.   
 
Cell Death Assay  
All cell death studies were performed on mass cultures at 14-15 DIV.  Mass cultures at this age 
contained an astrocyte monolayer, upon which neurons sit.  Thus, neurons have strong 
diffusional contact with the extracellular medium, but processes also exhibit some glial 
ensheathment (Mennerick et al., 1996).  Absolute ratios of astrocyte numbers to neuronal 
numbers from 19 fields in 4 platings was 5 ± 1 astrocytes to one neuron, assessed by counts of 
nuclei stained with Hoechst dye.  Although this is a larger astrocyte to neuron ratio than found in 
vivo, diffusional contact in the cultures is higher, thereby limiting transmitter pooling.  
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We used trypan blue dye to identify compromised neurons 24 h after the insult.  Culture medium 
was removed and replaced with 1 ml of 0.4% trypan blue dissolved in phosphate buffered saline.  
Cells were incubated in dye at 37° C for 5 min, washed with phosphate buffered saline, then 
fixed with 4% paraformaldehyde and 0.2% glutaraldehyde at room temperature.  Cells were 
visualized with a 20x objective using both phase-contrast and brightfield microscopy to confirm 
healthy neuronal profiles (phase-contrast) and verify trypan blue uptake (brightfield).  The total 
numbers of dead and intact neurons were counted and expressed as a percentage of trypan blue 
positive dead cells to total cells.  The average of ten microscope fields for each condition was 
treated as a single data point for purposes of statistics.  Although trypan blue in principle may 
miss apoptotic cell death in which membranes remain uncompromised until late in the 
degeneration process, the total number of viable plus non-viable cells did not differ statistically 
between control and hypoxia conditions (p = 0.4, n = 6 experiments).  Therefore, our assay 
accounted for all or nearly all cells compromised by the insult.  We also cannot exclude that 
possibility that some trypan-blue positive cells could recover following insult.  However, this 
possibility was minimized by use of the 24 h latent period between insult and assessment.  In 
most cases by this time point trypan-positive cells no longer had discernable plasma membranes 
under brightfield or phase contrast optics.    
 
Electrophysiology  
Whole-cell recordings were performed at room temperature from neurons cultured for 10-15 
days using a Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA, USA).  For 
recordings, cells were transferred to an extracellular solution containing (in mM): 138 NaCl, 4 
KCl, 2 CaCl2, 10 glucose, 10 HEPES, 0.01 glycine (a saturating concentration for the co-agonist 
37 
 
site on the NMDA receptor), 0.001 2,3-dihydroxy-6-nitro-7-sulfonyl-benzo[f]quinoxaline 
(NBQX) at pH 7.25.  In some experiments, D-2-Amino-5-phosphonovalerate (D-APV, 10-50 
µM) was added to block NMDARs as indicated.  Experiments in which synaptic NMDARs were 
preblocked with 10 µM dizocilpine maleate (MK-801) prior to recording or to hypoxic challenge 
used a bath solution with lowered Ca
2+
 (1 mM), 50 µM bicuculline, no added NBQX, and no 
added Mg
2+
, unless otherwise indicated.  The tip resistance of patch pipettes was 3-6 Mwhen 
filled with an internal solution containing (in mM): 130 potassium gluconate, 2 NaCl, 0.1 EGTA, 
and 10 HEPES at pH 7.25, adjusted with KOH.  In experiments examining current responses to 
exogenous agonists, cesium methanesulfonate was used in place of potassium gluconate to block 
potassium channels.  Holding voltage was typically -70 mV.  Access resistance for synaptic 
recordings (8-10 M) was compensated 80-100%.  For autaptic responses, cells were stimulated 
with 1.5 ms pulses
 
to 0 mV from -70 mV to evoke transmitter release.  In experiments in which 
NMDAR EPSCs were examined, AMPAR EPSCs and GABAergic IPSCs were blocked with 1 
µM NBQX and 25 µM bicuculline respectively.  Drugs were applied with a gravity-driven local 
perfusion system from a common tip.  The estimated solution exchange times were <100 ms (10-
90% rise), estimated from junction current rises at the tip of an open patch pipette.   
 
Multi-Electrode Array Studies 
Experiments were performed as previously described (Mennerick et al., 2010). Briefly, 
multielectrode arrays (MEAs) were coated with poly-D-lysine and laminin per the 
manufacturer’s instructions, and dispersed cultures were grown as described above.  At DIV7 
and DIV10, 1/3 of the media was removed and replaced with fresh Neurobasal supplemented 
with B27 and glutamine. Recordings were made with the MEA-60 recording system 
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(MultiChannel Systems, Reutlingen, Germany) with the headstage in an incubator set at 29°C 
and equilibrated with 5% CO2 in room air with no additional humidity. The lower temperature 
was necessary because the electronics in the headstage generate ~7°C of excess heat. The MEA 
itself rested on a heating plate inside the headstage to maintain the cultures at 37°C. To allow 
extended recordings in the dry incubator, cultures were covered with a semipermeable membrane 
that allows diffusion of oxygen and carbon dioxide but not water (Potter and DeMarse, 2001). 
Data were amplified 1100 times and sampled at 5 kHz. Spikes were detected by threshold 
crossing of high pass filtered data. The threshold was set individually for each contact at five 
standard deviations above the average RMS noise level. Baseline data were recorded in culture 
media. We then recorded activity in culture media containing an additional 50 µM glutamate. 
Finally, we collected another data set in original growth media.  Statistics were performed on 30 
minute treatment periods. 
 
Data analysis 
Electrophysiology data acquisition and analysis were performed primarily using pCLAMP 10 
software (Molecular Devices).  All cell counts and electrophysiological measurements were 
processed with Microsoft Excel and are presented as mean ± S.E.M.  Statistical significance was 
determined using a Student’s two-tailed t test with a Bonferroni correction for multiple 
comparisons where appropriate.  Data plotting, statistical analysis and figure preparation were 
performed with Sigma Plot (Systat; San Jose, CA) and Adobe Photoshop (San Jose, CA, USA).  
Decay time constants were measured using standard exponential fitting functions using the 
variable metric algorithm in pClamp software. 
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Drugs 
All drugs were obtained from Sigma (St. Louis, MO, USA) except for D-APV, NBQX, and 
TBOA which were obtained from Tocris (Ellisville, MO, USA) and GPT from Roche 
(Indianapolis, IN, USA).  GPT was supplied as a suspension in 3.2 M ammonium sulfate and 
was prepared by pelleting out the suspended protein with 32,500 rpm centrifugation, removing 
the supernatant and dissolving in HEPES-buffered saline (138 mM NaCl, 4 mM KCl, 10 mM 
HEPES). This procedure resulted in a small volume of residual suspension medium in final 
working solutions (discussed in Results).  
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RESULTS 
Memantine shows strong synaptic receptor blockade during sustained or repetitive activation 
To begin to assess the potential role of synaptic and extrasynaptic receptors in excitotoxic cell 
death mediated by endogenous glutamate, we first examined effects of the neuroprotective open-
channel blocker memantine.  Cultures were subjected to 2.5 h of hypoxia and allowed to recover 
for 24 h to capture delayed cell loss using a trypan blue stain.  Under these conditions, we 
consistently achieved robust cell death of approximately 50% (Figure 2.1).  We found that 
memantine at concentrations below 10 µM conferred only variable and trend-level protection 
from hypoxic excitotoxicity, but 10 µM memantine clearly protected neurons (Figure 2.1).  This 
is consistent with previous reports suggesting that concentrations ≥ 5 µM memantine are 
neuroprotective (Chen et al., 1998; Volbracht et al., 2006).  We therefore focused additional 
studies on 10 µM memantine. 
 
Memantine is selective for extrasynaptic receptors over synaptic receptors when the presentation 
of glutamate to synaptic receptors is transient, which is the case under physiological conditions 
(Lester et al., 1990; Xia et al., 2010).  However, the basis for memantine’s apparent selectivity 
remains unclear.  Memantine could possess a higher affinity for extrasynaptic versus synaptic 
receptor populations.  Alternatively, as an open-channel blocker, memantine’s selectivity could 
arise as a result of phasic versus sustained patterns of synaptic versus extrasynaptic receptor 
activation (Johnson and Kotermanski, 2006; Xia et al., 2010).  To distinguish these alternatives, 
we developed protocols to equivalently activate synaptic and extrasynaptic receptor populations, 
using sustained agonist presentation.   
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During hypoxia, glutamate may accumulate tonically to activate both synaptic and extrasynaptic 
receptors.  To partly simulate tonic glutamate build up, we used sustained glutamate (1 µM) 
application onto NMDAR populations and evaluated antagonism by 10 µM memantine.  The 
concentration of glutamate was chosen to be less than the EC50 concentration of 2.3 µM (Patneau 
Figure 2.1.  10 µM Memantine protects against hypoxic insults.  A. Brightfield photomicrographs 
of a representative experiment demonstrating the protection from different concentrations of 
memantine during hypoxia.  Neurons were exposed to control (95% O2, 5% CO2, top left panel) or 
hypoxic (95% N2, 5% CO2, top right and bottom panels) conditions for 2.5 h in the presence (bottom 
panels) or absence (top panels) of indicated memantine concentrations.  Cultures were stained for cell 
death with trypan blue 24 h post insult.  Trypan-positive nuclei are apparent (arrows).  Brightness and 
contrast of panels were digitally adjusted individually to approximately match background brightness 
levels.  Scale bar: 20 µm.  B. Average neuronal survival across the four conditions in panel A.  
Asterisks denote p < 0.05 by a two-tailed student t test.  NS denotes not significant.  N = 5 independent 
experiments in mass cultures.  
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and Mayer, 1990).  We used a low concentration of NMDA to probe the availability of receptors 
before and after conditioning with glutamate plus memantine (Figure 2A).  When NMDA was 
re-applied following conditioning, currents exhibited an initially reduced response (red trace 
inset in Figure 2.2A).  This initial suppression (red trace in Figure 2A inset) is attributable to 
memantine bound to (trapped in) closed NMDAR channels (Johnson and Kotermanski, 2006; 
Kotermanski et al., 2009).  When all NMDAR populations were activated with glutamate, 
memantine inhibited currents by approximately 80% compared to the baseline NMDA currents   
(Figure 2.2A, D).  During the sustained NMDA re-application, current re-emerged gradually as 
channels were re-opened and allowed trapped memantine to dissociate.  
 
We next enriched responses for extrasynaptic NMDARs by eliciting action potential-dependent 
EPSCs in the presence of the slowly dissociating open-channel blocker MK-801 (Figure 2.2B, 
left inset).  Memantine antagonism at the enriched extrasynaptic NMDAR pool was again 
assessed by NMDA re-application and showed similar initial memantine inhibition compared to 
the total NMDAR pool (Figure 2.2A, B, D).  To determine whether memantine blocked synaptic 
receptor channels during sustained exogenous glutamate application, we examined evoked 
NMDAR EPSCs on neurons before and after the memantine antagonism protocol (Figure 2.2C).  
Memantine inhibition of EPSCs was strong, although slightly weaker than antagonism exhibited 
at isolated extrasynaptic receptors (Figure 2.2D).  These results are consistent with the idea that 
extrasynaptic receptors are slightly more sensitive to memantine than synaptic receptors 
(Okamoto et al., 2009; Xia et al., 2010).  However, the strong inhibition of synaptic receptors at 
neuroprotective memantine concentrations suggested that synaptic receptors deserve attention as 
possible targets of memantine and as mediators of toxicity.   
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Figure 2 examines effects of memantine on tonically activated NMDAR populations.  It is also 
possible that synaptic receptors are phasically but repeatedly activated during endogenous 
insults.  Although low memantine concentrations (1 µM) have been comprehensively evaluated 
for effects on repetitive activation of synaptic receptors, neuroprotective concentrations of 
memantine (10 µM) have not been fully investigated.  We found that 10 µM memantine applied 
Figure 2.2. (Previous Page) Memantine shows significant trapping block of synaptic NMDARs 
during tonic activation.  A. Trapping protocol performed on all receptors on a synaptically isolated 
microculture hippocampal neuron: Baseline NMDAR current was recorded with exogenous NMDA 
(10 µM), followed by application of a low concentration of glutamate (Glu, 1 µM) and the co-
application of glutamate and memantine (10 µM).  The expected EC50 concentrations of the agonists 
are 2.3 µM for glutamate and 35 µM for NMDA (Patneau and Mayer, 1990).  Note that a saturating 
glycine concentration (10 µM) was used throughout the experiment to diminish NMDAR 
desensitization (Lester et al., 1993; Wilcox et al., 1996).  Agonist and antagonist were washed away 
with saline containing 10 µM D-APV, to maintain channels in a non-conducting state (Kotermanski et 
al., 2009), for 30 seconds prior to reapplication of NMDA.  Memantine relief from block (untrapping) 
occurred during the second NMDA application.  Inset: expanded view of region outlined in black and 
red boxes, demonstrating the trapping apparent with initial NMDA re-application.  The red trace 
represents the initial current following memantine application attributable to unblocked receptor 
channels.  The black trace represents the corresponding NMDA current prior to memantine exposure 
for comparison.  B.  Memantine inhibition of extrasynaptic receptors.  The experiment was similar to 
panel A, except that synaptic receptors were blocked by repetitive EPSCs in the presence of 10 µM 
MK-801 (left lower inset), leaving mainly extrasynaptic receptors to respond to NMDA and glutamate 
applications.  The right lower inset shows the degree of memantine inhibition in the isolated 
extrasynaptic receptor population.  C. Memantine trapping in synaptic receptors.  Autaptic NMDA-
mediated EPSCs before and after trapping protocol where memantine (10 µM) was coapplied with 
glutamate (1 µM) to all receptors.  Memantine and glutamate were washed away for 30 seconds with 
D-APV containing saline (trace not shown) before evoking an EPSC.  EPSCs were significantly 
depressed compared to the initial baseline EPSC.  D. Average normalized amplitude of test responses 
following trapping.  The initial amplitude, prior to unblock, (e.g., red trace in A and B insets) was 
normalized to peak NMDA current (e.g., black traces in A and B insets) for total and extrasynaptic 
values in the graphs.  Asterisk denotes p < 0.05, student t test.  As a comparison, parallel control 
experiments used 10 µM D-APV in place of memantine (APV bars; traces not shown) in the total 
receptor (panel A) and synaptic receptor block (panel C) protocols.  D-APV did not exhibit residual 
antagonism, and there was no appreciable rundown of responses in these conditions.  N = 5-10 cells 
per condition.   
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continuously while evoking NMDA EPSCs initially produced only about 30% inhibition.  
However, over the course of multiple stimuli, inhibition reached ~80% (n = 5; Figure 2.3) and 
recovered very little with memantine washout (Figure 2.3B), suggesting inhibition by 
memantine bound to closed channels.  Steady-state inhibition was likely not achieved in these 
experiments; with additional stimulation it is possible that memantine might inhibit EPSCs more 
completely.  Nevertheless, the observations demonstrate that neuroprotective concentrations of 
memantine strongly antagonize synaptic receptors when receptors are repetitively activated.   
 
Although the absolute magnitude of memantine’s effect was likely exaggerated in these 
experiments by the absence of Mg
2+
, which is known to interact with memantine antagonism 
(Kotermanski and Johnson, 2009), the results confirm that memantine’s selectivity arises largely 
as a result of different dynamics of agonist presentation at synaptic and extrasynaptic receptors.  
If during hypoxic insult the mode of agonist presentation is synaptic but becomes more sustained 
or repetitive than under physiological conditions, then it is possible that memantine (and other 
neuroprotective NMDAR antagonists) act by blocking synaptic receptors.  This would contradict 
recent evidence that extrasynaptic receptors play a privileged role in excitotoxicity. 
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The source of hypoxic glutamate is synaptic 
In contemplating a role for synaptic receptors in toxicity during energy deprivation, we 
started by considering the assumption that the source of hypoxic glutamate is synaptic.  There is 
some experimental support for the idea that synaptic release is a major source of glutamate 
during energetic insults (Rothman, 1983; Kaplan et al., 1989; Monyer et al., 1992; Andrade and 
Rossi, 2010).  The major alternative mechanism of glutamate release is glial reverse glutamate 
uptake, which may occur under particularly severe conditions of oxygen-glucose deprivation 
combined with chemical ischemia (Jabaudon et al., 2000; Rossi et al., 2000).  Reverse transport 
could produce excessive tonic glutamate presumably most concentrated at extrasynaptic regions 
where transporters are primarily localized (Danbolt, 2001; Gouix et al., 2009) although synaptic 
NMDARs could also be recruited since they comprise the majority of cellular receptors 
(Rosenmund et al., 1995; Harris and Pettit, 2007).  We reasoned that if reverse uptake 
participates strongly in hypoxic glutamate release, blocking the (reverse) activity of transporters 
Figure 2.3: Progressive memantine block of synaptic receptors during repetitive 
stimulation of a microculture neuron.  A. Autaptic baseline NMDA-mediated EPSCs 
(black), after initial memantine (10 µM) presentation (brown), and after sustained 
memantine application during repeated stimulation (red).  EPSCs were evoked every 30 
seconds, and baseline was stabilized (black) prior to application of 10 µM memantine.  
Memantine application began 30 s prior to first “memantine” response (brown trace). B. 
Average normalized progressive inhibition summarized from 5 cells.  Arrow designates 
partial relief from trapping upon memantine washout (Saline).  
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during hypoxia would be protective.  However, if transporters remove toxic levels of glutamate 
released synaptically, then blocking transporters would exacerbate the damage.  Thus, to test the 
role of glutamate transporters during hypoxia, we co-applied DL-threo--Benzyloxyaspartic acid 
(TBOA), a broad-spectrum, non-substrate glutamate transporter inhibitor (Shimamoto et al., 
2004), during hypoxia.  We found that application of TBOA significantly exacerbated cell death, 
suggesting that glutamate transporters normally play a protective role in hypoxia (p < 0.05, n = 5, 
Figure 2.4).  Although these results do not directly determine the NMDAR populations 
responsible for cell death, the data are consistent with a synaptic rather than an extrasynaptic 
source of glutamate.  
To initially test whether milder synaptic receptor activity can be toxic to neurons, we 
queried whether bicuculline, commonly used to enhance synaptic activity, could kill neurons.  
Indeed, 5 h treatment of cells with 50 µM bicuculline, 10 µM glycine, 2 mM Ca
2+
 and no added 
Mg
2+
 produced mild but reliable D-APV sensitive neurotoxicity measured 24 h later (82 +/- 3% 
vs. 90 +/- 2% cell survival, p<0.05, n=6). Although this is a mild effect, it demonstrates that 
prolonged and excessive synaptic activity may kill neurons, in contrast to the prevailing idea that 
any synaptic receptor activation is neuroprotective (Hardingham and Bading, 2010).   
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Figure 2.4:  Glutamate transporters protect from hypoxic insults.  DL-threo--Benzyloxyaspartic 
acid (TBOA; 100 µM), a non-substrate, broad-spectrum glutamate transporter blocker, was used to 
diminish reverse or forward contributions of glutamate transporters during an insult.  Culture medium 
was removed and replaced with conditioned medium from sibling cultures containing TBOA.  
Neurons were then incubated under hypoxic conditions for 2.5 h, and original medium was replaced 
until assessment of survival 24 h later.  A. Representative photomicrographs of sample fields from a 
mass culture in control (No Hypoxia) or insult (Hypoxia) conditions with and without TBOA, as 
indicated.  Note prominent trypan-positive nuclei, indicated by arrows.  Scale bar: 20 µm.  B. Survival 
across conditions summarized from 5 independent experiments.  TBOA significantly exacerbated cell 
death (asterisk, p < 0.05, two tailed t test). 
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Selective synaptic receptor block protects against hypoxia and exogenous insults.  
The evidence that neuroprotective memantine exhibits strong synaptic receptor (EPSC) block 
during sustained or repetitive receptor activation, coupled with data suggesting that the glutamate 
source in hypoxia is synaptic, prompted us to investigate whether synaptic NMDARs may 
mediate cell death during hypoxia.  Hypoxia is an insult that we and others have employed as a 
model of excitotoxic damage (Rothman, 1983; Hogins et al., 2011).  Unlike bath application of 
NMDA or glutamate, other common experimental excitotoxic challenges, hypoxia triggers 
endogenous glutamate release.  In this sense, then, energetic insults like hypoxia are more similar 
to in vivo insults such as ischemia and stroke (Choi and Rothman, 1990; Lipton, 1999).  To test 
the hypothesis that excessive activation of synaptic NMDARs during hypoxia mediates cell 
death, we selectively blocked synaptic receptors prior to hypoxia using the very slowly 
dissociating, use-dependent antagonist, MK-801.  This protocol has been previously employed 
extensively (Hardingham and Bading, 2002; Ivanov et al., 2006; Liu et al., 2007; Stanika et al., 
2009; Bordji et al., 2010; Stark and Bazan, 2011; Zhang et al., 2011).  First, we exchanged the 
culture medium for isoosmotic defined recording solution (see Materials and Methods) 
containing 10 µM MK-801 for 15 minutes.  The preblock bath also contained low (1 mM) Ca
2+
 
concentration, 50 µM bicuculline (to decrease network inhibition), no Mg
2+
 and 10µM glycine.  
This solution exchange prevented background glutamate in the culture medium from activating 
receptors, thus minimizing the chance of non-specific MK-801 block.  Low Ca
2+
 concentration 
ensured a low quantal content for each action potential, minimizing spillover onto extrasynaptic 
receptors (Mennerick and Zorumski, 1995).  Furthermore, we omitted 4-aminopyridine, a 
potassium-channel blocker commonly used in the preblock protocol (Hardingham et al., 2002; 
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Bordji et al., 2010; Zhang et al., 2011), but which may enhance quantal content and spillover 
onto extrasynaptic receptors.  
 
This synaptic NMDAR preblock protocol abolished NMDA mediated EPSCs in mass cultures in 
which toxicity experiments were performed with relatively little reduction in normal synaptic 
activity, measured by AMPA receptor-mediated EPSCs (Figure 2.5A).  AMPA EPSCs 
sometimes changed amplitude or frequency following MK-801 preblock (Figure 2.5A2), but 
there was no consistent direction of these changes, and the overall charge transfer mediated by 
AMPAR over 30 s was not statistically different than pre-treatment levels (Figure 2.5C).  
Preblock with MK-801 preserved approximately 30% of bath-applied NMDA current (Figure 
2.5B-C), consistent with previous studies suggesting that ~70% of cellular NMDARs are 
synaptic (Rosenmund et al., 1995; Harris and Pettit, 2007).  Following this synaptic preblock 
protocol, we replaced the original culture medium and subjected the neurons to hypoxia.  
Preblocking synaptic receptors successfully reduced cell death, evaluated 24 h following insult, 
from 45 ± 4% to 17 ± 2% (p < 0.05, n = 10) during a 2.5 h hypoxic insult (Figure 2.5D).   
 
Previous studies investigating the role of synaptic and extrasynaptic receptors in excitotoxic 
insults typically used exogenous insults in which glutamate or NMDA are bath applied to 
neurons (Sattler et al., 2000; Hardingham et al., 2001; Hardingham et al., 2002; Papadia et al., 
2008).  This insult may activate more extrasynaptic receptors than hypoxic insult.  Therefore, we 
hypothesized that selectively blocking synaptic receptors should not protect against an 
exogenous insult (Hardingham et al., 2002).  We selectively blocked synaptic receptors prior to 
insult with 50 µM glutamate, which we found killed approximately as many neurons as hypoxia 
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over 2.5 h.  Surprisingly, we found that selective synaptic receptor block significantly protected 
against exogenous glutamate (Figure 2.5E).  We hypothesized that this may partly result from 
increased network activity promoted by exogenous glutamate. This would lead to excessive 
synaptic receptor activation that could contribute to glutamate-mediated death. To test this we 
recorded from a network of dissociated neurons using a multi-electrode array (MEA) before and 
during treatment with 50 µM glutamate. Exogenous glutamate produced a mild but reliable and 
reversible increase in network activity in our cultures (p<0.05 in 4 out of 4 experiments analyzed 
with ANOVA and pairwise t-test, Figure 2.5F). Over the four experiments, the mean increase in 
array-wide spike rate was 45 ± 22 % over baseline.  It seems unlikely that this degree of 
enhanced synaptic activity accounts fully for the neuroprotective effects of synaptic NMDAR 
preblock (see Discussion).   In aggregate, these data suggest that synaptic NMDARs play a 
critical excitotoxic role across a variety of insult paradigms.  
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MK-801 synaptic preblock protects strongly against hypoxic damage, but protection is 
incomplete (Figure 2.5D2).  Residual cell death could be caused by NMDAR-independent 
toxicity, rendering even complete MK-801 antagonism ineffective.  To test this we applied 10 
µM MK-801 before and during the hypoxic insult, and we continued the MK-801 incubation 
during the post-insult recovery period (24 h).  Despite the constant presence of MK-801, we still 
found incomplete protection (Figure 2.6A).  We also directly examined whether total (synaptic 
Figure 2.5 (Previous Page): Synaptic NMDAR block significantly protects against hypoxic and 
exogenous glutamate insults.  Mass culture neurons (14-15 DIV) were incubated for 15 minutes in 
recording saline containing 1 mM Ca
2+
, no added Mg
2+
, bicuculline (50 µM), glycine (10 µM) and 
MK-801 (10 µM). Neurons were returned to original media prior to exposure to hypoxia (2.5h).  A1-
A2. Bicuculline-induced NMDA spontaneous EPSCs (sEPSCs) isolated with NBQX and recorded in 
the absence of bath MK-801 were abolished following preblock (A1, right) with little change in 
AMPA receptor-mediated sEPSCs isolated in the absence of NBQX and presence of D-APV (A2) in 
the same cell.  B. Preblock reduced exogenous NMDA currents compared to control, untreated sibling 
cultures, representing block of synaptic receptors and retention of functional extrasynaptic receptors.  
C. Summary data indicating the remaining percentage across NMDA EPSCs, AMPA EPSCs and total 
NMDA current (n =8-12).  The reduction in INMDA with preblock represents the expected percentage of 
extrasynaptic receptors estimated previously (Rosenmund et al., 1995).  D1. Representative 
photomicrographs of neurons exposed to 2.5 h hypoxia with or without preblock conditioning.  
Arrows indicated trypan-positive neurons, labeled 24 h following insult.  Conditions are indicated by 
text labels.  Scale bar: 20 µm.  D2. Summary data indicating that synaptic NMDAR preblock 
significantly protected neurons against hypoxia.  Asterisk denotes p < 0.05, two tailed Student’s t test.  
N = 10 independent experiments.  E. Preblock also significantly protected neurons against 2.5 h of 50 
µM glutamate (Glu; no receptor antagonists present in the Glu bath).  Asterisk denotes p < 0.05 two 
tailed student t test.  N = 5 experiments. F. Multielectrode array (MEA) recordings from mass cultures 
in presence of glutamate (50 µM). Raster plots for baseline, glutamate and wash conditions from a 
representative experiment are shown with array-wide spike detection rates (ASDR) across conditions. 
Glutamate significantly increased the firing rate in 4 out of 4 independent experiments (asterisk, 
p<0.05 with ANOVA and pairwise t-test).  The summary panel reflects 30 min of data in each 
condition from the single experiment represented in the rasters. 
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and extrasynaptic) NMDAR preblock could confer full protection.  This was achieved by co-
incubation with 50 µM NMDA plus 10 µM MK-801 prior to hypoxic insult.  We found that the 
total receptor preblock protocol was also incompletely protective against hypoxic damage and 
exerted protection quantitatively similar to synaptic preblock (Figure 2.6B).  To verify that MK-
801 unblocking is unlikely to underlie the incomplete block, we recorded NMDAR currents 
immediately after total preblock and immediately after total preblock then 2.5 h hypoxia.  
Currents immediately following the insult showed only modest recovery (Figure 2.6C).  
Average current amplitudes were -57.5 ± 6.8 pA (recorded immediately following preblock, n = 
10), -194.0 ± 29.0 pA (preblocked, recorded post-hypoxia, n = 8), and -2146.9 ± 306.7 pA 
(control, unblocked, n = 5).  These observations are consistent with the idea that little relief of 
block occurs as a result of insult-induced depolarization and channel activation.  Finally, the 
small residual death associated with MK-801 antagonism in Figures 2.5D, 2.5E, 2.6A, and 2.6B 
is also similar to the cell death we previously observed with complete block of all NMDA and 
AMPA-type glutamate receptors during hypoxia (Hogins et al., 2011).  Taken together, this 
previous and present evidence is consistent with the idea that non-glutamatergic mechanisms 
contribute to hypoxic damage in this model (Newell et al., 1995; Besancon et al., 2008), and 
selective synaptic preblock confers nearly the full measure of possible NMDAR-related 
protection in this model.  Extrasynaptic NMDARs do not appear to be significantly involved in 
the residual toxicity.   
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Figure 2.6: MK-801 partial protection results from non-NMDAR related toxicity and not from 
MK-801 unblock.  A. Mass culture neurons were exposed to hypoxia or control conditions in the 
presence or absence (control) of MK-801 (10 µM) during and after a 2.5 h insult.  Despite the 
continual presence of MK-801, hypoxic protection, although significant, was not complete (hypoxia 
alone vs. hypoxia with MK-801, p< 0.05; MK-801 alone vs. hypoxia with MK-801, p<0.05, two-
tailed t test with Bonferroni correction for multiple comparisons, n = 7).  B. Total NMDAR preblock 
protocol: Neurons were exposed to NMDA (50 µM) and MK-801 (10 µM) for 15 minutes in 
recording solution containing no Mg
2+
  and 2 mM Ca
2+
 and then returned to conditioned culture 
medium prior to exposure to hypoxic insult.  Total receptor block significantly protected against a 
hypoxic insult, but not completely (hypoxia alone vs. hypoxia preblock, p < 0.05; preblock alone vs. 
hypoxia preblock, p < 0.05, t test with Bonferroni correction for multiple comparisons, n = 4).  C. To 
test whether MK-801 escaped the NMDA channel during hypoxic insult to explain partial protection 
in B, NMDA currents (10 µM) were recorded in unblocked control cultures (No Preblock, n = 5), 
immediately after the total NMDAR preblock protocol (Preblock: pre-hypoxia, n = 10), and then 
after a preblock protocol, followed by hypoxia (Preblock, Post-Hypoxia, n = 8).  Little unblock was 
evident following 2.5 h hypoxia (representative traces shown, see Results for quantification).  
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Although we took care to minimize spillover during our blocking protocol by reducing 
bath calcium concentration, reducing calcium also enhances excitability (Frankenhaeuser and 
Hodgkin, 1957). This could counteract the effect of lowering quantal content and result in 
perisynaptic receptor activation and MK-801 block. To minimize any enhancement in 
excitability caused by low divalent cation concentration, we omitted bicuculline in our preblock 
solution and instead added 200 nM of the positive allosteric GABAA receptor modulator 
allopregnanolone (3α5αP) to the low-calcium bath. This protocol significantly reduced the 
frequency of spontaneous EPSCs but did not abolish activity (p<0.05, n=8, Figure 2.7A). When 
MK-801 was added to this more conservative preblock protocol, we still observed significant 
protection against 2.5 hypoxia (46.2 +/- 6.5% vs. 69.7 +/- 5.6 % cell survival, p<0.05, n=5, 
Figure 2.7B). This offers further evidence that synaptic receptors play a vital role in hypoxic 
excitotoxic death. 
 
Reduction of extrasynaptic glutamate does not protect against hypoxia. 
As an independent approach to evaluating the role of synaptic receptors in hypoxic damage, we 
next queried whether selectively reducing contributions of extrasynaptic NMDARs would 
protect against hypoxic damage.  If damage arises mainly through synaptic receptors, then 
reducing extrasynaptic receptor contributions should offer little protection.  If extrasynaptic 
receptors do contribute strongly to damage (Hardingham et al., 2002), perhaps alongside 
synaptic receptors, reducing their activation would be protective.  To selectively eliminate 
sustained extrasynaptic NMDAR contributions, we used glutamate pyruvate transaminase 
(GPT), which catalyzes pyruvate-dependent glutamate degradation.  Degradation is too slow for 
GPT to strongly affect the transient, high glutamate concentration in the synaptic cleft, but GPT 
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significantly depresses the activation of extrasynaptic receptors by synaptic overflow (Rossi and 
Slater, 1993; Rusakov and Kullmann, 1998; Turecek and Trussell, 2000).   
 
Figure 2.7: Decreasing synaptic activity during preblock still yields protection.  A. The 
GABAA receptor allosteric modulator allopregnanolone (3α5αp) replaced bicuculline and 
reduced reduced NMDA mediated sEPSC frequency in mass cultures.  Bar graph shows overall 
postsynaptic charge transfer from 10 s periods (asterisk p<0.05, two tailed student t test, n=5). 
B. MK-801 in the 3α5αp preblock solution significantly protected against 2.5 h hypoxic insult 
(asterisk p<0.05, two tailed student t test, n=5). 
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Figure 2.8: Specificity of glutamate pyruvate transaminase for tonic but not synaptic 
glutamate.  A1. Glutamate pyruvate transaminase (5 U ml
-1
) with 2 mM sodium pyruvate (GPT + 
pyruvate) significantly depressed current in a microculture neuron in response to exogenous 
glutamate (Glu, 1 µM).  A2. GPT had little effect on exogenous NMDA (10 µM) current in the 
same cell, suggesting minimal direct effect on NMDAR function.  B. GPT with pyruvate 
minimally depressed NMDA mediated EPSCs.  EPSCs were evoked every 30 seconds, and 
baseline was stabilized prior to application of GPT.  C. Summary data indicating the significant 
selective reduction of tonic glutamate effects over phasic, synaptic effects by enzymatic 
degradation (8.2 ± 2.1% vs. 83.9 ± 4.1%, p < 0.05, two tailed t test, n=8-12).  
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Consistent with this previous literature, we found that 5 U ml
-1
 GPT plus 2 mM pyruvate 
strongly reduced currents in response to exogenous application of glutamate (1 µM, representing 
a sub-EC50 concentration), but GPT had a minimal effect on NMDA EPSCs (Figure 2.8).   
 
As previously demonstrated in other preparations (Rossi et al., 2002), we found that GPT 
significantly protected neurons against excitotoxicity induced by 2.5 h of 50 µM glutamate 
(Figure 2.9A).  This suggests that the GPT strategy is effective against toxicity mediated by 
tonic glutamate buildup.  However, when tested against hypoxic excitotoxicity, GPT was not 
protective and instead exacerbated death (Figure 2.9B).  This exacerbation resulted from 
residual contaminants in the supplier’s enzyme formulation (see Materials and Methods), since 
equivalent vehicle suspension alone resulted in indistinguishable exacerbation (21 ± 1% survival 
in hypoxia + GPT, 24 ± 4% survival with vehicle suspension control in hypoxia (p > 0.05), while 
hypoxia alone yielded 46 ± 2% survival in 6 independent, paired experiments on sibling 
cultures). As with GPT, the vehicle control did not affect survival in the absence of hypoxia, and 
the exacerbation was D-APV insensitive (data not shown).  Although the basis of the vehicle 
effects on hypoxic damage remains unclear, the quantitative similarity of the effect in the 
presence and absence of GPT suggests that exacerbation did not mask a protective effect of GPT 
during hypoxia.  These results are again consistent with the idea that synaptic receptors can 
mediate excitotoxicity when the source of glutamate is synaptic. 
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Figure 2.9: Glutamate pyruvate transaminase protects against exogenous glutamate damage 
but does not protect against hypoxic damage.  A. GPT protected against an exogenous insult.  
Medium was exchanged for conditioned medium from sibling cultures containing 5 U ml
-1
 GPT and 
2 mM pyruvate (GPT).  Glutamate (Glu; 50 µM) was directly added to the enzyme-containing dishes 
for 2.5 h.  Conditioned medium was added at the end of the insult, and cells were evaluated for cell 
death 24 h post-insult.  GPT significantly protected against exogenous glutamate (asterisk denotes p 
< 0.05, two-tailed t test, n = 5).  B. GPT did not protect against hypoxia.  Culture medium from the 
mass culture was exchanged for conditioned medium from sibling dishes containing 5 U ml
-1
 GPT 
and 2 mM pyruvate, and neurons were exposed to hypoxia.  Original medium was replaced at the end 
of the insult, and neurons were stained for cell death using trypan blue 24 h post-insult.  GPT did not 
protect.  The exacerbation was linked to residual suspension from the supplier’s formulation 
(asterisk, p<0.05, two tailed t test; n = 14). See Results.  
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DISCUSSION 
The extrasynaptic NMDAR excitotoxicity hypothesis proposes an attractive dichotomy between 
trophic synaptic receptor activation and toxic extrasynaptic receptor activation (Hardingham et 
al., 2002; Papadia et al., 2008).  In part the extrasynaptic hypothesis is built on neuroprotection 
by the use-dependent NMDAR channel blocker memantine, which has been suggested to be 
selective for extrasynaptic receptors (Lipton, 2007; Leveille et al., 2008; Xia et al., 2010).  Here 
we demonstrated that a neuroprotective concentration of memantine shows only weak selectivity 
for extrasynaptic NMDARs when the pattern of synaptic and extrasynaptic receptor activation 
(channel opening) is identical.  The extrasynaptic receptor hypothesis also posits that synaptic 
receptor blockade should not exhibit neuroprotection during excitotoxic insults and may in fact 
exacerbate damage.  In contrast, we demonstrated that synaptic NMDAR blockade is 
neuroprotective, especially when the excitotoxic insult is mediated by synaptic glutamate release.  
Our results contradict the strong form of the extrasynaptic NMDAR excitotoxicity hypothesis 
and suggest that at least some excitotoxic insults act mainly through over-activation of synaptic 
NMDARs.  
 
Our data suggest that memantine possesses similar actions at extrasynaptic and synaptic 
receptors.  Although extrasynaptic receptors may be enriched in NR2B subunits (Groc et al., 
2006), offering a potential substrate for selectivity, memantine exhibits no clear subunit 
selectivity (Blanpied et al., 1997).  A previous study of memantine found evidence for selectivity 
at extrasynaptic receptors, but this study did not directly test the contribution of transient versus 
sustained receptor activation in memantine’s apparent selectivity (Xia et al., 2010).  Our results 
suggest that the pattern of receptor activation is the most important determinant of memantine’s 
apparent selectivity, consistent with memantine’s open-channel block mechanism (Chen and 
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Lipton, 1997).  Transient receptor activation during brief transmitter presence limits the amount 
of memantine channel block during synaptic activation, especially at low memantine 
concentrations.  By contrast, sustained activation of receptors facilitates memantine inhibition.  
Previous studies assessed memantine’s selectivity using a low concentration (1 µM) (Okamoto et 
al., 2009; Xia et al., 2010), whereas we focused on a 10-fold higher concentration that we and 
others have documented to be neuroprotective (Figure 2.1) (Chen et al., 1998; Volbracht et al., 
2006).  Our results demonstrate that synaptic receptors (EPSCs) can be strongly blocked by this 
concentration if they are activated by either sustained or repetitive agonist presentation.  Either 
pattern or both patterns could apply to excitotoxic insults such as hypoxia.  It should be noted 
that our measurements (Figures 2.2 and 2.3) were performed at -70 mV in the absence of 
extracellular Mg
2+
.  It is likely that under pathophysiological conditions such as hypoxia, the 
absolute level of memantine block for both extrasynaptic and synaptic receptors will be reduced 
by physiological Mg
2+
 and by hypoxic depolarization (Kotermanski and Johnson, 2009; Xia et 
al., 2010). 
 
We also provide evidence that synaptic receptors can play a critical role in mediating excitotoxic 
death during a moderate hypoxic challenge.  Blocking synaptic NMDARs protected against 
hypoxia.  Key to interpreting this result is the selectivity of our strategy for preblocking synaptic 
receptors.  For our MK-801 preblocking protocol, we followed protocols established in the 
literature (Hardingham et al., 2002; Papadia et al., 2008).  We also defined the synaptic receptor 
population conservatively by preblocking in bath solutions designed to limit glutamate spillover 
during synaptic activity, and we ensured minimal background glutamate levels by preblocking in 
fresh, defined bath solution.  Most importantly, we directly verified the selectivity of our 
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preblock strategy (Figure 2.5).  Finally, we complemented MK-801 preblock experiments with 
tests of the effect of enzymatic degradation of glutamate.  GPT failed to protect against hypoxic 
damage but significantly reduced damage to exogenous glutamate.  This result suggests strongly 
that tonic buildup at extrasynaptic receptors is not a major source of toxic glutamate under 
conditions of our hypoxia experiments. A recent study has also shown that tonic NMDAR 
activity may not play a critical role in excitotoxic insults, particularly in certain neuronal 
populations vulnerable to excitotoxic insult (Povysheva and Johnson, 2012). 
 
We cannot exclude the possibility that under some conditions extrasynaptic NMDARs may play 
a more pronounced role in excitotoxicity than we observed here.  Insults of altered severity may 
promote a larger toxic role for extrasynaptic receptors.  For instance, reverse glutamate transport 
has been shown to play a prominent role in glutamate release under very extreme conditions of 
metabolic poisoning plus oxygen/glucose deprivation (Rossi et al., 2000).  Neuronal and glial 
transporters are mainly excluded from synapses (Danbolt, 2001), so release by reverse glutamate 
transport may promote a more prominent role for extrasynaptic receptors in toxicity than in our 
studies.  Additional conditions fostering an extrasynaptic receptor role could include cell types 
with a large percentage of extrasynaptic receptors or networks with weak synaptic connectivity.  
Finally, we note that previous studies have rarely rigorously verified the degree of synaptic 
receptor block in the oft-used MK-801 preblock protocol.  This leaves open the possibility that 
significant numbers of synaptic receptors remained unblocked in these studies and may have 
contributed to toxicity attributed to extrasynaptic receptors.  
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A related issue concerns the definition of synaptic receptors.   Our studies, like previous work, 
used an operational definition of synaptic NMDARs: receptors that are blocked by MK-801 
when synaptically activated.  Although our estimates of synaptic and extrasynaptic receptor 
percentages agree with previous estimates, it is likely too simplistic to dichotomize receptor 
populations.  The literature’s operational definition can be affected by factors that promote 
transmitter spillover, for instance, and that variably recruit perisynaptic receptors. There is also 
growing realization that complex trafficking pathways can dynamically affect exchange between 
these two populations of surface receptors (Gladding and Raymond, 2011).  
 
We were surprised that toxicity in response to 50 µM glutamate was also strongly reduced by 
synaptic NMDAR block (Figure 2.5E).  This protection could be explained in at least two ways.  
First, synaptic receptors constitute the majority of NMDARs (Rosenmund et al., 1995; Harris 
and Pettit, 2007).  Thus, synaptic receptor block may have protected by simply blocking a large 
number of receptors.  A second possibility is that exogenous agonist, perhaps acting 
preferentially at extrasynaptic receptors (Sinor et al., 2000; Hardingham et al., 2002) evoked 
secondary synaptic glutamate release from the network, contributing to the observed death 
(Monyer et al., 1992).  By this explanation, extrasynaptic receptors act indirectly, as a conduit to 
trigger synaptic NMDAR toxicity.  MEA data showed a significant increase in overall network 
activity during prolonged glutamate exposure, consistent with the idea that synaptic activity is 
increased by exogenous glutamate.  However, toxicity from network disinhibition with 
bicuculline was milder and required longer than glutamate treatment required.  Thus, while 
repetitive synaptic activity can be toxic, the effects of exogenous glutamate are unlikely to be 
explained by the increase in network synaptic activity alone.    Rather, direct activation of 
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synaptic receptors by glutamate probably mediates most of the effect of synaptic receptor 
preblock protection.  Regardless of whether synaptic NMDAR activation is direct from 
exogenous glutamate or indirect from synaptic glutamate, our data offer strong evidence that 
synaptic receptors can be neurotoxic in multiple circumstances, including energy deprivation and 
insults induced by exogenous agonist.   
 
Our results are in broad agreement with a previous paper that selectively disrupted synaptic 
NMDAR function with actin depolymerization and observed neuroprotection from glutamate 
released during oxygen/glucose deprivation (Sattler et al., 2000).  However, manipulations of 
actin polymerization can also have presynaptic effects which could confound interpretations 
(Morales et al., 2000; Yao et al., 2006; Andrade and Rossi, 2010).  Our approach avoided this 
potential complication.  The previous study showed that toxicity to exogenous glutamate was not 
prevented by actin depolymerization, apparently implicating extrasynaptic receptors (Sattler et 
al., 2000).  This is in apparent conflict with our studies in which synaptic receptor blockade 
prevented exogenous excitotoxicity (Figure 2.5E).  This discrepancy is likely explained by the 
fact that actin depolymerization did not decrease the total number of surface receptors; rather, it 
relocated synaptic receptors to non-synaptic membrane.  Therefore, our approach reduced overall 
toxic Ca
2+
 load in response to exogenous glutamate, whereas the Sattler et al. approach did not. 
 
Excitotoxicity is a complex phenomenon that is mediated in part by over activation of NMDARs.  
The extrasynaptic NMDAR hypothesis of excitotoxicity has been one of the most exciting 
proposals in the glutamate toxicity field in recent years, in part because of the clinical 
implications.  However, our observations substantially undermine two arms of the extrasynaptic 
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NMDAR hypothesis.  First, we find that memantine at neuroprotective concentrations 
significantly blocks synaptic receptors during sustained or repetitive stimulation as likely 
experienced during excitoxicity-triggering insults.  Second, we demonstrate that synaptic 
receptor activation, proposed to be uniquely protective, is toxic during at least some endogenous 
and exogenous excitotoxic insults.  Our findings point towards a need to consider synaptic 
receptor contributions when developing therapeutics for disorders with excitotoxic components.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
REFERENCES 
Andrade AL, Rossi DJ (2010) Simulated ischaemia induces Ca
2+
-independent glutamatergic 
vesicle release through actin filament depolymerization in area CA1 of the hippocampus. 
J Physiol 588:1499-1514. 
Bekkers JM, Richerson GB, Stevens CF (1990) Origin of variability in quantal size in cultured 
hippocampal neurons and hippocampal slices. Proc Natl Acad Sci USA 87:5359-5362. 
Besancon E, Guo S, Lok J, Tymianski M, Lo EH (2008) Beyond NMDA and AMPA glutamate 
receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends 
Pharmacol Sci 29:268-275. 
Blanpied TA, Boeckman FA, Aizenman E, Johnson JW (1997) Trapping channel block of 
NMDA-activated responses by amantadine and memantine. J Neurophysiol 77:309-323. 
Bordji K, Becerril-Ortega J, Nicole O, Buisson A (2010) Activation of extrasynaptic, but not 
synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and 
increases amyloid-production. J Neurosci 30:15927-15942. 
Chen HS, Lipton SA (1997) Mechanism of memantine block of NMDA-activated channels in rat 
retinal ganglion cells: uncompetitive antagonism. J Physiol 499:27-46. 
Chen HSV, Wang YF, Rayudu PV, Edgecomb P, Neill JC, Segal MM, Lipton SA, Jensen FE 
(1998) Neuroprotective concentrations of the N-methyl--aspartate open-channel blocker 
memantine are effective without cytoplasmic vacuolation following post-ischemic 
administration and do not block maze learning or long-term potentiation. Neuroscience 
86:1121-1132. 
Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic 
neuronal death. Annu Rev Neurosci 13:171-182. 
Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65:1-105. 
Dick O, Bading H (2010) Synaptic activity and nuclear calcium signaling protect hippocampal 
neurons from death signal-associated nuclear translocation of FoxO3a induced by 
extrasynaptic N-methyl-D-aspartate receptors. J Biol Chem 285:19354-19361. 
Frankenhaeuser B, Hodgkin AL (1957) The action of calcium on the electrical properties of 
squid axons. J Physiol 137:218-244. 
Gladding CM, Raymond LA (2011) Mechanisms underlying NMDA receptor 
synaptic/extrasynaptic distribution and function. Mol Cell Neurosci 48:308-320. 
Gouix E, Leveille F, Nicole O, Melon C, Had-Aissouni L, Buisson A (2009) Reverse glial 
glutamate uptake triggers neuronal cell death through extrasynaptic NMDA receptor 
activation. Mol Cell Neurosci 40:463-473. 
68 
 
Groc L, Heine M, Cousins SL, Stephenson FA, Lounis B, Cognet L, Choquet D (2006) NMDA 
receptor surface mobility depends on NR2A-2B subunits. Proc Natl Acad Sci U S A 
103:18769-18774. 
Hardingham G, Bading H (2002) Coupling of extrasynaptic NMDA receptors to a CREB shut-
off pathway is developmentally regulated. Biochim Biophys Acta 1600:148 - 153. 
Hardingham G, Arnold F, Bading H (2001) Nuclear calcium signaling controls CREB-mediated 
gene expression triggered by synaptic activity. Nat Neurosci 4:261 - 267. 
Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: 
implications for neurodegenerative disorders. Nat Rev Neurosci 11:682-696. 
Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic 
NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5:405-
414. 
Harris A, Pettit D (2007) Extrasynaptic and synaptic NMDA receptors form stable and uniform 
pools in rat hippocampal slices. J Physiol 584:509 - 519. 
Hogins J, Crawford DC, Jiang X, Mennerick S (2011) Presynaptic silencing is an endogenous 
neuroprotectant during excitotoxic insults. Neurobiol Dis 43:516-525. 
Huettner JE, Baughman RW (1986) Primary culture of identified neurons from the visual cortex 
of postnatal rats. J Neurosci 6:3044-3060. 
Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, 
Turski L, Olney JW (1999) Blockade of NMDA receptors and apoptotic 
neurodegeneration in the developing brain. Science 283:70-74. 
Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, Medina I (2006) Opposing 
role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular 
signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol 
572:789 - 798. 
Jabaudon D, Scanziani M, Gähwiler  BH, Gerber U (2000) Acute decrease in net glutamate 
uptake during energy deprivation. Proc Natl Acad Sci U S A 97:5610-5615. 
Johnson JW, Kotermanski SE (2006) Mechanism of action of memantine. Curr Opin Pharmacol 
6:61-67. 
Kaplan TM, Lasner TM, Nadler JV, Crain BJ (1989) Lesions of excitatory pathways reduce 
hippocampal cell death after transient forebrain ischemia in the gerbil. Acta 
Neuropathologica 78:283-290. 
Kotermanski SE, Johnson JW (2009) Mg
2+
 imparts NMDA receptor subtype selectivity to the 
Alzheimer's drug memantine. J Neurosci 29:2774-2779. 
69 
 
Kotermanski SE, Wood JT, Johnson JW (2009) Memantine binding to a superficial site on 
NMDA receptors contributes to partial trapping. J Physiol 587:4589-4604. 
Lester RA, Tong G, Jahr CE (1993) Interactions between the glycine and glutamate binding sites 
of the NMDA receptor. J Neurosci 13:1088-1096. 
Lester RAJ, Clements JD, Westbrook GL, Jahr CE (1990) Channel kinetics determine the time 
course of NMDA receptor-mediated synaptic currents. Nature 346:565-567. 
Leveille F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A (2008) 
Neuronal viability is controlled by a functional relation between synaptic and 
extrasynaptic NMDA receptors. FASEB J 22:4258-4271. 
Lipton P (1999) Ischemic cell death in brain neurons. Physiol Rev 79:1431 - 1568. 
Lipton SA (2007) Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci 
8:803-808. 
Liu Y, Wong T, Aarts M, Rooyakkers A, Liu L, Lai T, Wu D, Lu J, Tymianski M, Craig A, 
Wang Y (2007) NMDA receptor subunits have differential roles in mediating excitotoxic 
neuronal death both in vitro and in vivo. J Neurosci 27:2846 - 2857. 
Mennerick S, Zorumski C (1995) Presynaptic influence on the time course of fast excitatory 
synaptic currents in cultured hippocampal cells. J Neurosci 15:3178-3192. 
Mennerick S, Benz A, Zorumski CF (1996) Components of glial responses to exogenous and 
synaptic glutamate in rat hippocampal microcultures. J Neurosci 16:55-64. 
Mennerick S, Que J, Benz A, Zorumski CF (1995) Passive and synaptic properties of 
hippocampal neurons grown in microcultures and in mass cultures. J Neurophysiol 
73:320-332. 
Mennerick S, Chisari M, Shu HJ, Taylor A, Vasek M, Eisenman LN, Zorumski CF (2010) 
Diverse voltage-sensitive dyes modulate GABAA receptor function. J Neurosci 30:2871-
2879. 
Monyer H, Giffard RG, Hartley DM, Dugan LL, Goldberg MP, Choi DW (1992) Oxygen or 
glucose deprivation-induced neuronal injury in cortical cell cultures is reduced by tetanus 
toxin. Neuron 8:967-973. 
Morales M, Colicos MA, Goda Y (2000) Actin-dependent regulation of neurotransmitter release 
at central synapses. Neuron 27:539-550. 
Newell DW, Barth A, Papermaster V, Malouf AT (1995) Glutamate and non-glutamate receptor 
mediated toxicity caused by oxygen and glucose deprivation in organotypic hippocampal 
cultures. J Neurosci 15:7702-7711. 
70 
 
Okamoto S-i, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, 
Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA 
(2009) Balance between synaptic versus extrasynaptic NMDA receptor activity 
influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15:1407-1413. 
Olney JW, Labruyere J, Price MT (1989) Pathological changes induced in cerebrocortical 
neurons by phencyclidine and related drugs. Science 244:1360-1362. 
Papadia S, Soriano FX, Leveille F, Martel M-A, Dakin KA, Hansen HH, Kaindl A, Sifringer M, 
Fowler J, Stefovska V, McKenzie G, Craigon M, Corriveau R, Ghazal P, Horsburgh K, 
Yankner BA, Wyllie DJA, Ikonomidou C, Hardingham GE (2008) Synaptic NMDA 
receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 11:476-487. 
Patneau DK, Mayer ML (1990) Structure-activity relationships for amino acid transmitter 
candidates acting at N-methyl-D-aspartate and quisqualate receptors. J Neurosci 10:2385-
2399. 
Potter SM, DeMarse TB (2001) A new approach to neural cell culture for long-term studies. J 
Neurosci Methods 110:17-24. 
Povysheva NV, Johnson JW (2012) Tonic NMDA receptor-mediated current in prefrontal 
cortical pyramidal cells and fast-spiking interneurons. J Neurophysiol. 
Rosenmund C, Feltz A, Westbrook G (1995) Synaptic NMDA receptor channels have a low 
open probability. J Neurosci 15:2788-2795. 
Rossi DJ, Slater NT (1993) The developmental onset of NMDA receptor-channel activity during 
neuronal migration. Neuropharmacology 32:1239-1248. 
Rossi DJ, Oshima T, Attwell D (2000) Glutamate release in severe brain ischaemia is mainly by 
reversed uptake. Nature 403:316-321. 
Rossi P, Sola E, Taglietti V, Borchardt T, Steigerwald F, Utvik JK, Ottersen OP, Köhr  G, 
D'Angelo E (2002) NMDA receptor 2 (NR2) C-terminal control of NR open probability 
regulates synaptic transmission and plasticity at a cerebellar synapse. J Neurosci 22:9687-
9697. 
Rothman SM (1983) Synaptic activity mediates death of hypoxic neurons. Science 220:536-537. 
Rothman SM, Olney JW (1987) Excitotoxity and the NMDA receptor. Trends Neurosci 10:299-
302. 
Rusakov DA, Kullmann DM (1998) Extrasynaptic glutamate diffusion in the hippocampus: 
ultrastructural constraints, uptake, and receptor activation. J Neurosci 18:3158-3170. 
Sattler R, Xiong Z, Lu W-Y, MacDonald JF, Tymianski M (2000) Distinct roles of synaptic and 
extrasynaptic NMDA receptors in excitotoxicity. J Neurosci 20:22-33. 
71 
 
Shimamoto K, Sakai R, Takaoka K, Yumoto N, Nakajima T, Amara SG, Shigeri Y (2004) 
Characterization of novel L-threo--benzyloxyaspartate derivatives, potent blockers of 
the glutamate transporters. Mol Pharmacol 65:1008-1015. 
Sinor JD, Du S, Venneti S, Blitzblau RC, Leszkiewicz DN, Rosenberg PA, Aizenman E (2000) 
NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical 
neurons in vitro. J Neurosci 20:8831-8837. 
Soriano F, Papadia S, Hofmann F, Hardingham N, Bading H, Hardingham G (2006) 
Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal 
excitability. J Neurosci 26:4509 - 4518. 
Stanika RI, Pivovarova NB, Brantner CA, Watts CA, Winters CA, Andrews SB (2009) Coupling 
diverse routes of calcium entry to mitochondrial dysfunction and glutamate 
excitotoxicity. Proc Natl Acad Sci U S A 106:9854-9859. 
Stark DT, Bazan NG (2011) Synaptic and extrasynaptic NMDA receptors differentially modulate 
neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection. J Neurosci 
31:13710-13721. 
Tong G, Jahr CE (1994) Multivesicular release from excitatory synapses of cultured 
hippocampal neurons. Neuron 12:51-59. 
Turecek R, Trussell LO (2000) Control of synaptic depression by glutamate transporters. J 
Neurosci 20:2054-2063. 
Volbracht C, Van Beek J, Zhu C, Blomgren K, Leist M (2006) Neuroprotective properties of 
memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 
23:2611-2622. 
Wilcox KS, Fitzsimonds RM, Johnson B, Dichter MA (1996) Glycine regulation of synaptic 
NMDA receptors in hippocampal neurons. J Neurophysiol 76:3415-3424. 
Xia P, Chen H-sV, Zhang D, Lipton SA (2010) Memantine preferentially blocks extrasynaptic 
over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 30:11246-
11250. 
Yao J, Qi J, Chen G (2006) Actin-dependent activation of presynaptic silent synapses contributes 
to long-term synaptic plasticity in developing hippocampal neurons. J Neurosci 26:8137-
8147. 
Zhang SJ, Buchthal B, Lau D, Hayer S, Dick O, Schwaninger M, Veltkamp R, Zou M, Weiss U, 
Bading H (2011) A signaling cascade of nuclear calcium-CREB-ATF3 activated by 
synaptic NMDA receptors defines a gene repression module that protects against 
extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damage. J 
Neurosci 31:4978-4990. 
 
72 
 
Chapter 3 
 
“Indistinguishable synaptic pharmacodynamics of the NMDAR channel 
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ABSTRACT 
Memantine and ketamine, voltage- and activation-dependent channel blockers of NMDA 
receptors (NMDARs), have enjoyed a recent resurgence in clinical interest. Steady-state 
pharmacodynamic differences between these blockers have been reported, but it is unclear 
whether the compounds differentially affect dynamic physiological signaling.  Here we explored 
non-equilibrium conditions relevant to synaptic transmission in hippocampal networks in 
dissociated culture and hippocampal slices.  Equimolar memantine and ketamine had 
indistinguishable effects on the following measures: steady-state NMDA currents, NMDAR 
EPSC decay kinetics, progressive EPSC inhibition during repetitive stimulation, and 
extrasynaptic NMDAR inhibition.  Therapeutic drug efficacy and tolerability of memantine have 
been attributed to fast kinetics and strong voltage dependence.  However, pulse depolarization in 
drug presence revealed a surprisingly slow and similar time course of equilibration for the two 
compounds, although memantine produced a more prominent fast component (62 vs. 48%) of re-
equilibration.  Simulations predicted that low gating efficacy underlies the slow voltage-
dependent relief from block.  This prediction was empirically supported by faster voltage-
dependent blocker re-equilibration with several experimental manipulations of gating efficacy. 
EPSP-like voltage commands produced drug differences only with large, prolonged 
depolarizations unlikely to be attained physiologically.  In fact, we found no difference between 
drugs on measures of spontaneous network activity or acute effects on plasticity in hippocampal 
slices.  Despite indistinguishable synaptic pharmacodynamics, ketamine provided significantly 
greater neuroprotection from damage induced by oxygen glucose deprivation, consistent with the 
idea that under extreme depolarizing conditions, the biophysical difference between drugs 
becomes detectable.  We conclude that despite subtle differences in voltage dependence, during 
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physiological activity, blocker pharmacodynamics are largely indistinguishable and largely 
voltage independent.  
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INTRODUCTION 
Memantine and ketamine are activation-dependent and voltage-dependent NMDA receptor 
(NMDAR) channel blockers. Memantine is neuroprotective and is used to enhance cognition in 
dementia (Ditzler, 1991; Lipton, 2005). Ketamine is an anesthetic and analgesic with 
psychotomimetic effects and abuse potential (Krystal et al., 1994), but it has drawn recent 
attention as a fast acting antidepressant (Zarate et al., 2006; Aan Het Rot et al., 2012).  The 
drugs’ pharmacodynamics are similar, but the literature suggests small steady-state differences. 
Because physiological activity is not inherently steady-state, we explored cellular and receptor-
level drug differences under dynamic conditions.    
 
Ketamine and memantine both require channel opening for access to and for exit from the 
NMDAR channel (Parsons et al., 1993; Lipton, 2005; Johnson and Kotermanski, 2006; Gilling et 
al., 2009; Kotermanski et al., 2009).  During sustained, steady-state agonist presentation, 
memantine may display slightly faster kinetics of block than ketamine (Gilling et al., 2009). 
Further, memantine has been found to bind two sites with differing dependence on channel 
opening, leading to partial trapping upon channel closure.  Meanwhile, ketamine exhibits full 
trapping (Blanpied et al., 1997; Gilling et al., 2009; Kotermanski et al., 2009), although there is 
some evidence for two ketamine sites (Orser et al., 1997).  Contrary to agonist presentation in 
most previous studies, physiological, synaptic agonist presentation is brief and transient (Lester 
et al., 1990; Clements et al., 1992). This non-steady state profile of agonist presentation could 
influence activation-dependent channel blockers and accentuate any pharmacodynamic 
differences.  Memantine might be a selective antagonist for extrasynaptic NMDAR populations 
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(Okamoto et al., 2009; Xia et al., 2010; Wroge et al., 2012). However, whether this effect is 
secondary to the more sustained agonist presentation at extrasynaptic versus synaptic receptors is 
unclear, and whether ketamine shares any extrasynaptic receptor selectivity has not been 
explored. 
 
Both drugs are also voltage dependent.  At sustained positive potentials memantine appears to 
exhibit weaker block (more voltage dependence) than ketamine (Gilling et al., 2009).  
Depolarization, like agonist presentation, is rarely sustained during physiological activity except 
under pathophysiological conditions.  How transient depolarization interacts with NMDAR 
blocker actions is unclear.  Sufficiently rapid dissociation during EPSPs could preserve transient 
synaptic transmission while blocking low-level, tonic extrasynaptic activation (Lipton, 2005; 
Gilling et al., 2009). On the other hand, if drug re-equilibration is slow relative to EPSP duration, 
drugs may have largely voltage-independent effects except under the most extreme conditions. 
 
Our study focused on non-equilibrium agonist presentation and rapid voltage changes applicable 
to synaptic transmission.  In a number of paradigms the drugs exhibit remarkable similarities. 
The sole distinction observed was a difference in the apparent voltage dependence of the drugs in 
whole-cell, voltage-pulse experiments.  Simulations revealed that the apparent voltage 
dependence could result from differences in channel opening/closing rates while blocker is 
bound and need not involve changes in microscopic voltage dependence of drug action. The 
difference between drugs did not manifest under most physiological conditions because of the 
low open probability of the NMDAR channel (Rosenmund et al., 1995; Chen et al., 1999), which 
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did not allow sufficient opportunity for dissociation of either drug during transient, synaptic-like 
depolarizations. The drugs also behaved similarly in their effects on spontaneous network 
activity and induction of plasticity.  Differences only emerged under extreme depolarization 
during oxygen and glucose deprivation, where memantine proved the weaker neuroprotectant. 
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 MATERIALS AND METHODS 
Cell cultures. Hippocampal cultures were prepared as either mass cultures or microcultures (as 
indicated in figure legends) from postnatal day 1-3 male and female rat pups anesthetized with 
isoflurane, under protocols consistent with NIH guidelines and approved by the Washington 
University Animal Studies Committee.  Methods were adapted from earlier descriptions 
(Huettner and Baughman, 1986; Bekkers et al., 1990; Tong and Jahr, 1994; Mennerick et al., 
1995).  Hippocampal slices (500 m thickness) were digested with 1 mg ml-1 papain in 
oxygenated Leibovitz L-15 medium (Life Technologies, Gaithersburg, MD, USA).  Tissue was 
mechanically triturated in modified Eagle's medium (Life Technologies) containing 5% horse 
serum, 5% fetal calf serum, 17 mM D-glucose, 400 μM glutamine, 50 U ml-1 penicillin and 50 
μg ml-1 streptomycin.  Cells were seeded in modified Eagle's medium at a density of ~650 cells 
mm
-2 
as mass cultures (onto 25 mm cover glasses coated with 5 mg ml
-1
 collagen or 0.1 mg ml
-1
 
poly-D-lysine with 1 mg ml
-1
 laminin) or 100 cells mm
-2
 as "microisland" cultures (onto 35 mm 
plastic culture dishes coated with collagen microdroplets on a layer of 0.15% agarose).  Cultures 
were incubated at 37° C in a humidified chamber with 5%CO2/95% air.  Cytosine arabinoside 
(6.7 μM) was added 3-4 days after plating to inhibit glial proliferation.  The following day, half 
of the culture medium was replaced
 
with Neurobasal medium (Life Technologies) plus B27 
supplement (Life Technologies).  
 
HEK cell transfection. HEK293 cells were grown and split when 50-75% confluent in 
Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum, 1 mM glutamine with 
penicillin/streptomycin. One day prior to transfection, cells were split and plated directly on 35 
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mm plastic dishes. When 30-50% confluent, cells were transferred to Opti-Med transfection 
media and transfected using Lipofectamine 2000 with GluN1a and GluN2A or GluN2B in a 1:3 
ratio. GluN subunit DNA constructs were gifts of Drs. Elias Aizenman and Jon Johnson 
(University of Pittsburgh). Green fluorescent protein (GFP; 0.05 µg) was used as a transfection 
efficiency marker. After 2-4 h, transfection medium was removed and replaced with culture 
medium containing 100 µM ketamine to prevent excitotoxicity (Boeckman and Aizenman, 
1996).  For recordings performed 48-72 h following transfection, medium was removed and 
washed repeatedly with ketamine-free recording solution.  Repetitive agonist application before 
data collection and interleaved experimental conditions ensured complete removal of blocker 
prior to experiments.  
  
Electrophysiology. Whole-cell recordings were performed at room temperature from neurons 
cultured for 5-10 days (depending on the experiment) using a Multiclamp 700B amplifier 
(Molecular Devices, Sunnyvale, CA, USA) and Digidata 1440A converter using Clampex 10.1 
software.  Young cells were favored for biophysical experiments to minimize voltage-clamp 
errors and older, synaptically mature cells were used for EPSC measurements. GFP-positive 
HEK cells were recorded 2-5 days post-transfection. For recordings, cells were transferred to an 
extracellular (bath) solution containing (in mM): 138 NaCl, 4 KCl, 2 CaCl2, 10 glucose, 10 
HEPES, and 0.05 D-2-Amino-5-phosphonovalerate (D-APV), pH 7.25 adjusted with NaOH. 
Solutions were perfused over the cells using a gravity-driven local perfusion system from a 
common tip. The estimated solution exchange times were <100 ms (10-90% rise), estimated 
from junction current rises at the tip of an open patch pipette. For synaptic recordings, these 
solutions contained (in mM) 0.01 glycine, 0.001 2,3-dihydroxy-6-nitro-7-sulfonyl-
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benzo[f]quinoxaline (NBQX) and 0.025 bicuculline methobromide and contained no D-APV. 
For exogenous NMDA application during voltage perturbations, 0.25 mM CaCl2 was used (in 
APV-free perfusion solutions) to minimize Ca
2+
-dependent NMDAR desensitization (Zorumski 
et al., 1989), and 250 nM tetrodotoxin was added to prevent network activity. During network 
activity studies (Figure 9), all blockers were eliminated and 2 mM Ca
2+
, 1 mM Mg
2+ 
and 1 µM 
glycine were used.  During HEK cell recordings antagonists and tetrodotoxin were omitted. 
Unless otherwise noted, exogenous NMDA concentration was 300 µM. In experiments using 
tricine, 10 mM tricine was added to external solutions and pH was adjusted to 7.25.  The tip 
resistance of patch pipettes was 3-6 Mwhen filled with an internal solution containing (in 
mM): 130 potassium gluconate, 0.5 CaCl2, 5 EGTA, 4 NaCl, and 10 HEPES at pH 7.25, adjusted 
with KOH.  Potassium was used as the main cation for autaptic stimulation to preserve action 
potential waveform, but in experiments examining current responses to exogenous agonists, 
cesium methanesulfonate or cesium gluconate was used in place of potassium gluconate to block 
potassium channels and improve spatial voltage clamp quality.  Holding voltage was typically -
70 mV unless otherwise noted.  Access resistance (8-10 M was compensated 80-100% for 
EPSC measurements. For
 
evoked EPSCs, cells were stimulated with 1.5 ms pulses
 
to 0 mV from 
-70 mV to evoke autaptic transmitter release (Mennerick et al., 1995).  
 
Artificial EPSP (αEPSP) waveforms were generated in Excel using the following equation: 
Vm=Vmax((t/)*exp(1-t/)); Vmax was set to values varying from 0 mV to +70 mV, yielding a  
maximum depolarization to -20 mV from the holding potential of -90 mV, and  was either 30 
ms  (for short EPSPs) or 300 ms (for long EPSPs).  The resulting data were converted to a 
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command waveform in Clampfit 10.1.  Voltage-gated sodium currents were suppressed with 250 
nM tetrodotoxin for this experiment. 
 
For network activity analysis, mass cultures were seeded on multielectrode arrays (MEAs, 
Multichannel Systems) (Mennerick et al., 2010). Recordings were performed 15 days in vitro.  
For figures and statistics, effects of drugs over a 30 min recording period were compared with 
the average of activity (30 min) before drug administration and following drug washout. Array-
wide spike detection rate was measured as the total number of spikes across the entire array in 
each second of recording.  Bursts were defined as three or more spikes on a single contact with 
an inter-spike interval (ISI) less than a critical duration of 150 ms (Wagenaar et al., 2006). Burst 
duration was the interval between the first spike and the last spike in a burst.   
 
Hippocampal Slices. Slices were harvested from 28-32 day-old male albino rats under isoflurane 
anesthesia (Tokuda et al., 2010). For electrophysiology, hippocampal slices were transferred to a 
submerged recording chamber with continuous bath perfusion of artificial cerebrospinal fluid 
(124 NaCl, 5 KCl, 2 MgSO4, 2 CaCl2, 1.25 NaH2PO4, 22 NaHCO3, 10 glucose, bubbled with 
95% O2/5% CO2) at 2 ml/min at 30° C. Extracellular recordings were obtained from the apical 
dendritic layer of the CA1 region elicited with 0.1 ms constant current pulses through a bipolar 
stimulating electrode placed in stratum radiatum. EPSPs were monitored using a half-maximal 
stimulus based on a baseline input–output curve. After establishing a stable baseline, long-term 
potentiation (LTP) was induced by applying a single 100 Hz × 1 s high frequency stimulus 
(HFS) using the same intensity stimulus as used for monitoring. Long-term depression (LTD) 
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was induced with 1 Hz low-frequency stimulation (LFS) for 15 min. An input–output curve was 
repeated 60 min following induction protocols for statistical comparisons of changes in EPSP 
slopes at half-maximal intensity. Signals were digitized and analyzed using PCLAMP software 
(Molecular Devices, Union City, CA).   
 
Oxygen Glucose Deprivation: Culture medium in mass cultures (13–14 DIV) was exchanged for 
minimum essential medium (MEM, Life Technologies, catalog no. 11090-081) with no added 
glutamine or glucose, supplemented with 10 μM glycine immediately prior to hypoxia exposure 
in a commercially available chamber (Billups-Rothenberg), humidified and saturated with 95% 
nitrogen and 5% CO2 at 37°C, for 2.5 h.  Drugs were added directly to culture medium before 
oxygen-glucose deprivation (OGD).  The gas exchange followed the specifications of the 
chamber manufacturer (flow of 20 L/min for 4 min to achieve 100% gas exchange).  Following 
OGD, cells were returned to their original medium and incubated under standard culture 
conditions until the cell death assay (24 h later). We used Hoechst 33342 (5 μM) to identify all 
nuclei and propidium iodide (3 μM) for 30 minutes to stain nuclei of cells with compromised 
membranes. Five 10x microscope fields were quantified per condition per experiment, yielding > 
100 total neurons for each condition.  Ratios of healthy neurons were quantified as the fraction of 
propidium iodide-negative neuronal nuclei to total neuronal nuclei.  Automated cell counting 
algorithms (ImageJ software) were used for cell counts. Toxicity experiments were treated as a 
dependent sample design, in which sibling cultures plated in identical media exposed to hypoxia 
at the same time were compared by repeated measures statistics.    
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Simulations. NEURON software (Carnevale and Hines, 2006) was used to generate simulations 
of voltage step perturbations. The kinetic scheme used for the NMDAR, and rate constants were 
adapted from previous work (Blanpied et al., 1997).  
 
Data Analysis. Electrophysiology data acquisition and analysis were performed primarily using 
pCLAMP 10 software (Molecular Devices). MEA data were analyzed with Igor Pro 
(Wavemetrics, Lake Oswego, OR). All electrophysiological measurements were processed with 
Microsoft Excel and are presented as mean ± S.E.M.  Statistical significance was determined 
using a Student’s one-tailed or two-tailed t test, unless indicated otherwise, with a Bonferroni 
correction for multiple comparisons where appropriate, and significance was taken as p < 0.05.  
One-tailed tests were reserved for later experiments on network function and toxicity, after a 
hypothesis about the direction of difference between memantine and ketamine emerged based on 
the difference in voltage dependence between drugs.  Data plotting, statistical analysis, and curve 
fitting to the Hill equation were performed with SigmaPlot (Systat; San Jose, CA). Figure 
preparation was performed in SigmaPlot and Adobe Photoshop (San Jose, CA, USA).  Decay 
time constants were measured using standard exponential fitting functions using a least-squares 
minimization algorithm or a Chebyshev transform in pClamp software. 
 
Materials. All drugs were obtained from Sigma (St. Louis, MO, USA) except for D-APV and 
NBQX (Tocris). Culture media was obtained from Life Technologies.  
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RESULTS 
Indistinguishable modulation of NMDAR EPSCs by memantine and ketamine at constant 
voltage 
To aid the choice of ketamine and memantine concentrations for our studies, we examined drug 
effects during sustained NMDA application in cultured dissociated hippocampal neurons (Figure 
3.1A,B). Consistent with other studies (Gilling et al., 2009; Kotermanski and Johnson, 2009; 
Traynelis et al., 2010), both drugs behaved similarly at equimolar concentration. Although 
memantine’s IC50 was 2.1 μM and ketamine’s was 1.5 μM, these values were statistically 
indistinguishable (Figure 3.1C). The values are likely a slight overestimate because block did 
not always reach a steady state at low antagonist concentrations.  However, in subsequent 
experiments, equimolar concentrations inevitably yielded indistinguishable steady-state effects at 
negative membrane potentials, even with prolonged blocker application.  
 
 
Figure 3.1. Memantine and ketamine have indistinguishable IC50s A, B.  Inhibition of NMDAR 
current was evaluated for memantine (A) and ketamine (B) as indicated in dissociated hippocampal 
cultures at day in vitro (DIV) 9-10. Increasing concentrations of the drugs (0.1, 1, 10, 100 μM) were 
applied to hippocampal neurons in the constant presence of 30 μM NMDA. Peak current is 
truncated for clarity. C. Concentration-response curves, with IC50s estimated from fits to the Hill 
equation (N=6).  Memantine IC50: 2.1 µM (Hillcoeff: 1), Ketamine IC50: 1.5 µM (Hillcoeff: 1) 
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As use-dependent NMDAR antagonists, both memantine and ketamine require NMDAR channel 
activation to block the channel. Thus, the temporal parameters of NMDAR activation strongly 
affect the blocking ability of memantine and ketamine. During steady-state receptor activation, 
the blocker equilibrates with its binding site, and kinetic differences between blockers may be 
masked. Steady-state agonist presentation also poorly recapitulates physiological events where 
agonist presentation is brief and NMDAR activation is transient (Lester et al., 1990; Clements et 
al., 1992). To investigate if memantine and ketamine exhibit kinetic differences that result in 
differential modulation of the NMDAR during synaptic activity, we measured evoked NMDA-
EPSC amplitude and decay kinetics in the presence of drug. Drugs were applied using an 
interleaved protocol, and EPSCs were allowed to recover to baseline between drug applications. 
With 20 s drug pre-application that persisted through EPSC stimulation, we found that both 
drugs equivalently accelerated EPSC decay (Figure 3.2A). NMDAR EPSC kinetics exhibited 
biexponential decay, as previously observed (Lester et al., 1990).  Both time constants of decay 
were accelerated in the presence of memantine or ketamine, and the contribution of the fast 
component of decay increased.  There was no detectable difference between equimolar 
memantine and ketamine in any of these properties (Figure 3.2B).     
 
If memantine and ketamine differ in their ability to dissociate from closed channels, the drugs 
may have differing effects on peak EPSC amplitudes during intermittent, repetitive synaptic 
agonist presentation.  To test this, we evoked NMDAR EPSCs continuously at a frequency of 
0.04 Hz to allow complete recovery from presynaptic, frequency-dependent facilitation and 
depression (Mennerick et al., 1995). We found that the time course of progressive block by 
ketamine and memantine during this continuous stimulation was indistinguishable (Figure 3.3). 
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The similarity of progressive block by memantine and ketamine suggests similar binding rates 
for the two drugs at -70 mV.  
 
Figure 3.2. Memantine and ketamine effects on NMDAR EPSCs are indistinguishable. A. 
Autaptic EPSCs from solitary neurons 10-12 DIV were measured in the presence of saline, 
memantine (10 μM), and ketamine (10 μM). Memantine and ketamine sweeps alternated with 
saline (5 sweeps) to restore EPSC to baseline. 2-3 replicate sweeps for each condition were 
averaged. Bi-exponential fits for the three conditions (blue, saline; red, memantine; green, 
ketamine) are overlaid on the raw traces. Inset shows scaled traces on an expanded time scale to 
indicate the fit of the initial fast component and the similarity of drug effects. B.  Parameters 
from bi-exponential curve fitting of the decay phase of the EPSC. Memantine and ketamine both 
significantly accelerated the bi-exponential decay kinetics of the EPSC (fast and slow  and the 
relative contribution, *p<0.05, Student’s t-test), but effects did not differ between drugs (N=8).  
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Memantine has been described as a selective blocker of extrasynaptic NMDARs over synaptic 
NMDARs, when compared with the very slowly reversible channel blocker MK-801 (Xia et al., 
2010). However, recent studies have suggested that apparent selectivity may result from 
differences in time course of agonist presentation to extrasynaptic vs. synaptic NMDARs rather 
than memantine affinity for extrasynaptic populations (Wroge et al., 2012). Memantine has not 
previously been compared with channel blockers of similar kinetics.  Because memantine and 
ketamine exhibited similar actions at synaptic NMDARs (Figure 3.2, 3.3), we hypothesized that 
they may equivalently inhibit extrasynaptic populations. We pharmacologically enriched 
extrasynaptic NMDARs by stimulating autaptic EPSCs at 0.04 Hz in the presence of MK-801 
until maximum synaptic block was reached (Figure 3.4A1, B1).  We then activated the resulting 
enriched extrasynaptic NMDARs with 30 µM NMDA and challenged these remaining NMDARs 
with 2 µM memantine or ketamine.  We were unable to distinguish the degree of block during 10 
Figure 3.3. Memantine and ketamine reach 
maximal synaptic block with similar time-
course.  A. Memantine (10 μM) block of 
autaptic NMDAR EPSCs generated with 0.04 
Hz stimulation. Indicated are saline (black), 
first memantine application (dark red) and 
final memantine sweep (bright red). B. 
Identical protocol with 10 μM ketamine: dark 
green is first application, bright green is final 
sweep. C. Amplitudes of successive sweeps 
are graphed as a percentage of initial baseline 
amplitude. Memantine and ketamine did not 
differ in the degree or rate of block over 
successive applications (N=5, p>0.05, 
Student’s t test). Memantine data are 
reproduced from (Wroge et al., 2012).  
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s co-application (Figure 3.4A2, B2; 77 ± 3% inhibition for memantine, 75 ± 2% inhibition for 
ketamine; n = 6, p>0.05). As another approach, we used established protocols to block synaptic 
NMDARs in neuronal networks using 15 minute bath incubation with MK-801 (10 μM) and 
bicuculline (50 μM) (Hardingham and Bading, 2002; Wroge et al., 2012). We have shown that 
this protocol blocks NMDAR EPSCs without blocking AMPAR EPSCs (Wroge et al., 2012). 
Memantine and ketamine also similarly blocked the enriched extrasynaptic population isolated in 
this manner (71 ± 4% inhibition for memantine, 76 ± 3% for ketamine, p=0.36). Our results 
demonstrate that memantine and ketamine act indistinguishably from each other at enriched 
extrasynaptic populations; thus memantine is not unique in its effects on extrasynaptic 
NMDARs.    
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We noted that inhibition by 2 µM memantine or ketamine at enriched extrasynaptic receptor 
populations in Figure 3.4 appeared to be stronger than expected from Figure 3.1.  This could 
result from selectivity of both drugs for extrasynaptic receptor populations.  However, when we 
tested the total receptor population, memantine inhibited NMDAR currents by 70 ± 2% (n = 8), 
statistically indistinguishable from an effect on MK-801-isolated extrasynaptic receptors in a 
matched comparison group with similar experimental conditions (72 ± 4%, n = 6; p = 0.6).   
 
Figure 3.4. Memantine and ketamine block extrasynaptic NMDARs equally. A1, B1. 
Synaptic NMDARs were blocked by the slowly reversible open-channel blocker MK-801 
(10 µM) during stimulation of autaptic EPSCs (0.04 Hz). A2, B2. Isolated extrasynaptic 
NMDARs were activated by 30 µM NMDA and challenged with an IC50 concentration of 
memantine (A2, 2 µM) or ketamine (B2, 2 μM). The relative block achieved by 
memantine or ketamine at the end of the application compared to steady state control 
NMDA response measured immediately before drug application did not differ between the 
two drugs (see Results for values, p>0.05 Student’s t-test, N=6).   
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A second factor distinguishing isolated extrasynaptic receptor activation from total receptor 
activation is the number of activated receptors and therefore the level of Ca
2+
 influx. Since the 
overall Ca
2+
 load is expected to be lower with isolated extrasynaptic receptors (representing 
~30% of the total receptor pool), desensitization could be reduced and blocker effects could be 
altered.  To test whether external calcium concentration affects blocker potency, we measured 
memantine (2 μM) block of steady-state NMDA responses in high (2 mM) Ca2+ or low (0.25 
mM) Ca
2+
. We found both conditions resulted in indistinguishable block (2 mM Ca
2+
: 72 ± 2% 
vs. 0.25 mM Ca
2+
: 70 ± 2%, n=8, p>0.05). These data also suggest that external calcium itself 
has little effect on blocker potency.  Thus, similar to our previous conclusions (Wroge et al., 
2012), we find little evidence for drug selectivity for extrasynaptic receptors.   
 
Re-equilibration in response to voltage pulses reveals subtle differences between drugs.   
Memantine and ketamine, as positively charged channel blockers, display strong voltage 
sensitivity (Gilling et al., 2009). Previous studies suggest that memantine may exhibit slightly 
more steady-state voltage dependence than ketamine (Gilling et al., 2009).  To explore kinetic 
differences that might underlie such effects, we recorded NMDA responses during a voltage 
pulse from -70 mV to +50 mV in the presence and absence of either memantine or ketamine. 
Although both drugs equivalently inhibited NMDA responses at -70 mV, memantine exhibited 
weaker inhibition than ketamine during a 10 s pulse to +50 mV (Figure 3.5A, B). 
 
We examined the time course of  the approach toward a new (reduced) steady-state level of 
inhibition at +50 mV (time course of re-equilibration) by generating time-resolved inhibition 
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plots (Frankiewicz et al., 1996), created by dividing the leak-subtracted current trace in the 
presence of blocker by the leak-subtracted trace in the presence of NMDA alone and displayed 
as a percentage.  The time course of blocker re-equilibration was bi-exponential for both drugs 
(Figure 3.5A1, A2, lower panels), and the fast and slow time constants were indistinguishable 
(Figure 3.5A, C). However, memantine’s fast component of re-equilibration was slightly but 
significantly more prominent than ketamine’s (Figure 3.5C, right). Consistent with the faster 
kinetics of memantine, weighted time constants for the return pulse to -70 mV also differed (0.8 
± 0.07 s for memantine, 1.3 ± 0.06 s for ketamine, p < 0.05).   
 
In summary, voltage-pulse relaxation analyses uncovered two interesting aspects of drug actions 
that we pursued further in subsequent experiments.   First, the data above yielded blocker re-
equilibration weighted time constants of 1.2 ± 0.2 s for memantine and 2.1 ± 0.6 s for ketamine 
at +50 mV.  This slow overall time course of re-equilibration for both drugs was surprising and 
seems in contrast to the previous suggestion that fast kinetics may permit normal synaptic 
transmission and therapeutic tolerability (Lipton, 2005).  We explored the underlying mechanism 
of slow voltage dependence below.  Second, memantine exhibited slightly faster voltage-
dependent blocker re-equilibration as a result of a more prominent fast component. We explored 
the physiological and pathophysiological relevance of this difference in subsequent studies.    
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Low channel gating efficacy limits time course of blocker re-equilibration 
Prior work examining voltage-dependent channel blockers has found that the time course of re-
equilibration in response to voltage pulses can provide direct estimates of drug binding and 
unbinding rate constants (Adams, 1977; Jin et al., 2009). However, the slow re-equilibration we 
observed yields kon and koff values for memantine and ketamine that are inconsistent with those 
derived by other methods (Blanpied et al., 1997; Gilling et al., 2009). NMDA receptor channels 
have a low gating efficacy at full agonist occupancy with peak Po 0.04-0.35 depending on 
experimental conditions and subunit composition (Rosenmund et al., 1995; Chen et al., 1999). In 
contrast, nicotinic and glycine receptors possess peak Po near 0.9 (Jin et al., 2009).  Because 
Figure 3.5. Memantine exhibits a significantly larger fast component of voltage-dependent re-
equilibration following a voltage-pulse depolarization.  A1-A2. 300 μM NMDA alone (black) or 
during steady-state block current of 10 μM memantine (red, A1) or 10 μM ketamine (green, A2) 
during a voltage step from -70 mV to +50 mV. Drugs were interleaved on the same cell, with NMDA 
application to relieve block. Traces are displayed after digital baseline saline subtraction. Gray line 
indicates 0 pA. Memantine and ketamine effects are shown as a percentage of baseline NMDA 
control (obtained by digital ratio) below original traces. B. The percent block of NMDA currents 
achieved by both memantine and ketamine at -70 mV (prior to voltage step) were identical but 
inhibition at +50 mV was significantly lower for memantine than ketamine  (n=14 *P<0.05, Two 
way ANOVA with replication and Bonferroni correction for multiple comparisons). C. The 
relaxation from block at -70 mV to the new steady-state at +50 mV was fit with a bi-exponential 
curve. Memantine traces showed a significantly stronger fast component compared to ketamine 
(N=14,*p<0.05, Student t-test).   
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channel opening is required for blocker binding and dissociation (Chen and Lipton, 1997), we 
reasoned that the slow blocker re-equilibration might result from this low Po rather than slow 
drug binding/dissociation kinetics. A low gating efficacy might limit the rate of memantine and 
ketamine re-equilibration following a step perturbation of voltage.  
 
To test this, we simulated a voltage-pulse protocol. We used a kinetic scheme from previous 
work (Blanpied et al., 1997) and previously established rate constants (Figure 3.6A legend).   
The scheme accommodates previous observations of low agonist efficacy and gating of the 
blocked channel (Blanpied et al., 1997) but neglects desensitization and multiple open and closed 
states (Popescu and Auerbach, 2003). Although simplified, the model has fewer free parameters 
than more complex models, and it has proven useful in prior analyses.  Thus, it represents a 
useful heuristic tool for our subsequent experimental tests. Simulation in the absence of blocker 
resulted in a Po of 0.03, similar to experimentally derived values for hippocampal neurons 
(Rosenmund et al., 1995).  Because NMDAR channel gating only exhibits weak inherent voltage 
sensitivity (Jahr and Stevens, 1987; Clarke and Johnson, 2008), voltage-dependence of gating 
was not incorporated into the model, and Po remained constant at both -70 mV and at +50 mV, 
while the change in driving force was simulated (Figure 3.6B black trace). 
 
We simulated the effect of 10 µM blocker with binding properties given in Figure 6B legend 
(gray trace).  The voltage dependence of the blocker was simulated by altering its koff value e-
fold per 31.5 mV (Kotermanski and Johnson, 2009). Inhibition at -70 mV was relieved following 
a pulse to +50 mV with a single-exponential  of 1.4 s. To examine how channel gating affects 
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re-equilibration we altered efficacy by increasing β and β’ 10-fold. This manipulation caused the 
relaxation time constant during a step to +50 mV to decrease approximately 10-fold to 163 ms, 
(Figure 3.6B, red trace; Figure 3.6C). A further increase in efficacy (1000-fold increase in 
opening rate) yielded a Po > 0.9, and the resulting relaxation time constant was consistent with 
drug binding kinetics (Figure 6C,  =0.002 s, equivalent to 1/(kon + koff)).  Although performed 
with a simplified gating scheme, these simulations demonstrate in principle that inefficient 
gating rate limits the re-equilibration of drug.  Previous investigations have verified the 
assumptions of high Po for voltage-pulse relaxation analysis of other channels (Adams, 1977; Jin 
et al., 2009), but binding and dissociation rate constants for low Po NMDARs cannot be directly 
derived from whole-cell, voltage-pulse relaxations.     
 
Another possible explanation for the slow time course of unblock could be slow dissociation 
kinetics of the drugs.  We simulated the effect of altering koff for the blocker 10-fold. This 
resulted in substantially less steady-state block but little change in the time course of re-
equilibration at positive voltages (Figure 3.6B, blue trace). We conclude, therefore, that drug 
unbinding kinetics likely do not explain the slow time constants.   
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Figure 3.6 . Simulations demonstrate that 
low Po slows voltage-dependent re-
equilibration of blocker.  A. Kinetic scheme 
used in the simulations. Rate constants were 
adapted from Blanpied et al 1997 and were: 
ka+=2 µM
-1
 s
-1
, ka-=40 s
-1
, =5.2 s-1, =130 s-1, 
kon=14.9 µM
-1
 s
-1
, koff=7.6 s
-1
, ′=0.3 s-1, 
′=35.4 s-1, ka+′= 0.2 µM
-1
 s
-1
, ka-′=0.02 s
-1
, 
[NMDA]=300 µM, [blocker]=10 µM. B. 
Output of the simulation replicating a voltage 
jump in the presence (gray) and absence 
(black) of a voltage-dependent open-channel 
blocker of the NMDAR. Voltage dependence 
of the open channel blocker was achieved by 
decreasing koff by e-fold per 31.5 mV 
(Kotermanski and Johnson, 2009). Colored 
traces are as depicted in the legend. See 
Materials and Methods for more details of the 
simulation. Simulation output (representing 
channels in the A2R* state) was normalized to 
initial NMDA-only amplitude (3.8% of 
receptors for the black, gray and blue traces, 
28.6% for the red trace). Changing blocker 
dissociation (blue) reduced steady state block 
but did not appreciably alter the re-
equilibration kinetics at +50 mV. By contrast, 
accelerating channel opening (red) sped re-
equilibration kinetics during wash on/off at -70 
mV and following the pulse to +50 mV. C. 
Calculated rate constants derived from tau of 
re-equilibration at positive potentials at 
varying efficacies, plotted as a function of Po 
(altered by incrementing β and β’ in 10-fold 
steps). Simulation output (black line) is 
compared to simulation input (gray line). Po 
needed to approach 1 (0.97) to retrieve values 
of the same order of magnitude of simulation 
input. Calculated rate constants for memantine 
from our data in Figure 5 are also plotted as 
red lines. Horizontal lines are for reference 
purposes and are not a function of Po.  
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Experimentally increasing gating efficacy speeds blocker re-equilibration.  
Our modeling predicts that increasing Po should speed re-equilibration of channel blockers at 
positive potentials. To test this in our neuronal population, we manipulated levels of extracellular 
glycine. As a necessary co-agonist, glycine levels control NMDAR gating. We found that 
decreasing bath glycine levels from 10 μM to 0.2 μM significantly slowed memantine re-
equilibration (10 μM vs. 0.2 μM glycine: weighted tau 0.97 ± 0.15 s vs. 2.8 ± 0.3 s, n=8, 
p<0.05).  
 
To test this further, we took advantage of the fact that diheteromeric GluN1/GluN2A NMDARs 
have higher efficacy than diheterometic GluN1/GluN2B receptors (Chen et al., 1999). These 
subunits are present in nearly all NMDARs in cultured hippocampal neurons (Tovar and 
Westbrook, 1999).  We heterologously expressed GluN2A or GluN2B, along with GluN1, 
subunits in HEK293 cells and measured the time course of memantine re-equilibration at +50 
mV in the presence of 300 µM NMDA.  As expected if gating kinetics rate limit blocker 
behavior, we found that memantine re-equilibration at positive potentials was significantly faster 
in NMDARs containing GluN2A subunits (468 ± 67 ms, weighted ) than in those containing 
GluN2B subunits (709.3 ± 94.4 ms weighted ; p<0.05, Student’s t test, n=20-22; Figure 3.7A, 
B).  Ketamine retained its property of slightly slowed voltage-dependent re-equilibration 
compared with memantine at both GluN2 isoforms (770 ± 146 ms for GluN2A, 1727 ± 334 ms 
for GluN2B, p < 0.05 at each). Steady-state inhibition for memantine at -70 mV of GluN2A-
containing vs. GluN2B-containing receptors was 93 ± 1% vs. 98 ± 1% (p < 0.05 n=20-22). The 
slight difference we found is consistent with previous work showing that memantine is weakly 
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selective for GluN2B receptors with an IC50 ~2-fold higher for GluN2A over GluN2B 
populations (Kotermanski and Johnson, 2009). When memantine and ketamine were compared 
on the same GluN2A- or GluN2B-bearing cell, both drugs displayed a weak preference for 
GluN2B-containing receptors (GluN2A vs. GluN2B: memantine: 90 ± 2% vs. 97 ± 2% p < 0.05 
and ketamine: 92 ± 2% vs. 98 ± 2%, p < 0.05 n=7), once again highlighting very similar effects 
of the two channel blockers.   
 
As a more direct and sensitive test of the hypothesis that gating efficacy dictates the slow re-
equilibration, we took advantage of selective inhibition of GluN2A-containing receptors by low 
(nanomolar) concentrations of ambient zinc, which decreases open probability of GluN2A 
receptors, likely by affecting gating efficacy (Paoletti et al., 1997; Erreger and Traynelis, 2008; 
Gielen et al., 2009; Amico-Ruvio et al., 2011).  We buffered ambient zinc in our extracellular 
bath solution using 10 mM tricine to relieve the effects of contaminating Zn
2+
 and found that 
NMDA responses from GluN2A, but not GluN2B, currents were significantly potentiated (71 ± 
13% increase in GluN2A, n=8, p<0.05 vs. 9 ± 2%, n=8, p>0.05 in GluN2B, Figure 3.6C1, D1). 
Correspondingly, we found acceleration of memantine re-equilibration time course at +50 mV in 
the presence of tricine in GluN2A receptors (487 ± 134 ms in absence of tricine vs. 135 ± 26 ms 
in presence of tricine, n = 8, p<0.5; Figure 3.7C2, D2).  Blocker re-equilibration at GluN2B 
NMDARs was not significantly affected by tricine (545 ± 61 ms in absence of tricine vs. 630 ± 
135 ms in presence of tricine, n = 8; Figure 3.7C2, D2). Taken together, our data strongly 
suggest that the low Po of the fully liganded NMDAR rate limits blocker re-equilibration, 
effectively trapping memantine and ketamine in the channel despite high agonist concentration.  
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Memantine and ketamine show little unblock during mild to moderate artificial EPSPs 
We found that memantine exhibited a stronger fast component of relaxation (62% vs. 48%) 
following a pulse to +50 mV compared to ketamine (Figure 3.5).  Because both blockers re-
equilibrate slowly following strong depolarization, it is unclear what impact this subtle drug 
difference would have during EPSPs.  Synaptic depolarizations are briefer and smaller than the 
voltage pulses to +50 mV and therefore may not elicit the drug difference observed in Figure 
3.5.  To explore the size and duration of EPSPs necessary to elicit a difference between drug 
actions, we designed a voltage-command waveform that mimicked EPSPs of different amplitude 
and duration (see Materials and Methods).  By examining current responses in the presence of 
Figure 3.7. Experimentally 
increasing Po speeds re-
equilibration. A-B.  GluN2A 
containing NMDA receptors exhibit 
faster re-equilibration of memantine 
[10M] than GluN2B containing 
receptors. C1, D1. 10 mM tricine 
potentiates NMDA currents in 
GluN1/GluN2A-transfected HEK 
cells but not GluN1/GluN2B cells. 
C2, D2. Tricine speeds re-
equilibration of memantine at 
positive voltages in GluN2A-
containing but not GluN2B-
containing receptors. See Results for 
quantification.  
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300 µM NMDA alone and in the presence of NMDA plus 2 µM memantine or ketamine, we 
created inhibition plots analogous to those in Figures 3.5 and 3.7.  We found that at mild to 
moderate depolarizations (up to a peak voltage of -55 mV) memantine and ketamine displayed 
little unblock and acted very similarly during short duration artificial EPSPs (αEPSPs; Figure 
3.8C1). Memantine unblock diverged strongly from that of ketamine only with strong, prolonged 
αEPSPs   (compare Figure 3.8C1, 3.8C2). These data suggest that weak synaptic activity is 
insufficient to relieve synaptic memantine or ketamine block. However stronger activity reveals 
drug differences consistent with observations from voltage-pulse experiments. It is possible that 
the prolonged, strong EPSPs in this experiment mimic the effects of high-frequency nervous 
system activity.  If so, we might expect that spontaneous network activity or high-frequency 
stimulation used to induce LTP might be differentially affected by memantine and ketamine.  
These ideas were tested in subsequent experiments. 
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Figure 3.8. Differences in voltage dependence are detectable only with large, broad 
depolarizations.  A1-A2. Hippocampal neurons were voltage clamped using an artificial EPSP 
(αEPSP) voltage command waveform of short (A1,  = 30 ms) or long (A2,  = 300 ms) duration.  
Cells were bathed in saline, NMDA alone (300 μM), then memantine (2 μM) plus NMDA.  In each 
condition from a Vm of -90 mV, consecutive sweeps simulated EPSPs of increasing amplitude (Vm at 
maximum: -72.5, -55, -37.5,-20 mV). Leak currents in saline were subtracted from each experimental 
condition. Traces represent percent inhibition of the NMDA-only current during the smallest 
depolarization (-72.5 mV, dark red) and largest (-20 mV, bright red), so upward excursion of the 
traces represents relief from drug-induced inhibition. B1-B2. Same protocol for ketamine (2 μM) 
(traces, dark green: -72.5 mV, bright green: -20 mV). C1, C2.  Peak block at each potential for each 
EPSP duration for memantine and ketamine. Colored circles correspond to the conditions represented 
by the traces in A-B. There was no significant interaction between drug and voltage with the brief 
EPSPs (C1, two-way ANOVA, “N.S.,” not significant).  However a significant interaction emerged 
with prolonged EPSPs, with memantine exhibiting more unblock than ketamine upon strong 
depolarization (C2, *p<0.05, drug by voltage interaction, 2 way ANOVA, N=5-6). 
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Memantine and ketamine suppress network activity similarly but diverge in neuroprotective 
ability with extreme depolarization 
Our EPSP data suggest that memantine may more effectively escape the NMDAR channel 
during strong depolarization than ketamine, but it is unclear whether physiological activity 
achieves sufficiently prolonged, strong depolarization to reveal a drug difference, even with 
temporal summation of EPSPs and associated spiking. Furthermore, continuous agonist 
application inherent in the design of Figure 3.8 may have facilitated drug dissociation during 
depolarization.  To test directly whether the subtle difference in voltage dependence, apparent 
under the controlled conditions of Figure 3.8, is detectable under conditions of physiologically 
transient depolarization and agonist presentation, we took a two-pronged approach. We 
examined network effects of the channel blockers using both single-cell recording and network 
activity analysis using multi-electrode arrays. First, using whole-cell recording in hippocampal 
cultures, we measured AMPAR-mediated, network-driven EPSCs as a measure of network 
activity (Figure 3.9A, B). Although NMDAR function was inhibited in the recorded cell by bath 
Mg
2+
 and voltage clamp to -70 mV, NMDARs in the surrounding network were free to 
contribute to spontaneous activity.  We found that a low concentration (2 μM) of memantine and 
ketamine had negligible effects on network activity and did not differ from each other (Figure 
3.9B). In part the weak effects could be due to the presence of physiological Mg
2+
 and glycine 
concentrations (1 mM and 1 μM respectively). Given that the weak effects of the antagonists 
may render differences indiscernible, we increased the antagonist concentration to 10 µM.  At 
this concentration both drugs suppressed network activity by ~30% (memantine: 25 ± 6%, 
ketamine: 32 ± 7%, n=12, Figure 3.9B), but we could again detect no differences between the 
drugs (p>0.05 paired t-test, Figure 3.9B).  
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As a second approach, we measured network activity using multi-electrode-arrays (MEAs) to 
monitor spiking across the network.  MEA recordings permitted us to examine network 
synchrony and spatial relationships not captured by single-cell recordings.  These recordings 
were performed at 37°C and with divalent cations present to mimic physiological conditions.  
We recorded network activity in the presence of 10 µM memantine or ketamine relative to 
baseline activity recorded before drug application and after drug washout (Figure 3.9C). Both 
drugs strongly suppressed network activity as measured by array-wide spike detection rate 
(ASDR) and measures of bursting (Figure 3.9D).  Effects of the two drugs were 
indistinguishable across all measured parameters. 
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Figure 3.9.  Network effects of memantine and ketamine.  A. A neuron was voltage clamped at -70 
mV in a blocker free external solution containing 1 µM glycine. Network activity was measured as 
AMPA-driven sEPSCs onto the neuron over 60 s intervals. Network activity was allowed to stabilize 
for 2 min before baseline data collection, and drugs were allowed 60 s of equilibration before 
recording.  Memantine and ketamine (10 µM) were interleaved between saline recordings, and 
presentation order was reversed from cell to cell.  B. Synaptic activity was quantified as the sum of  
charge transfers exceeding a threshold of 7.5 pA over the 60 s of recording time.  Activity in drug was 
compared with the average activity during baseline and washout conditions.  At 2 µM there was no 
significant effect of either drug on synaptic activity (n=6). However, at 10 µM both drugs depressed 
activity, but depression did not significantly differ between drugs (n =12). C. Multi-electrode array 
(MEA) recordings from cultures in the presence of control media (baseline) or 10 µM memantine or 
ketamine. Representative raster plots are shown from one experiment using sibling cultures for 
memantine and ketamine. D. Overall statistics for array-wide and network properties summarized and 
normalized to baseline. Asterisks indicate significant differences from baseline (indicated by dotted 
gray line). Memantine and ketamine did not significantly differ from each other in any parameter 
tested (n = 10, 2-tailed, unpaired t-test). ASDR: array wide spike detection rate. Bursts were defined as 
described in the Materials and Methods.  
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To explore effects in more intact networks, we examined the effects of ketamine and memantine 
on synaptic plasticity in hippocampal slices.  At concentrations up to 10 µM, neither drug acutely 
affected the induction of long-term potentiation (LTP) elicited by 100 Hz stimulation for 1 s 
(Figure 3.10A). On the other hand, both drugs at concentrations of 1 µM and 10 µM inhibited 
long-term depression (LTD) induction, evoked by prolonged 1 Hz low-frequency stimulation 
(Figure 3.10B).  The difference in effects between the two forms of NMDAR-induced plasticity 
could result from differences in stimulation parameters or other factors (see Discussion).  
Regardless, these results extend the profile of similar pharmacodynamics between the two drugs 
to well-established protocols of plasticity induction and highlight another non-steady-state 
condition (repetitive stimulation) in which the drugs behave quite similarly. 
 
Although the biophysical differences between memantine and ketamine were not evident during 
three assays of physiological and stimulated activity, extreme conditions that evoke prolonged 
NMDAR activation might reveal differences between drugs predicted by Figure 3.8.  To test this 
we challenged cultured hippocampal neurons with OGD and evaluated the neuroprotective 
effects of memantine and ketamine.  In this system synaptic NMDARs play a dominant role in 
mediating excitotoxicity (Wroge et al., 2012).  At the same concentration (10 µM) used for 
network studies, ketamine was significantly more neuroprotective than memantine (Figure 
3.11).  We conclude that under extreme conditions of pathophysiological NMDAR activation, a 
pharmacodynamic difference between memantine and ketamine appears. 
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Figure 3.10: Memantine and ketamine’s effects on LTP and LTD induction. A. LTP induction 
(100 Hz for 1 s, arrow, HFS) was unaffected by 10 µM memantine or ketamine (preapplied for 15 min 
as indicated).  B. LTD induction (1 Hz for 15 min, white bar) was blocked by both drugs (10 µM, 
preapplied for 15 min).   Drugs were administered for the durations shown by the black bars.  LTP and 
LTD in control slices are shown by black circles (A) and white triangles (B).  Six slices were tested 
for each experimental condition in A and B.  Insets show representative fEPSP waveforms.  Data was 
collected and analyzed by Y. Izumi 
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Figure 3.11.  Ketamine promotes 
stronger neuroprotection than 
memantine against OGD.  A.  
Representative fields from DIV13-15 
hippocampal cultures exposed to 2.5 h 
OGD, allowed to recover for 24 h, 
then assayed with propidium iodide 
(red, 3 μM) to stain nuclei of 
compromised neurons.  Propidium 
iodide image is superimposed on a 
phase contrast image.  Drugs were 
evaluated at 10 µM and were present 
during OGD only.  B. Protection index 
of memantine and ketamine was 
calculated by normalizing survival in 
all OGD conditions to survival of an 
untreated sibling dish, and plotting 
drug effects relative to OGD alone. 
Open circles and gray lines indicate 
results of individual experiments using 
sibling cultures treated at the same 
time (n=9). Colored circles are 
averages across all experiments. 
Ketamine neuroprotection was 
significantly greater than memantine 
(p=0.01, paired t-test).  
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DISCUSSION 
Memantine and ketamine exhibit remarkably different clinical properties despite similar activity 
as NMDAR activation-dependent channel blockers.  Our results suggest only slight 
pharmacodynamic differences in voltage dependence between drugs, even under non-steady-
state conditions, that do not become relevant until cells are challenged with pathophysiological 
depolarization and NMDAR activation (OGD).  Thus, pharmacokinetic and dosing differences 
may be more likely than pharmacodynamic differences to explain clinical differences (but see 
Kotermanski et al., 2013) 
 
We aimed to determine whether the two drugs differ in non-equilibrium synaptic actions, which 
have not been explored in detail previously.  Similarities in steady-state block may belie kinetic 
differences that could become more evident during non-steady state conditions of physiological 
activity.  By analogy, the well-known calcium chelators EGTA and BAPTA have similar Kd 
values but differ 100-fold in their kon and koff values.  Differences between these buffers are not 
easily appreciated under equilibrium conditions.  However, the faster buffer BAPTA much more 
effectively depresses synaptic vesicle release during non-equilibrium, depolarization-elicited 
Ca
2+
 influx (Rozov et al., 2001).   In the case of memantine and ketamine, by contrast, steady-
state similarities do not mask non-steady state dissimilarities.  
 
One pharmacodynamic difference may be a selective inhibition by memantine of extrasynaptic 
receptors (Okamoto et al., 2009; Xia et al., 2010).  However, we found that memantine and 
ketamine have indistinguishable actions even at extrasynaptic NMDARs.  Previous experiments 
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arguing for a selective effect of memantine on extrasynaptic receptors compared memantine with 
the slowly dissociating open-channel blocker MK-801 (Xia et al., 2010), but our results 
demonstrate that memantine holds no extrasynaptic preference over ketamine.  Any preference 
for extrasynaptic receptors is likely to result from the slow, sustained agonist presentation of 
ambient neurotransmitter at extrasynaptic receptors, rather than drug preference for certain 
receptor populations (Wroge et al., 2012). 
 
A second hypothesis to explain memantine’s therapeutic profile involves its rapid kinetics 
coupled with its strong voltage dependence. These properties are proposed to allow memantine 
to dissociate rapidly during transient synaptic depolarization and preserve synaptic transmission 
(Parsons et al., 1993; Frankiewicz et al., 1996; Lipton, 2005). During sudden voltage changes, 
contrary to our expectations and previous results (Frankiewicz et al., 1996), we found that 
memantine and ketamine both equilibrated slowly, suggesting little relief from block during 
synaptic depolarization and agonist presentation.     
 
Our conclusion that the efficiency of channel gating affects the time course of relief from block 
during depolarization has implications for prior work investigating blocker kinetics. Past 
estimates of memantine binding kinetics differ by several orders of magnitude across different 
studies (Blanpied et al., 1997; Gilling et al., 2009).  Our results provide a partial resolution.  
Studies using voltage pulses (Frankiewicz et al., 1996) or offset currents following drug washout 
(Gilling et al., 2009), will be susceptible to errors in kon/koff estimates, resulting from low gating 
efficacy.  Some studies of other cell types have found that memantine re-equilibrates at positive 
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potentials much faster than we observed (Frankiewicz et al., 1996).  Although we do not have a 
complete explanation for this discrepancy, one possibility is that the receptors from different 
neuronal populations used in previous work exhibited higher efficacy, yielding faster apparent 
drug re-equilibration (Figure 3.6).    
 
Despite slow overall kinetics, memantine yielded faster voltage-dependent relief from block than 
ketamine and more steady-state relief from block with strong depolarization. What is the basis 
for this difference between drugs?  We suggest that it may reflect differences in channel gating 
while drug is bound.  Although the model that we used does not capture many complexities of 
NMDAR channel gating (Popescu and Auerbach, 2003), it allowed us to test whether differences 
in gating can in principle explain experimentally observed drug differences. We used the 
baseline blocking parameters from Figure 3.6 to represent ketamine-like block.  From this 
baseline, we attempted to recapitulate features of memantine block by doubling ′ (opening rate 
of blocker-bound NMDAR). We first doubled ′ to maintain identical steady-state block at -70.  
This led to a speeding of time course of re-equilibration but no change in steady-state block at 
+50 mV (not shown).  However, if ′ was increased by somewhat less, the simulated steady-state 
block at -70 mV was still very similar to baseline (likely experimentally indistinguishable, Figure 
12), the time course of re-equilibration was accelerated, and the apparently stronger steady-state 
voltage dependence of memantine was recapitulated (Figure 3.12).  Thus, by altering channel 
opening/closing with blocker bound, the two most important differences between memantine and 
ketamine in our experiments were captured.  Note that the apparent voltage dependent drug 
differences were mimicked without adjusting the microscopic voltage dependence (e-fold per 
31.5 mV for both drugs) or microscopic kinetics of drug binding.  Although this explanation for 
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drug differences remains hypothetical, it is attractive in its simplicity and its reliance on the 
previously proposed nature of blocker action (Akk and Steinbach, 2003, Blanpied et al., 2005).   
 
This difference in voltage dependence of the drugs was the sole difference detected, and we 
investigated its potential physiological significance with four experiments: artificial EPSPs, two 
measures of network activity, and plasticity induction.  These results suggest that acute effects of 
the drugs are indistinguishable acting on neuronal circuits in dissociated culture and brain slices.   
This conclusion holds for a wide range of temperatures (22° for sEPSCs, 30° for slices, and 37° 
for MEA recordings) and under conditions in which divalent cation concentrations were near 
physiological 1-2 mM (all studies of physiological activity and toxicity). Thus, although we 
might expect voltage-dependent differences between memantine and ketamine to accumulate 
during spontaneous or evoked high-frequency activity, differences were not evident in our assays 
of network spiking or plasticity induction.  
Figure 3.12: Altering receptor gating while blocker is bound recapitulates experimentally 
observed differences between memantine and ketamine. Simulation output depicted as percent 
NMDA response in the presence of blocker, using the kinetic scheme in Figure 6 (0% at dotted line 
represents full block) for baseline (black, β’: 0.3 s-1, α’: 35.4 s-1, same as Figure 6) and adjusted rate 
constants (red, β’: 0.6 s-1, α’: 55.4 s-1). Adjusted kinetic values were reached by doubling β’ and then 
manipulating α’ to yield similar steady-state block at -70 mV.  Faster kinetics of gating in the blocked 
states resulted in a faster time course of re-equilibration (gray lines represent exponential fits; =883 
ms for red 1393 ms for black) and increased apparent steady-state voltage dependence, similar to the 
experimental difference between memantine (faster, more voltage dependence) and ketamine (slower, 
weaker voltage dependence).  
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The differential effects on LTD vs. LTP of both drugs could have several explanations. 
Differential effects on LTD could reflect selective inhibition of extrasynaptic NMDARs (Xia et 
al., 2010), which have been preferentially associated with LTD (Papouin et al., 2012). However, 
our previous work and results herein suggest little selectivity for extrasynaptic vs. synaptic 
receptors in hippocampal preparations when agonist presentation is held constant (Wroge et al., 
2012; Wild et al., 2013).  LTD also appears to preferentially involve GluN2B-containing 
receptors (Liu et al., 2004; Izumi et al., 2005; Izumi et al., 2006). The slight preference of both 
ketamine and memantine for GluN2B-containing receptors (Figure 3.7) could therefore 
participate in the differential block of LTD.  Another contributor could be differences in 
induction protocols themselves (900 pulses over 900 s vs. 100 pulses over 1 s).  LTD induction is 
associated with less postsynaptic charge transfer than LTP induction (Dudek and Bear, 1992; 
Bear, 1995). This would seem to favor block during LTP induction.  However, NMDAR 
responses during LTD are associated with less overall membrane depolarization, a condition 
favoring block. Tonic receptor activation (Sah et al., 1989; Povysheva and Johnson, 2012) and 
associated accumulated block may also be greater during the longer blocker incubation 
associated with LTD.  Finally, LTP inhibition may require a greater fractional block of receptors 
than LTD inhibition. Previous work showed that 4-6 h of memantine incubation is required to 
inhibit LTP, with an IC50 of ~12 µM.  (Frankiewicz et al., 1996). It is unclear why such a long 
incubation should be required, as much briefer incubation was sufficient in our studies to block 
LTD, and blocker effects on spontaneous activity in MEA recordings inevitably equilibrated by 
<15 min.  It is possible that channel block achieved early in incubation in the Frankiewicz et  al. 
study resulted in complicated downstream signaling cascades, similar to effects seen with 
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ketamine (Autry et al., 2011) and other NMDAR antagonists (Zorumski and Izumi, 2012). 
Regardless of the multifactorial nature of the differential effects of blockers on plasticity, the 
indistinguishable actions of the drugs during plasticity induction emphasize their remarkable 
similarity under varied conditions.  
 
Despite statistical indistinguishability in most assays, ketamine proved more neuroprotective 
than memantine against OGD damage.  We have previously shown that during in vitro OGD 
under our conditions, damage is mainly NMDAR mediated (Hogins et al., 2011; Wroge et al., 
2012).  In the present experiments, we predicted that the sustained depolarization and receptor 
activation produced by OGD would reveal the difference in voltage dependence predicted from 
experiments in Figures 3.5 and 3.8.  Indeed, memantine proved slightly less neuroprotective, 
presumably because of the slightly faster and more complete block relief with depolarization.  
The result is ironic since memantine is the clinically indicated neuroprotectant.  If memantine is 
the better clinical neuroprotectant, off-target effects or other in vivo factors may explain the 
discrepancy with our results. 
 
In summary, we find that the clinically important drugs memantine and ketamine are largely 
pharmacologically indistinguishable under both steady-state and non-equilibrium conditions.  A 
slight difference in voltage dependence is the sole characteristic that distinguishes the drugs.  
Only under severe depolarizing conditions of OGD was this biophysical difference revealed as a 
neuroprotective difference between drugs.  
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ABSTRACT 
Memantine and ketamine are clinically used open channel blockers of the N-methyl-D-aspartate 
receptor (NMDAR) that exhibit remarkable pharmacodynamic similarities despite strikingly 
different clinical profiles. Our previous work highlighted the importance of NMDA channel 
gating in unmasking differences between memantine and ketamine, but it is unclear how positive 
allosteric modulators (PAMs) might impact the pharmacodynamics of blocker actions and 
blocker differences. We used two different positive allosteric modulators: SGE-201, an analogue 
of an endogenous oxysterol 24-hydroxycholesterol, and pregnenolone sulfate (PS), to test how 
positive modulation of channel function alters blocker behavior and whether modulation reveals 
pharmacodynamic differences in single-cell and network effects of ketamine and memantine. 
SGE-201 and PS had no effect on steady-state block or voltage dependence of a channel blocker. 
In contrast, both PAMs increased the actions of memantine and ketamine on phasic EPSCs, but 
neither revealed underlying pharmacodynamic differences. SGE-201 accelerated the time course 
of re-equilibration of blockers during voltage jumps.  SGE-201 also unmasked differences 
between the blockers in neuronal networks – measured either by suppression of activity in multi-
electrode arrays or by neuroprotection against a mild excitotoxic insult. We found that either 
potentiating NMDARs while maintaining the basal activity level or increasing 
activity/depolarization without potentiating NMDAR function is sufficient to unveil 
pharmacodynamic blocker differences in suppressing network function and in neuroprotection. 
Although positive modulation does not reveal pharmacodynamic differences between NMDAR 
blockers at a constant voltage, it does unveil differences during spontaneous network activity. 
We propose that endogenous modulator tone of NMDA receptors in different brain regions may 
underlie differences in the effects of NMDAR blockers on behavior. 
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INTRODUCTION 
Memantine and ketamine are two clinically important NMDAR open-channel blockers. Despite 
prominent clinical differences, the drugs’ pharmacodynamic properties are strikingly similar 
(Gilling et al., 2009; Emnett et al., 2013). We recently showed that strong depolarization reveals 
biophysical differences between the blockers, but transient depolarization during physiological 
activity is not sufficient to unveil this difference (Emnett et al., 2013).  This, in part, results from 
the low open probability of the fully liganded NMDAR channel (Rosenmund et al., 1995; Emnett 
et al., 2013).  It remains unclear whether positive modulators of NMDAR function, which 
increase channel open probability, might alter blocker behavior and expose pharmacodynamic 
differences between the channel blockers during physiological or pathophysiological activity.  If 
so, areas of the nervous system affected by positive modulation may be sites relevant to the 
clinical differences between drugs.    
 
Both ketamine and memantine are trapping-type channel blockers (Chen et al., 1992; Chen and 
Lipton, 1997; Kotermanski et al., 2009) but have largely non-overlapping clinical applications.  
Channel opening is required for blocker association.  Channel gating can occur with blocker 
bound (Blanpied et al., 1997; Chen and Lipton, 1997), and blocker dissociates mainly from the 
open state of the channel.  Dissociation is dramatically accelerated by depolarization.   However, 
the low open probability of the channel is rate limiting for exit from the channel.  Upon strong, 
prolonged depolarization, memantine re-equilibrates faster than ketamine, but both drugs remain 
trapped during brief depolarizations associated with physiological activity (Emnett et al., 2013). 
Memantine is neuroprotective during ischemic injury and is modestly effective at stemming the 
cognitive decline of Alzheimer’s disease (Chen et al., 1998; Culmsee et al., 2004; Tariot et al., 
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2004; Babu and Ramanathan, 2009). Ketamine is an anesthetic and analgesic, and has recently 
generated excitement in psychiatry as a rapid-acting anti-depressant (Aan Het Rot et al., 2012; 
Marland et al., 2013; Murrough et al., 2013).  Although pharmacokinetic differences between the 
drugs likely participate in different clinical actions, pharmacodynamic differences might also 
contribute (Gilling et al., 2009; but see Kotermanski et al., 2013).  
 
The brain contains many endogenous positive allosteric modulators (PAMs) of NMDA channel 
function, including pregnenolone sulfate (PS) and 24S-hydroxycholesterol. PS is a neurosteroid 
that potentiates NMDA receptor function but also negatively modulates GABAA receptors (Wu 
et al., 1991; Horak et al., 2004). 24S-hydroxycholesterol is the major metabolite of brain 
cholesterol and accounts for nearly 50% of cholesterol’s turnover and clearance from the brain 
(Lund et al., 2003; Karu et al., 2007).  It is a potent PAM of NMDARs at concentrations found in 
vivo.  Its synthetic analogue SGE-201, which we employ in the present study, has experimental 
advantages, including superior water solubility and reversibility (Paul et al., 2013).  24S-
hydroxycholesterol and SGE-201 selectively potentiate NMDAR, but not AMPAR or GABAAR, 
mediated synaptic currents (Paul et al., 2013; Linsenbardt et al., 2014).      
 
Here we test the hypothesis that PAMs may unmask biophysical differences between channel 
blockers. In the first part of our work we evaluate the impact of positive allosteric modulators, 
pregnenolone sulfate and SGE-201, on trapping channel block.  We then evaluate the impact of 
the more specific modulator, SGE-201, on pharmacodynamic differences between ketamine and 
memantine, two blockers that exhibit very subtle pharmacodynamic differences at baseline. We 
hypothesize that positive modulation will increase the probability of blocker dissociation during 
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depolarization, thereby allowing physiological activity to unveil biophysical difference between 
blockers.  We find that pregnenolone sulfate and SGE-201 did not alter steady-state block but 
altered blocker actions during phasic agonist presentation. Despite accelerating kinetics of block, 
increasing channel open probability did not unmask blocker differences when voltage was 
constant. However, positive modulation did accelerate voltage-dependent blocker re-
equilibration into a time domain potentially relevant for synaptic responses. Exploiting the 
selectivity of SGE-201 for NMDARs, we found that SGE-201 exposes differences between the 
actions of memantine and ketamine on network activity and on cell survival following 
excitotoxic insult. Either NMDAR potentiation during basal network activity or strongly 
increased network activity without NMDAR potentiation was sufficient to unveil these 
pharmacodynamic differences. Thus, we conclude that unusually low channel open probability 
masks pharmacodynamic differences between ketamine and memantine, but PAMs expose this 
difference. We propose that differences in endogenous modulator tone in different areas of the 
nervous system could lead to differences between effects of memantine and ketamine on 
behavior.  
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MATERIALS AND METHODS 
Cell cultures. Hippocampal cultures were prepared as either mass cultures or microcultures (as 
indicated in figure legends) from postnatal day 1-3 female rat pups anesthetized with isoflurane, 
under protocols consistent with NIH guidelines and approved by the Washington University 
Animal Studies Committee.  Methods were adapted from earlier descriptions (Huettner and 
Baughman, 1986; Bekkers et al., 1990; Tong and Jahr, 1994; Mennerick et al., 1995).  
Hippocampal slices (500 μm thickness) were digested with 1 mg ml-1 papain in oxygenated 
Leibovitz L-15 medium (Life Technologies, Gaithersburg, MD, USA).  Tissue was mechanically 
triturated in modified Eagle's medium (Life Technologies) containing 5% horse serum, 5% fetal 
calf serum, 17 mM D-glucose, 400 μM glutamine, 50 U ml-1 penicillin and 50 μg ml-1 
streptomycin.  Cells were seeded in modified Eagle's medium at a density of ~650 cells mm
-2 
as 
mass cultures (onto 25 mm cover glasses coated with 5 mg ml
-1
 collagen or 0.1 mg ml
-1
 poly-D-
lysine with 1 mg ml
-1
 laminin) or 100 cells mm
-2
 as "microisland" cultures (onto 35 mm plastic 
culture dishes coated with collagen microdroplets on a layer of 0.15% agarose).  Cultures were 
incubated at 37° C in a humidified chamber with 5%CO2/95% air.  Cytosine arabinoside (6.7 
μM) was added 3-4 days after plating to inhibit glial proliferation.  The following day, half of the 
culture medium was replaced
 
with Neurobasal medium (Life Technologies) plus B27 supplement 
(Life Technologies).  
 
Xenopus oocyte expression: cRNA encoding rat NMDAR subunits was injected into stage V–VI 
oocytes harvested from sexually mature female Xenopus laevis frogs (Xenopus 1, Northland, 
MI). Frogs were anesthetized with 0.1% tricane (3-aminobenzoic acid ethyl ester) during a 
partial ovariectomy. Oocytes were defolliculated by shaking for 20 minutes at 37°C in 2 mg ml
-1
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collagenase dissolved in a calcium-free solution containing (in mM): 96 NaCl, 2 KCl, 1 MgCl2, 
and 5 HEPES, pH 7.4. Capped RNA for GluN1a and GluN2A subunits was prepared in vitro 
(mMESSAGE mMachine kit, Ambion, Austin, TX) from linearized pBluescript vectors. Subunit 
RNA was injected in equal parts (50 ng of total RNA). After injection, oocytes were incubated at 
18° C in ND96 solution containing (in mM): 96 NaCl, 2 KCl, 2 CaCl2, 1 MgCl2, and 5 HEPES, 
pH 7.4. ND96 was supplemented with pyruvate (5 mM), penicillin (100 U ml
-1
), streptomycin 
(100 μg ml-1), and gentamycin (50 μg ml-1).  
 
Electrophysiology. Whole-cell recordings were performed at room temperature from neurons 
cultured for 4-10 days (depending on the experiment) using a Multiclamp 700B amplifier 
(Molecular Devices, Sunnyvale, CA, USA) and Digidata 1440A converter with Clampex 10.1 
software.  Young cells were favored for biophysical experiments to minimize voltage-clamp 
errors, and older, synaptically mature cells were used for EPSC measurements. For recordings, 
cells were transferred to an extracellular (bath) solution containing (in mM): 138 NaCl, 4 KCl, 2 
CaCl2, 10 glucose, 0.01 µM glycine and 10 HEPES, pH 7.25 adjusted with NaOH, 25-50 µM  D-
APV was included until seal formation to prevent excitotoxicity.  Solutions with adjusted 
composition described below were perfused using a gravity-driven local perfusion system from a 
common tip. The estimated solution exchange times were <100 ms (10-90% rise), estimated 
from junction current rises at the tip of an open patch pipette. For synaptic recordings, these 
solutions contained (in μM) 2,3-dihydroxy-6-nitro-7-sulfonyl-benzo[f]quinoxaline (NBQX) and 
25 bicuculline methobromide or 10 gabazine. For exogenous NMDA application, 0.25 mM 
CaCl2 was used (in APV-free perfusion solutions) to minimize Ca
2+
-dependent NMDAR 
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desensitization (Zorumski et al., 1989), and 250 nM tetrodotoxin was added to prevent network 
activity. Unless otherwise noted, exogenous NMDA concentration was 30 µM.  
 
The tip resistance of patch pipettes was 3-6 MΩ when filled with an internal solution containing 
(in mM): 130 potassium gluconate, 0.5 CaCl2, 5 EGTA, 4 NaCl, and 10 HEPES at pH 7.25, 
adjusted with KOH.  Potassium was used as the main intracellular cation for autaptic stimulation 
to preserve action potential waveform, but in experiments examining current responses to 
exogenous agonists, cesium methanesulfonate replaced potassium gluconate to block potassium 
channels and improve spatial voltage clamp quality.  Holding voltage was typically -70 mV 
unless otherwise noted.  Access resistance (8-10 MΩ was compensated 80-100% for EPSC 
measurements. For
 
evoked EPSCs, cells were stimulated with 1.5 ms pulses
 
to 0 mV from -70 
mV to evoke autaptic transmitter release (Mennerick et al., 1995). EPSC decays were fit with a 
biexponential function in Clampfit using Levenberg Marquart or variable metric fit parameters. 
Weighted time constants (w) were calculated for data analysis.  
 
Oocyte responses to NMDA were recorded 2–5 days following RNA injection using a two-
electrode voltage clamp (OC725C amplifier; Warner Instruments, Hamden, CT) at a membrane 
potential of −70 mV. The bath solution was ND96 solution with the following changes: Mg2+ 
was omitted, Ba
2+
 replaced Ca
2+
 to avoid activation of endogenous Ca
2+
-dependent currents, and 
10 µM glycine was added. Glass recording pipettes (∼1 MΩ resistance) were filled with 3 M 
KCl. Compounds were applied by gravity to the oocytes using a multibarrel pipette with a 
common output tip. Data acquisition and analysis were performed with pCLAMP software 
(Molecular Devices).  
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Multi Electrode Arrays: Mass cultures were seeded on multielectrode arrays (MEAs, 
Multichannel Systems) for network analysis (Mennerick et al., 2010). Recordings were 
performed 14-15 days in vitro.  For figures and statistics, effects of drugs over a 30 min 
recording period were compared with the average of activity (30 min) before drug administration 
and following drug washout. If a PAM (such as cyclothiazide or SGE-201) was present, the 
baseline recordings contained the PAM.  Array-wide spike detection rate was measured as the 
total number of spikes across the entire array in each second of recording, averaged across the 
entire recording (Wagenaar et al., 2006; Mennerick et al., 2010).  Average ASDRs are given in 
the figure legends.  Because of the large differences in absolute baseline ASDR among cultures 
(Wagenaar et al., 2006), statistics were performed on drug effects normalized to baseline ASDR.  
 
To reduce activity to baseline levels in the presence of SGE-201 on NMDAR blockers, we 
titrated NBQX or TTX concentration in the presence of the PAM.  We employed 100 nM NBQX 
(N = 5) or 10 nM TTX (N = 6).  Experiments in which activity was not reduced below 2-fold 
from baseline were excluded from analysis.  Trends with both activity blockers were similar, so 
results were pooled for analysis.   
 
Hypoxia: Mass cultures (13–14 DIV) were exposed to hypoxia in a commercially available 
chamber (Billups-Rothenberg, Del Mar, CA), humidified and saturated with 95% nitrogen and 
5% CO2 at 37°C, for 2.5 h. The gas exchange followed the specifications of the chamber 
manufacturer (flow of 20 L min
-1
 for 4 min to achieve 100% gas exchange).  Original medium 
was exchanged for conditioned media containing the specified drugs immediately prior to 
hypoxia exposure. Following hypoxia, cells were returned to their original medium and 
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incubated under standard culture conditions until the cell death assay (24 h later). We used 
Hoechst 33342 (5 μM) to identify all nuclei and propidium iodide (PI, 3 μM) for 30 minutes to 
stain nuclei of cells with compromised membranes. Five 10x microscope fields were quantified 
per condition per experiment, yielding > 100 total neurons for each condition.  Ratios of healthy 
neurons were quantified as the fraction of propidium iodide-negative neuronal nuclei to total 
neuronal nuclei.  Automated cell counting algorithms (ImageJ software) were used for cell 
counts. Toxicity experiments were treated as a dependent sample design (Zar, 1999) in which 
sibling cultures plated in identical media and exposed to hypoxia at the same time were 
compared by repeated measures statistics.   
 
Drugs. SGE-201 was synthesized by previously published methods (Paul et al., 2013).   
Memantine, D-APV, NBQX and TTX were purchased from Tocris (UK). (R, S) ketamine, 
bicuculline methobromide, gabazine, PS, and cyclothiazide were purchased from Sigma (St. 
Louis).  
 
 
 
 
 
 
 
 
 
128 
 
RESULTS 
Positive allosteric modulation does not alter steady-state inhibition by memantine.  
Previous studies are equivocal on whether channel open probability, usually manipulated with 
agonist concentration, influences steady-state inhibition by trapping channel blockers.  Here we 
used memantine to test the principle.  Inhibition by trapping blockers increases with agonist 
concentration in vitro and in simulations (Chen et al., 1992; Chen and Lipton, 1997), but other 
studies found that agonist concentration does not influence memantine IC50 (Gilling et al., 2007).  
To test whether PAMs that increase channel open probability influence the steady-state potency 
of trapping-type blockers, we generated concentration-inhibition plots for memantine in the 
presence and absence of SGE-201 or pregnenolone sulfate (PS) in Xenopus oocytes expressing a 
homogeneous receptor population of GluN1a/GluN2A subunits. Pregnenolone sulfate (50 µM) 
increased peak responses to 30 µM NMDA 3.0 ± 0.3 fold (N =7) but failed to significantly 
influence memantine IC50 (Figure 4.1A-B).  Similarly, SGE-201 (1 µM) potentiated NMDA 
responses 3.4 ± 0.5 fold (N =11) but did not affect steady-state inhibition by memantine (Figure 
4.1C-D).   We also tested the comparator channel blocker ketamine, which we and others have 
shown to be pharmacodynamically very similar to memantine (Gilling et al., 2009; Emnett et al., 
2013).  Figure 4.1E-G shows that positive modulation by SGE-201 also did not affect the IC50 
for ketamine block.  This demonstrates that conclusions about the effect of positive modulation 
extend to other similar trapping channel blockers.     
 
This result suggests that increasing channel open probability does not significantly affect the 
potency of trapping channel blockers.  To extend these results, we examined steady-state 
memantine inhibition at both positive and negative membrane potentials to test whether PAMs 
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interact with the voltage dependence of inhibition (Figure 4.2A-B).  For these studies we used 
cultured neurons, where kinetics of block could be more readily examined in whole-cell 
recordings. We found that neither PS nor SGE-201 influenced steady-state inhibition observed 
with a fixed concentration of memantine (Figure 4.2C-D).  Both the onset and offset time 
constant of block at -70 mV, significantly decreased with SGE-201 (Figure 4.2E). The alteration 
in kinetics is consistent with a mechanism of allosteric modulation that increases channel open 
probability, enhancing blocker access to its channel binding site. The effect of PS on blocker 
onset/offset time constants was much weaker than that of SGE-201, and neither rate constant was 
significantly altered (Figure 4.2F). This is consistent with the observation that although PS 
potentiated peak NMDA current, it had less effect on steady-state current.  This is likely 
explained by the mixed potentiating/inhibiting actions of PS (Horak et al., 2004). These results 
suggest that SGE-201 may be a purer potentiator and/or have a different mechanism of action 
than PS.  
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Figure 4.1: Positive allosteric modulation does not affect steady-state memantine IC50. A. NMDA (30 
µM) responses in Xenopus oocytes injected with GluN1a-GluN2A receptor RNA were recorded in the 
absence and then presence of increasing concentrations of memantine (0.3, 1, 3, 30 μM) in saline or in the 
presence of PS (50 µM). Memantine concentrations are indicated below the top trace.  B.  Concentration-
response curves in control conditions and in the presence of PS (N = 11).  Solid lines represents fits to the 
Hill equation of the form I = Imax * C
n
 / (IC50
n 
+ C
n
), where Imax is maximum current in the absence of 
agonist, C is antagonist concentration, n is the Hill coefficient, and IC50 is the concentration inhibiting 50% 
of the response. Memantine IC50 was calculated to be 1.4 μM in the presence or absence of PS.  C and D. 
Representative traces and summary of memantine effects in the absence and presence of SGE-201 (1 µM; N 
= 7).  Solid lines represent fits to the Hill equation. Memantine IC50 values are 1.0 μM in the absence of 
SGE-201 and 1.1 μM in the presence of SGE-201.  Neither potentiator significantly altered IC50 
concentration of memantine (p>0.05, unpaired t-tests). E and F. Similar experiment as C and D except 
ketamine was employed as channel blocker.  IC50 values were 0.5 µM (absence of SGE-201; N = 11) and 0.6 
µM (presence of SGE-201; N = 5). There was no significant difference in calculated IC50s between control 
and SGE-201 treated cells (p> 0.05, unpaired t-test).   Although ketamine IC50 values trended lower than 
those for memantine, fits of individual cells produced average IC50 values that did not significantly differ 
from those of memantine (Emnett et al., 2013). 
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Figure 4.2.  Positive allosteric modulation does not affect the voltage dependence of 
memantine at steady-state. A-B. Representative traces depicting memantine (10 μM) block of a 
baseline NMDA (30 μM) response (A1, B1, black) and then from the same cell in the presence of 
SGE-201 (1 μM, blue, A2) or PS (50 μM, teal, B2) at holding potentials of -70 mV and +50 mV. 
SGE-201 and PS were pre-applied for one minute and subsequently co-applied with NMDA. C-D. 
Average block achieved at -70 or +50 mV in the absence or presence of SGE-201 (C) or PS (D). 
Neither SGE-201 nor PS altered steady-state memantine block at either holding potential (N.S. = not 
significant; p>0.05, unpaired t-test). E. SGE-201 significantly potentiated both peak and steady-state 
(SS) currents and significantly decreased the weighted time constant (w) of onset and the single 
time constant of offset  of memantine block at -70 mV (***p<0.001, *p<0.05; unpaired single-
sample t-test, N=9). F. PS also significantly potentiated the response at the peak and steady state, 
but did not significantly alter onset or offset time constants of memantine block. (***p<0.001, 
*p<0.05, unpaired single-sample t-test, N=10).   
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Positive allosteric modulation enhances EPSC suppression by memantine  
The actions of trapping channel blockers are strongly affected by temporal features of agonist 
presentation and ensuing NMDAR activation (Xia et al., 2010; Wroge et al., 2012; Emnett et al., 
2013).  Despite the lack of change in steady-state inhibition, perhaps transient, synaptic 
glutamate presentation to NMDARs supports a PAM-induced change in blocker effect because 
of faster blocker equilibration kinetics.  We tested this principle on evoked, recurrent EPSCs 
stimulated in hippocampal autapses challenged with PS  and with PS plus blocker (Figure 4.3).  
PS (50 µM) had prominent effects on the NMDAR EPSC decay time constant and also increased 
peak NMDAR EPSC amplitude (Figure 4.3A-B), resulting in a strong potentiation of 
postsynaptic charge  (Figure 4.3C).  From the potentiated baseline, PS exaggerated the effect of 
memantine on EPSC decay kinetics and on peak EPSC amplitude (Figure 4.3D-F). Thus, in 
contrast to steady-state effects of memantine, which are unaffected by PAMs, synaptic effects of 
the channel blocker are augmented by PAMs.   
 
SGE-201 has an apparently different mechanism of action compared with PS (Paul et al., 2013).  
We previously showed that SGE-201 does not have a prominent effect on EPSC decay time 
course (Paul et al., 2013).  Consistent with this, in the present dataset, SGE-201 marginally 
prolonged EPSC decays (weighted = 347± 17 ms, N = 33, vs. 408 ± 25 ms, N = 34; p=0.049). 
Conversely, SGE-201 enhanced peak amplitude roughly two-fold (control cells vs. SGE-201 
cells: -2.7 nA vs. -4.6 nA, p=0.01, N=33-34).  Thus, unlike PS, SGE-201 affected EPSC decay 
only weakly, with primary effects on EPSC peak amplitude.  Nevertheless, like PS, SGE-201 
enhanced memantine’s effects on EPSC decay (Figure  4.3G, I). 
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Positive allosteric modulation by SGE-201 fails to distinguish memantine from ketamine  
The interaction between PAMs and memantine on EPSCs shows that blocker function is altered 
by increasing channel open probability.  Does this alteration extend to other blockers, 
particularly ketamine?  We previously showed that biophysical differences between memantine 
and ketamine are unapparent when receptors are activated briefly and transiently by synaptic 
release in the absence of a PAM, and blocker differences are masked by low channel open 
probability (Emnett et al., 2013).   At a fixed membrane potential of -70 mV, we found that SGE-
201 also augmented the actions of ketamine (Figure 4.3H).  However, effects of ketamine and 
memantine were still indistinguishable (Figure 4.3I). The inability to distinguish memantine 
from ketamine persisted in a paradigm of progressive block (stimulation frequency 0.03 Hz in 
Figure 4.3 (Previous Page). Positive allosteric modulation does not differentiate between actions 
of memantine and ketamine during synaptic activation.  Representative NMDAR-EPSCs in saline 
(black) and with 50 μM PS (teal). Inset: scaled traces to highlight the prolonged EPSC decay. B. 
Summary of PS effect on the weighted time constant of EPSC decay (w; **p<0.01 paired t-test, N=9). 
C. PS potentiated the NMDAR EPSC peak amplitude and total charge (*p<0.05, unpaired t-test 
relative to baseline, N=9). D-E: Representative traces depicting memantine’s effects on NMDAR-
EPSCs in control conditions (D) or with PS (E). F. PS increased the effect of memantine on NMDAR 
EPSC decay kinetics (i.e., accelerated the decay), peak and charge transfer, measured as percent of 
memantine’s baseline in absence of PS (N=10-11, **p<0.01, *p<0.05).  G-H.  Autaptic EPSCs 
evoked in saline (black) or in SGE-201 (1 µM; blue) with or without memantine (dark and bright red 
traces respectively) or ketamine (dark and bright green traces, respectively). Saline and SGE-201 
traces are from separate cells, and SGE-201 was continuously present throughout recording.  I. SGE-
201 augmented the effect of memantine and ketamine (bright red and bright green bars) on W and 
charge transfer of the NMDA EPSC compared to baseline effects (dark red and dark green bars). 
There was no difference in the effects of memantine and ketamine (N=15-19, *p<0.05 unpaired t-test, 
within blocker comparison; p>0.05 unpaired t-test, between blocker comparison). J. Cumulative 
blocking plots in the continuous presence of memantine (red) or ketamine (green) during 0.03 Hz 
stimulation of EPSCs. Memantine and ketamine reached maximal block, measured by peak amplitude 
(left) or charge transfer (right), with indistinguishable time courses in the presence of SGE-201 and 
also recovered similarly, implying a similar degree of trapping (N=6, p>0.05, unpaired t-test).  
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the presence of blocker) and recovery from block (Figure 4.3J).  The similar recovery time 
course suggests that any differences in partial trapping between memantine and ketamine 
(Kotermanski et al., 2009) are not readily evident with synaptic activation of NMDARs.    
 
PAM shifts voltage-dependent blocker re-equilibration to a physiologically relevant time 
domain 
In the absence of NMDAR modulation, a difference between ketamine and memantine emerges 
in the rate constants of re-equilibration during strong depolarization.  Furthermore, increasing 
channel open probability by chelating a negative modulator (Zn
2+
) or raising glycine 
concentration speeds blocker re-equilibration (Emnett et al., 2013).  Accordingly, we found that 
SGE-201 accelerated re-equilibration kinetics of both memantine and ketamine during a voltage 
pulse (for memantine: 928±177 ms, control vs. 369 ± 40 ms, SGE-201 vs. ketamine: 1138 ± 164 
ms, control vs.  590 ± 46 ms N=19-20) (Figure 4.4). In the absence of modulator, kinetics are 
sufficiently slow that both ketamine and memantine remain trapped during physiological 
activity, leading to indistinguishable blocker effects during baseline activity.  However, SGE-201 
reduced re-equilibration time constants to values that could be influenced by excitatory 
postsynaptic potentials (EPSPs; Figure 4.4C).   
 
In summary, we found that PAMs influence non-steady state inhibition but not steady-state 
NMDAR inhibition by clinically interesting NMDAR channel blockers. PAM activity alone at a 
fixed membrane potential near rest was insufficient to reveal a difference between memantine 
and ketamine. However, oxysterol PAM activity speeds voltage-dependent re-equilibration.  In 
this case, oxysterols shift the kinetics of blocker actions into a time domain possibly relevant for 
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synaptic potentials and activity. Thus, we examined the differences between the drugs in 
measures of network activity and pathological depolarization to discern if oxysterol presence can 
unmask latent blocker differences (Emnett et al., 2013).  
 
Oxysterols unmask physiologically relevant differences between memantine and ketamine in 
neuronal networks.  
We have previously shown that memantine and ketamine suppress physiological network 
activity indistinguishably, measured by array-wide spike detection rate (ASDR) in MEA 
recordings.  We were able to unveil memantine and ketamine differences only during strong 
pathophysiological depolarization with oxygen-glucose deprivation (Emnett et al., 2013). In the 
present work we evaluated whether the acceleration of voltage-dependent blocker re-
equilibration in the presence of a PAM unmasks blocker differences.   
 
First, we tested whether SGE-201 increases network activity in a solely NMDAR-dependent 
manner (Figure 4.5A-B). SGE-201 (1 µM) approximately doubled ASDR, and the effect was 
entirely reversed by the high-affinity, non-competitive NMDAR antagonist MK-801 (15 μM) 
(Figure 4.5B).  This suggests that SGE-201’s neuromodulatory effects are specific for NMDAR 
function. This is unlike PAMs such as PS, Zn
2+
 chelators, arachidonic acid and other modulators, 
virtually all of which have important off-target effects (Deutsch et al., 1992; Fraser et al., 1993).  
Thus, SGE-201 offers a selective tool to evaluate the role of NMDAR efficacy in network 
function.  In contrast to previous results in which memantine and ketamine had indistinguishable 
effects on ASDR (Emnett et al., 2013) (replicated independently in Figure 4.5), SGE-201 
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unmasked a stronger effect of ketamine compared with memantine on ASDR, consistent with 
faster voltage-dependent re-equilibration kinetics of memantine (Figure 4.5D).  
 
Figure 4.4. Positive modulation accelerates blocker re-equilibration during voltage jumps to 
time domains relevant to synaptic transmission. A-B. Representative traces depicting baseline 
NMDA responses at -70 mV and +50 mV (300 μM, black) and NMDA plus SGE-201 (1 μM, 
blue). Currents in the absence of NMDA have been digitally subtracted.  The right panels show 
responses in the presence of memantine (A, 10 μM, red) and ketamine (B, 10 μM, green).  Right 
traces represent fractional responses calculated by dividing currents in the presence of blocker by 
currents in the absence of blocker, shown as a percentage of each baseline.  Dotted lines indicate 
0% and 100% of original NMDA current as indicated.  Solid black lines in right traces indicate 
least-squares bi-exponential fits to re-equilibration of the blocker at +50 mV.  C. The time course 
of re-equilibration after the voltage jump from -70 mV to +50 mV was estimated from fits like 
those in right panels of A and B for memantine and ketamine in the presence and absence of SGE-
201. SGE-201 accelerated the rate constant of re-equilibration to a time-domain potentially 
relevant to EPSPs (**p<0.01, paired t-test, N=19 each).  
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This difference could be unmasked as a direct result of the enhanced NMDAR channel open 
probability caused by SGE-201, or it could result from the more intense activity (depolarization), 
a secondary consequence of SGE-201 treatment.  To test whether enhanced activity alone is 
sufficient, we increased network firing without SGE-201 by applying the AMPAR PAM and 
presynaptic potentiator cyclothiazide (CYZ, 10 µM, Figure 4.6A) (Partin et al., 1993; Yamada 
and Tang, 1993; Ishikawa and Takahashi, 2001).  Average ASDR increased in the presence of 
Figure 4.5. SGE-201 unmasks memantine versus ketamine differences in suppression of network 
activity. A. Representative raster plots from MEAs depicting baseline and SGE-201 (1 µM) activity in 
normal medium and with medium containing 15 μM MK-801. B. SGE-201 potentiated MEA array-
wide-spike-detection rate (ASDR, baseline: 19.3 ± 8.2 without SGE-201 vs. 53.1 ± 33 with SGE-201). 
This effect was blocked by MK-801 (*p<0.05 compared to SGE-201 alone, N=6). C. Representative 
raster plots depicting baseline, memantine (10 μM), and ketamine (10 μM) conditions in the presence of 
SGE-201 (1 μM). Blocker recordings (30 min) were interleaved between baseline and wash periods 
(both 30 min). SGE-201 was included in the baseline, drug, and wash conditions. D. Normalized ASDR 
with memantine (10 μM) and ketamine (10 μM) compared to baseline response (average of the baseline 
and wash conditions). Dark red and green bars are normalized values in SGE-201-free conditions 
(baseline: 48 ± 9, N=10,  p>0.05, unpaired t-test, N=5 paired experiments) and represent an independent 
replication of earlier results (Emnett et al., 2013). Bright red and green bars are in the continual 
presence of SGE-201 (baseline: 56 ± 6, N=22,*p<0.05, unpaired t-test, N=11 paired experiments).  
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CYZ similar to the effect of SGE-201 (Figure 4.6B). As with SGE-201 potentiation, the increase 
in activity unmasked a significant difference between memantine and ketamine (Figure 4.6C). 
This suggests that sufficiently strong activity per se unmasks the biophysical difference between 
the NMDAR blockers.   
 
We then examined the effect of increasing channel gating alone with SGE-201, while 
counteracting the secondary increase in network activity with subsaturating concentrations of 
either 10 nM tetrodotoxin (TTX) or 100 nM NBQX.  Both inhibitors yielded similar trends so 
results were pooled.  In cultures in which the increase in ASDR by SGE-201 was inhibited 
(Figure 4.6B), the difference between memantine and ketamine in the presence of SGE-201 was 
preserved (Figure 4.6D). We conclude that either increased activity or positive NMDAR 
modulation in the context of basal activity is sufficient to reveal NMDAR blocker differences on 
network functioning. 
 
We also examined the implications of PAM activity for NMDAR-dependent excitotoxicity 
elicited by hypoxia.  We titrated the duration of hypoxia to yield ~50% cell death in the absence 
of SGE-201.  Under these conditions, there was only a trend-level difference between the 
neuroprotective effects of memantine and ketamine (Figure 4.7A-B). This contrasts with a more 
severe insult, which yielded a more pronounced difference between blockers consistent with the 
difference in voltage-dependent re-equilibration (Emnett et al., 2013).  In the presence of SGE-
201 (0.2 - 1 μM), which increased hypoxic damage, ketamine neuroprotection was significantly 
greater than that of memantine (Figure 4.7C). As with changes in network activity, we explored 
whether stronger depolarization or increased channel open probability is sufficient for the effects 
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observed.  To address this distinction, we repeated this experiment using exogenous NMDA as 
the excitotoxin in the presence of 0.5 µM tetrodotoxin.  This allowed us to control more 
precisely the level of depolarization experienced by cells in the presence of SGE-201 and to limit 
excitotoxic contributions of endogenous glutamate. Pilot experiments demonstrated that 8 µM 
NMDA for 2.5 h alone produced cell death similar to that observed with hypoxia.  Further 
experiments showed that 8 µM NMDA yielded depolarizing currents equivalent to those 
generated by 4-5 µM NMDA in the presence of 0.2 µM SGE-201 (Figure 4.8A).  Treating cells 
with 8 μM NMDA or with 4-5 μM NMDA plus SGE-201 resulted in similar cell death, verifying 
that we achieved the desired matching.  Nevertheless, effects of ketamine vs. memantine were 
markedly different in the two conditions. While both drugs alone protected equivalently against 
NMDA toxicity, ketamine protected significantly more than memantine when  SGE-201 was 
present (Figure 4.8B).  This suggests that when depolarization is matched, augmented channel 
function is sufficient to unmask a neuroprotective difference between memantine and ketamine.  
 
Our data from both network arrays and from excitotoxic insults suggest that either positive 
allosteric modulation in the context of basal depolarization or strong activity/depolarization 
alone can unmask differences between memantine and ketamine. Importantly, these modulators 
are capable of unveiling differences between memantine and ketamine in in vitro models of 
network and pathological activity.  
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Figure 4.6.  Excessive activity alone or basal activity plus SGE-201 differentiates the effects of 
NMDAR blockers on network function. A. Representative rasters depicting baseline conditions and 
10 µM cyclothiazide, cyclothiazide + memantine, and cyclothiazide + ketamine conditions. B. ASDR 
normalized to baseline following addition of cyclothiazide or SGE-201 (1 μM) + activity blockers (10 
nM TTX or 100 nM NBQX – see Methods). The dashed grey line indicates average potentiation 
achieved with SGE-201 alone. The dotted grey line represents no potentiation. Average raw ASDR 
values with CYZ were 86 ± 15 compared to 42 ± 11 before treatment. Raw ASDR values with SGE-
201 and activity blockers were 38 ± 7 compared to 42 ± 7 before treatment. C. In the presence of 
cyclothiazide, memantine and ketamine, each at 10 μM, strongly diverge in their ability to suppress 
ASDR (*p<0.05, N=7). D. The presence of SGE-201 induced a difference between memantine and 
ketamine, even in the presence of activity suppressors (*p<0.05, N=11) 
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Figure 4.7. SGE-201 presence reveals differences between memantine and ketamine 
neuroprotection during hypoxia. A. Hippocampal cultures were exposed to hypoxia (95% N2, 5% 
CO2, see methods), for 2.5 h. Cell death was assessed 24 h post insult using propidium iodide (PI, 3 
μM). Images depict representative fields (10X) of control, hypoxia, and memantine and ketamine 
dishes; red dots indicate dead (i.e PI positive) neurons. For analysis, Hoescht stain (5 μM) was also 
included to identify the total neuronal population (not shown). B. Without SGE-201, memantine and 
ketamine protected similarly against the hypoxic insult (survival with memantine: 67 ± 3% vs. 
ketamine: 72 ± 3%, p= 0.035, paired t-test, N=12). C. In the presence of 0.2-1 μM SGE-201, a 
significantly stronger difference emerged between memantine and ketamine neuroprotection (survival 
with memantine: 54 ± 3% vs. ketamine: 70 ± 3%, *p<0.05, within experiment paired t-test; p<0.001 
for a significant interaction between SGE-201 and blocker neuroprotection: 2-way ANOVA, N=8). 
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Figure 4.8. SGE-201 presence alone distinguishes neuroprotective effects with matched 
depolarization. A. Neuronal response to the indicated concentrations of NMDA and SGE-201. 4-5 
μM NMDA in the presence of 0.2 μM SGE-201 was equivalent to 8 μM NMDA alone. B. Normalized 
survival, relative to untreated cultures, is shown for the indicated concentrations of NMDA, SGE-201 
and memantine or ketamine. Although the amount of death achieved by baseline and SGE-201 alone 
was indistinguishable, suggesting similar depolarization, ketamine protected significantly more than 
memantine in the SGE-201 condition (N=5, *P<0.001, 2-way ANOVA). TTX (500 nM) was present 
throughout the entire toxicity experiment to prevent action potentials.  
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DISCUSSION 
Memantine and ketamine are of interest because of their clinical differences but similar 
underlying pharmacodynamic effects. We previously demonstrated that the low open probability 
of the NMDA receptor channel masks pharmacodynamic differences between the two drugs 
under basal conditions, and we found differences only when cells are subjected to extreme 
depolarization during oxygen-glucose deprivation (Emnett et al., 2013). However it was unclear 
whether positive modulation of NMDARs could unmask differences detectable during 
physiological network activity.  Here, we show that increasing NMDAR channel open 
probability with PAMs separates drug actions in measures of network activity and 
neuroprotection. These PAM-induced differences emerge only under conditions of dynamic 
depolarization, not during steady-state agonist presentation or at constant voltages near rest. Our 
results suggest that regions of the brain that exhibit strong endogenous modulation of NMDARs 
and/or particularly strong activity patterns may be a focus for understanding differences between 
the drugs in vivo.   
 
Previous work is equivocal on the point of whether blocker IC50 is affected by channel open 
probability, as manipulated with agonist concentration (Chen and Lipton, 1997; Gilling et al., 
2007).  As an uncompetitive antagonist, memantine requires channel opening for binding. While 
increasing agonist concentration certainly alters blocker access to the channel and speeds kinetics 
(Chen and Lipton, 1997), the effect on steady-state block is less clear.  A simple model of 
trapping block (Blanpied et al., 1997; Emnett et al., 2013) leads to a predicted shift in blocker 
IC50 from  0.27 µM to 0.11 µM with a change in agonist concentration from EC50 to EC90 
(Figure 4.9), in agreement with early work (Chen and Lipton, 1997).  However, the model may 
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not include complexities important for blocker action.  Later work failed to find any effect of 
agonist concentration on blocker IC50 (Gilling et al., 2007).  Using a different approach by 
manipulating channel behavior with PAMs we also found that IC50 concentrations are unaffected 
even up to a 3-fold increase in NMDA current (Figure 4.1). In addition, oxysterols accelerated 
kinetics of channel block, in agreement with previous work using agonist concentration to 
manipulate channel open probability (Chen and Lipton, 1997; Gilling et al., 2007; Gilling et al., 
2009).  Because our approach employed a baseline of relatively high agonist concentration, our 
results reduce the chances of underestimating steady-state block at low agonist concentrations 
resulting from extremely slow blocker onset kinetics (Gilling et al., 2007; Gilling et al., 2009).  
 
 
 
Figure 4.9 Predicted effects of agonist 
concentration on blocker IC50 from a simple 
trapping block model. The model is taken 
from previous work (Blanpied et al.  1997. J 
Neurophysiol 77: 309-323). A represents 
agonist, and B represents blocker.  EC50 and 
EC90 concentrations of agonist were chosen to 
simulate the ~2-fold increase in open 
probability typically observed with SGE-201 in 
the present work.  Simulations were performed 
with NEURON (Carnevale and Hines 2006. 
The Neuron Book. Cambridge University 
Press). Control was taken as the probability of 
A2R* during application of a simulated agonist 
(30 µM and 300 µM) in the absence of blocker 
(kon= 0).  Rate constants were the following, 
from Emnett et al. 2013. Mol Pharmacol 
84:935:  ka+=2 µM
-1
 s
-1
, ka-=40 s
-1
, =5.2 s-1, 
=130 s-1, kon=2 µM
-1
 s
-1
, koff=7.6 s
-1
, ′=0.3 s-1, 
′=35.4 s-1, ka+′= 0.2 µM
-1
 s
-1
, ka-′=0.02 s
-1
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The present work demonstrates different mechanisms for two lipophilic PAMs.  We previously 
demonstrated that SGE-201 and PS exhibit additive potentiation at saturating modulator 
concentrations, but SGE-201 and the endogenous oxysterol 24S-hydroxycholesterol occlude 
each other (Paul et al., 2013).  This implies different NMDAR sites for PS and oxysterols.  In 
addition, with prolonged agonist presentation, PS exhibits mixed potentiation and inhibition. It is 
also a potent antagonist at GABAA receptors, and it has presynaptic effects at some synapses 
(Park-Chung et al., 1999; Shen et al., 2000; Eisenman et al., 2003; Horak et al., 2004; Zamudio-
Bulcock and Valenzuela, 2011).  Despite their biophysical differences at NMDARs, the two 
PAMs had a similar impact on NMDAR trapping blockers.  
 
Due to its specificity for NMDARs and its purer PAM activity, SGE-201 is a better choice than 
PS to experimentally address the interaction between PAMs and NMDAR blockers during 
spontaneous network activity and hypoxic damage.  Our experiments in these two paradigms 
revealed that PAM activity alone, while holding the level of depolarization constant, reveals 
differences between memantine and ketamine that are normally only evident with biophysical 
manipulations, such as prolonged voltage pulses (Emnett et al., 2013). In the case of MEAs, this 
implies that normal synaptic depolarization is sufficient to unveil differences, but low basal 
channel open probability prevents this difference from emerging. As blocker access to its binding 
site in the channel pore increases, voltage dependent differences are revealed. In both of our 
paradigms, ketamine consistently had greater effect than memantine, including in excitotoxic 
neuroprotection. This is surprising given memantine’s role as a clinical neuroprotectant but 
consistent with our previous findings (Emnett et al., 2013).  Memantine’s primary clinical use is 
in Alzheimer’s disease, where NMDA hyperfunction likely has a limited role in damage 
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(Newcomer et al., 2000).  It is possible that memantine’s has a neuroprotective effect in this 
context unrelated to NMDAR function.  
 
We previously demonstrated that a difference between memantine and ketamine could emerge 
during prolonged pathological depolarization during oxygen glucose deprivation (Emnett et al., 
2013). Here we show, in MEAs, that neuronal activity alone can also reach levels that unmask 
drug differences, even in the absence of added PAM. We found that a two-fold increase in 
spiking from baseline in the presence of cyclothiazide differentiated the blockers.  Interestingly, 
cyclothiazide was also associated with weaker suppression of network activity by both blockers, 
in comparison to blocker effects in the presence of SGE-201 (Figures 4.6-4.7).  Cyclothiazide, 
which prolongs AMPAR EPSCs (Partin et al., 1993), could result in a stronger envelope of 
subthreshold depolarization or intense bursting not evident in ASDR measures.  Either 
explanation could explain the reduced effectiveness of the voltage dependent blockers. 
Consistent with the former explanation, we previously showed that EPSP prolongation (achieved 
with voltage-clamp waveforms) is predicted to unmask biophysical differences between 
memantine and ketamine (Emnett et al., 2013).    
 
A recent study showed ketamine blocks spontaneous NMDAR miniature EPSCS more than 
memantine but only in the presence of physiological magnesium (Gideons et al., 2014).  This 
recent study further extends the idea that blockade of spontaneous transmission underlies 
ketamine’s antidepressant behavioral effect (Autry et al., 2011; Kavalali and Monteggia, 2012). 
However, the basis for selective Mg
2+
 dependent reduction in memantine’s effect is unclear since 
Mg
2+
 shifts the effects of both channel blockers similarly (Kotermanski and Johnson, 2009).  In 
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the present work, MEA and toxicity studies were performed in Mg
2+
-containing solutions and yet 
we were unable to discern a difference between the blockers during basal, non-potentiated, 
activity (Figure 4.6, 4.8). This suggests that any differential effects of the drugs on spontaneous, 
quantal, synaptic transmission do not strongly influence network activity under our conditions, 
even when physiological Mg
2+
 is present.  On the other hand, differences between drugs on 
spontaneous transmission evident in the Gideons et al. study could have effects that went 
undetected in the time frame of our experiments.  As it stands, our results offer an alternative 
explanation for distinct effects of memantine and ketamine. Of course, we cannot exclude the 
possibility that drug effects on spontaneous vs. evoked transmission converge in vivo.  
 
There are a variety of factors that can influence NMDAR channel open probability and thereby 
NMDAR blocker actions in vivo. Different receptor subunits (NR2A-D) are known to have 
different open probabilities and could influence NMDAR blocker effects given different regional 
expression patterns of the subunits (Monyer et al., 1994).  Additionally, co-agonist (glycine, D-
serine) concentrations are potentially subject to modulation (Papouin et al., 2012). Locally or 
regionally varied levels of co-agonist could modulate effects of channel blockers such as 
memantine and ketamine (Emnett et al., 2013). Zn
2+
, protons (pH), and arachidonic acid are 
other allosteric modulators that could vary and influence the cellular effects of NMDAR channel 
blockers.  PS has been investigated for many years as a possibly physiologically relevant PAM 
(Majewska and Schwartz, 1987; Schumacher et al., 2008).  However, its concentrations in situ 
are unlikely to reach those that affect NMDAR function (Liere et al., 2004). 
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 In the present work we focus on a new class of PAM. The experimental tractability and 
selectivity of SGE-201 allowed us to provide proof of principle that allosteric NMDAR 
modulation can directly affect NMDAR blocker actions during dynamic network function. This 
proof was not previously forthcoming because other PAMS such as PS have notable off-target 
effects.  24S-hydroxycholesterol is quite potent and endogenously may achieve local 
concentrations in mature tissue that modulate NMDAR function (McDonald et al., 2007). Tests 
to date suggest that this class of modulator may be much more selective for NMDARs than the 
modulators cited above (Paul et al., 2013).  
 
24S-hydroxycholesterol is produced by cholesterol 24-hydroxylase (CYP46A1).  Studies of 
transcript and protein distribution reveal that the enzyme is neuron specific.  Despite the high 
cholesterol content of myelin, it is not expressed in oligodendrocytes or other support cells, and 
its expression is mainly restricted to somatodendritic (postsynaptic) regions of principal cells and 
only some interneuron classes. Labeling varies regionally (Lund et al., 1999; Lein et al., 2007; 
Ramirez et al., 2008).  For instance, within the hippocampal formation, CA1 pyramidal neurons 
show stronger protein expression than dentate granule cells (Ramirez et al., 2008).  Therefore, 
endogenous oxysterol control of NMDAR function may vary by region and by cell type within a 
region.  Together with the other classes of aforementioned modulators, there could be a 
complicated system of controls over NMDAR gating that varies by brain area.  Future work 
could focus on these regional differences to better understand differences between memantine 
and ketamine in vivo.   
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In conclusion, if pharmacodynamics of NMDAR channel blockers contribute to their clinical 
differences, we propose that PAMs could contribute to such differences.  Modulators could 
include but aren’t limited to the novel modulator 24S-hydroxycholesterol.  In the presence of 
PAMs, blocker differences are unmasked in dynamic networks but not under steady state 
conditions.  Either PAM actions combined with basal depolarization/activity or strong 
depolarization/activity alone are sufficient to unmask blocker differences.  
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Chapter 5 
“Novel chemical biology tools reveal new insights into ketamine’s 
antidepressant actions” 
 
 
 
 
 
 
 
 
 
 
This chapter includes work performed/analyzed by others: 
Dr. David Reichert and Hairong Li synthesized the novel compounds discussed (alkyne-
norketamine and alkyne-norketamine amide).  
Dr. David Wozniak and Ann Benz administered the compounds to animals and performed and 
analyzed the results of behavioral testing (i.e forced swim test). Figure 5.1 
Xiaoping Xiang performed the click chemistry, photolabeling and antibody co-staining in 
hippocampal cultures. Figures 5.7-5.8 
Chapter was drafted with edits from Steven Mennerick 
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ABSTRACT 
Ketamine is of interest in neuropsychiatry as a rapid acting antidepressant.  It is rapidly 
metabolized into norketamine, which has a longer half-life (~12 h vs ~3 h) and biological 
activity possibly similar to ketamine. While NMDAR antagonism of cell-surface receptors likely 
is relevant for triggering antidepressant effects of ketamine, an alternative hypothesis suggests 
that ketamine may act at nascent intracellular NMDARs (Lester et al., 2012). If ketamine does 
permeate cells, other intracellular molecular and biochemical targets may also contribute. To 
explore the viability of this hypothesis we addressed its first requirement: cell permeability and 
intracellular accumulation. To do so, we exploited the versatility of bio-orthogonal click 
chemistry to develop new chemical biological tools that may help identify novel intracellular 
targets of ketamine and norketamine. We introduced an alkyne “click” handle into the 
ketamine/norketamine structure (alkyne-norketamine, A-NK) at the key nitrogen atom via 
alkylation with 5-iodo-1-pentyne. We first explored actions of ketamine, norketamine and A-NK 
in the rodent forced swim test (FST), a behavioral screen for antidepressant activity. Both 
ketamine and norketamine significantly reduced immobility in C57BL/6J mice at 3 and 10 
mg/kg, during the FST after a 3 h post-injection delay. These doses did not affect locomotor 
activity.  A-NK was also behaviorally active, reducing immobility at 10 mg/kg (p=0.019). We 
then examined NMDAR actions of all three compounds in hippocampal cultures, stressing 
dynamic conditions that mirror physiological activity. We found that norketamine was active but 
~4-fold less potent than ketamine, exhibited slower kinetics of block, and showed more steady-
state voltage dependence. A-NK showed even slower kinetics of block, but exhibited potency 
equivalent to norketamine and voltage dependence similar to ketamine, establishing itself as an 
NMDAR-active, bi-functional probe. Both compounds showed hallmarks of ketamine-like 
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trapping block of NMDARs during voltage pulses and agonist concentration pulses.  Imaging 
neurons following incubation with 10 µM A-NK revealed intracellular labeling following Cu
2+
 
catalyzed cycloaddition of azide-AlexaFluor488, demonstrating the utility of the probe for cell 
biological studies and revealing the potential for relevant intracellular targets. Interestingly, 
when we introduced the alkyne with an amide linkage, we abolished activity in all three 
measures: reduction in immobility during the FST, NMDAR block, and intracellular staining. 
The amide linkage may interfere with nitrogen protonation, hinting at the importance of a 
charged molecule for ketamine’s neuroactive and behavioral activity. Thus, we offer evidence 
that intracellular targets may be relevant to ketamine/norketamine’s antidepressant effects and 
advance first generation chemical biology tools to aid in their identification.  
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INTRODUCTION 
 Major depression is a disease that affects over 30 million individuals per year in the US, 
with roughly 20% or more unresponsive to traditional therapies (Kessler et al., 2003).  Recently, 
the discovery of ketamine as a potent and fast acting anti-depressant has brought welcome relief 
to sufferers of intractable major depressive disorder (Berman et al., 2000; Zarate et al., 2006; 
Aan Het Rot et al., 2012; Dowben et al., 2013; Murrough et al., 2013). However, ketamine also 
is a dissociative anesthetic and even at subanesthetic doses, imparts undesirable psychotomimetic 
effects (Krystal et al., 1994). Therefore, it is important to better understand the mechanism of 
ketamine’s behavioral effects to design more rapid acting therapeutics with fewer negative side 
effects.   
Ketamine acts as an open channel blocker of NMDA receptors, and its reduction in 
glutamate signaling triggers downstream modifications that may underlie antidepressant actions.  
NMDA receptor blockade can lead to downstream activation of the mammalian target of 
rapamycin (mTOR) pathway and activation of eukaryotic elongation factor 2 (eEF2), thus 
increasing protein translation and synaptogenesis (Li et al., 2010; Autry et al., 2011; Kavalali and 
Monteggia, 2012). A contrasting hypothesis suggests instead that ketamine permeates the plasma 
membrane and acts directly on nascent NMDA receptors to cause synaptogenesis independently 
of extracellular receptor block (Lester et al., 2012). If ketamine does permeate cells it may also 
act at additional, unknown, intracellular targets. These two hypotheses, obviously, differ in the 
locus of ketamine action. One way to explore locus of action would be to visually track 
intracellular accumulation of ketamine.  We and others have used fluorescently tagged molecules 
to track intracellular accumulation of various receptors or signaling molecules (Shu et al., 2009; 
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Peyrot et al., 2014). A version of ketamine that could be covalently linked to reporter molecules 
such as fluorophores could help reveal new targets for anti-depressants or other therapeutics. 
An additional limitation in the literature regarding rapid antidepressant actions is a 
myopic focus on ketamine itself. Once administered systemically, ketamine is rapidly 
metabolized into norketamine in the periphery. Norketamine has a significantly longer half-life 
(11 h vs. 2.5 h) compared to ketamine (Wieber et al., 1975). Although its plasma concentrations 
remain low relative to peak ketamine levels, it still persists longer than ketamine in vivo 
(ketamine: 200ng/ml, 40 min post infusion vs. norketamine: ~50 ng/ml, 230 min post-infusion) 
(Zarate et al., 2012).  Norketamine blocks NMDARs, but its pharmacodynamics is not well 
understood (Ebert et al., 1997).  Recent evidence suggests that norketamine has more potent 
actions than ketamine at classes of receptors other than NMDARs (Moaddel et al., 2013).  It is 
also unclear whether norketamine possesses the antidepressant activity of the parent compound.  
To address competing ideas regarding ketamine’s actions, we designed a novel analogue 
of norketamine/ketamine that could be used to visually track blocker accumulation in various 
cellular compartments. We attached an alkyne group to the central amine in the norketamine 
structure, thus enabling us to “click” the molecule to an azide-containing fluorophore and 
visualize analogue localization in cells. We found that ketamine, norketamine and this new 
“alkyne-norketamine” (A-NK) all reduced immobility in the forced swim test– a common screen 
for anti-depressant efficacy. Meanwhile, we characterized cellular actions of norketamine and 
ketamine under steady-state and dynamic conditions and found that A-NK retained many 
properties of the parent compounds at NMDARs. We also demonstrate the importance of 
protonation to activity at NMDARs, since eliminating the positive charge at the nitrogen atom by 
attaching the alkyne chain with an amide linkage (A-NK amide), abolished activity in all three 
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paradigms: behavioral activity, NMDAR antagonism, and intracellular staining. Thus, we 
introduce for the first time a bi-functional probe that retains electrophysiological and behavioral 
properties unique to ketamine and can be used in future studies to elucidate new targets for this 
drug.   
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MATERIALS AND METHODS 
Forced Swim Test. 2-2.5 post-natal month C57BL/6J mice (Jackson Labs) were administered the 
indicated concentrations of ketamine, norketamine, (3 mg/kg or 10 mg/kg in 0.9% NaCl or PBS) 
A-NK (10 mg/kg in 30% DMSO or 5% cremophor-EL), A-NK amide (6.5 mg/kg in 0.9% PBS 
with 7% cremophor-EL and 2% DMSO), or vehicle via intraperitoneal injection. Three hours 
post injection, the forced swim test (FST) was conducted. FST was assessed by releasing the 
animals two at a time (one treated, one vehicle) into separate chambers of a glass beaker filled 
with water. Animals were video-recorded and duration of immobility during the last 3 minutes of 
the 6 minute protocol (defined as lack of extraneous movement other than that required to keep 
floating) was measured by a blinded observer.  In preliminary studies with ketamine, mobility 
was assessed 3 h after administration. In this assay, animals were released into a cage fitted with 
mobility sensors and the amount of exploratory mobility was measured. At this time point we 
observed no reduction in mobility compared to vehicle-treated controls.  
Hippocampal cultures: Hippocampal cultures were prepared as either mass cultures or 
microcultures (as indicated in figure legends) from postnatal day 1-3 female rat pups 
anesthetized with isoflurane, under protocols consistent with NIH guidelines and approved by 
the Washington University Animal Studies Committee.  Methods were adapted from earlier 
descriptions (Huettner and Baughman, 1986; Bekkers et al., 1990; Tong and Jahr, 1994; 
Mennerick et al., 1995).  Hippocampal slices (500 μm thickness) were digested with 1 mg ml-1 
papain in oxygenated Leibovitz L-15 medium (Life Technologies, Gaithersburg, MD, USA).  
Tissue was mechanically triturated in modified Eagle's medium (Life Technologies) containing 
5% horse serum, 5% fetal calf serum, 17 mM D-glucose, 400 μM glutamine, 50 U ml-1 penicillin 
and 50 μg ml-1 streptomycin.  Cells were seeded in modified Eagle's medium at a density of ~650 
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cells mm
-2
 as mass cultures (onto 25 mm cover glasses coated with 5 mg ml
-1
 collagen or 0.1 mg 
ml
-1
 poly-D-lysine with 1 mg ml
-1
 laminin) or 100 cells mm
-2
 as "microisland" cultures (onto 35 
mm plastic culture dishes coated with collagen microdroplets on a layer of 0.15% agarose).  
Cultures were incubated at 37° C in a humidified chamber with 5%CO2/95% air.  Cytosine 
arabinoside (6.7 μM) was added 3-4 days after plating to inhibit glial proliferation.  The 
following day, half of the culture medium was replaced
 
with Neurobasal medium plus B27 
supplement (Life Technologies).  
 
Electrophysiology. Whole-cell recordings were performed at room temperature from neurons 
cultured for 4-10 days (depending on the experiment) using a Multiclamp 700B amplifier 
(Molecular Devices, Sunnyvale, CA, USA) and Digidata 1440A converter with Clampex 10.1 
software.  Young cells were favored for biophysical experiments to minimize voltage-clamp 
errors, and older, synaptically mature cells were used for EPSC measurements. For recordings, 
cells were transferred to an extracellular (bath) solution containing (in mM): 138 NaCl, 4 KCl, 2 
CaCl2, 10 glucose, 0.01 µM glycine and 10 HEPES, pH 7.25 adjusted with NaOH, 25-50 µM  D-
APV was included until seal formation to prevent excitotoxicity.  Solutions with adjusted 
composition described below were perfused using a gravity-driven local perfusion system from a 
common tip. The estimated solution exchange times were <100 ms (10-90% rise), estimated 
from junction current rises at the tip of an open patch pipette. For synaptic recordings, these 
solutions contained (in mM) 0.001 2,3-dihydroxy-6-nitro-7-sulfonyl-benzo[f]quinoxaline 
(NBQX) and 0.025 bicuculline methobromide or 0.01 gabazine. For exogenous NMDA 
application, 0.25 mM CaCl2 was used (in APV-free perfusion solutions) to minimize Ca
2+
-
dependent NMDAR desensitization (Zorumski et al., 1989), and 250 nM tetrodotoxin was added 
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to prevent network activity. Unless otherwise noted, exogenous NMDA concentration was 30 
µM.  
 
The tip resistance of patch pipettes was 3-6 MΩ when filled with an internal solution containing 
(in mM): 130 potassium gluconate, 0.5 CaCl2, 5 EGTA, 4 NaCl, and 10 HEPES at pH 7.25, 
adjusted with KOH.  Potassium was used as the main intracellular cation for autaptic stimulation 
to preserve action potential waveform, but in experiments examining current responses to 
exogenous agonists, cesium methanesulfonate replaced potassium gluconate to block potassium 
channels and improve spatial voltage clamp quality.  Holding voltage was typically -70 mV 
unless otherwise noted.  Access resistance (8-10 MΩ) was compensated 80-100% for EPSC 
measurements. For
 
evoked EPSCs, cells were stimulated with 1.5 ms pulses
 
to 0 mV from -70 
mV to evoke autaptic transmitter release (Mennerick et al., 1995). EPSC decays were fit with a 
bi-exponential function in Clampfit using Levenberg Marquart or variable metric fit parameters. 
Weighted time constants (w) were calculated for data analysis using Equation 1, where A1 refers 
to the amplitude of FAST and A2 refers to the amplitude of SLOW.  
 
Confocal Imaging: For evaluating labeling of A-NK and the amide derivative, stocks of 10 mM 
compound were prepared in DMSO and diluted to 10 µM in culture medium and applied to cells 
for 1 h at 37
o 
C.  Cells were then fixed with 4% paraformaldehyde and 0.05% glutaraldehyde for 
10 min.  Cells were washed with PBS and then exposed to click reaction labeling for 1 h in the 
dark using azide-conjugated AlexaFluor488 ( 1 µM). The click buffers contained 100 μM 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), 2mM (+)- Sodium L-ascorbate in 
(1) 
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ddH2O, 1μM Alexa AF-488 in DMSO, 1mM CuSO4. For antibody co-labeling experiments, we 
incubated in 10 µM A-NK for 1 h at 37 
o
C and fixed cells with 4% paraformaldehyde in 
phosphate buffered saline for 10 min. After washing, we incubated in primary antibody (anti-PDI 
(Abcam), Giantin (Covance), or COX IV (Abcam) at 1:2000) in 4% normal goat serum and 
0.04% triton in phosphate buffered saline for 2 h.  Cells were subsequently incubated in 
secondary antibody (AlexaFluor647, 1:500) for 1 h, then clicked (azide-488) for another hour in 
the above conditions.  
LogP and pKa derivations: LogP and pKa values were calculated using software available on the 
Virtual Computational Chemistry Laboratory, www.vcclab.org (Tetko et al., 2005). LogP values 
are represented as the average ± SD of the output by 6 different algorithms consulted for the 
calculation. pKa values were calculated using SPARC online software (Hilal and Karickhoff, 
1995) or were obtained from the literature (Cohen and Trevor, 1974). 
Drugs:  (R,S)-Ketamine and (R,S)- norketamine were obtained from Tocris. Both compounds 
were racemic mixtures. Nonracemic (R,S)-A-NK and (R,S)-A-NK amide were synthesized by 
Hairong Lai and David Reichert as follows. Norketamine was synthesized using previously 
published methods (Jose et al., 2013) and the alkyne (Compound 1) or amide (Compound 2) 
linkages were attached using the following procedure, described by Hairong Lai.  
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Alkyne-Norketamine, A-NK (1):  
Norketamine (13 mg, 0.058 mmol) and finely grounded potassium carbonate (16 mg, 0.12 
mmol) were mixed in N, N-dimethylformamide; HBTU: N,N,N′,N′-Tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (DMF,0.5 mL) in a 5-mL reaction tube vessel. 
5-Iodo-1-pentyne (33.8 mg, 0.17 mmol) was added to the solution. The tube was sealed and the 
reaction solution was heated to 100 °C for 24 hr. After the reaction solution was cooled down to 
room temperature, the solution was dissolved in dichloromethane (5 mL), and washed with 10% 
sodium thiosulfate (1 mL × 2), and brine (1 mL × 2). The organic phase was separated and dried 
over anhydrous sodium sulfate. The solution was filtered under vacuum and concentrated to 
viscous liquid. The crude product was purified by column chromatography on a silica gel with 
the elution of hexane: ethyl acetate (3:2) to afford a light yellow viscous liquid (16 mg, 95.2%). 
Alkyne-Norketamine Amide, A-NK amide (2):   
4-Pentynoic acid (10.8 mg, 0.11 mmol) and HBTU (43.7 mg, 0.12 mmol) were mixed well in 
DMF (200 µL) in a 1-mL vial. N, N-diisopropylethylamine (60 µL, 0.34 mmol) was added to the 
solution and the reaction solution was stirred for 15 min. Then norketamine (19 mg, 0.085 mmol) 
in DMF (65 µL) was added to the solution, and the reaction solution was stirred at room 
temperature overnight. The crude product was purified on a short silica column with the elution 
of hexane: ethyl acetate (3:2) to afford a yellow viscous liquid (17 mg, 65.7%).  
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RESULTS 
Norketamine and A-NK suppress immobility in the forced swim test assay.  
 Ketamine has known anesthetic and anti-depressant properties. Its major metabolite, 
norketamine, retains the anesthetic properties of ketamine at high doses and contributes to 
anesthesia (Leung and Baillie, 1986) but it is unclear whether it participates in the anti-
depressant effect. Moreover, although ketamine is believed to largely work through NMDA 
receptor blockade, a recent hypothesis has proposed that ketamine may permeate the cell 
membrane and facilitate its downstream consequences through intracellular effects, possibly in 
the ER membrane and Golgi (Lester et al., 2012). To test the viability of this hypothesis we 
needed a behaviorally active compound that could also be used to visually track 
ketamine/norketamine inside the cell. 
  Copper catalyzed Huisgen cycloaddition, a popular bio-orthogonal variant of click 
chemistry, allows one to covalently link an alkyne containing molecule with an azide containing 
molecule (Lutz and Zarafshani, 2008).  An array of fluorophores and other markers are available 
as azide and alkyne conjugates to facilitate visualization, biochemistry, and other uses.  We 
attached an alkyne group to the nitrogen atom of ketamine and tested whether the resulting 
compound retained the behavioral activity of the parent compounds. The alkyne was attached via 
two different linkage chains, alkyl or amide. The structures are represented alongside ketamine 
and norketamine in Figure 5.1A. 
To test whether ketamine alone, and not its metabolites, is capable of inducing an anti-
depressant effect when administered systemically, we treated animals with ketamine or 
norketamine and measured immobility time during the Forced Swim Test (FST), a standard 
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protocol used to screen for anti-depressant potential (Lucki, 1997; Browne and Lucki, 2013). In 
line with previous studies, ketamine significantly reduced immobility after a 3 mg/kg or 10 
mg/kg dose assessed 3 h after drug administration (Gideons et al., 2014) (Figure 5.1B). 
Interestingly, we found that the same concentrations of norketamine also caused a significant 
reduction in immobility time (Figure 5.1C). Thus, we demonstrate that ketamine does not 
entirely account for its anti-depressant effects; downstream metabolism may also contribute.  We 
then tested both alkyne compounds in the FST.  We found that A-NK but not the amide 
derivative was active when tested at equivalent concentrations (Figure 5.1D-E).   
Given ketamine’s known sedative effects we measured animal mobility at the time point 
when the FST was administered (3 h post administration). We found no differences in overall 
ambulatory mobility or in rearing frequency at either concentration of ketamine (Figure 5.1F-
G). Preliminary studies with the other compounds are ongoing but also suggest a lack of an 
effect. 
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Figure 5.1. Ketamine, norketamine and alkyne-norketamine (A-NK), but not A-NK amide, 
reduce immobility time in the FST. A. Chemical structures of ketamine, norketamine, A-NK and A-
NK amide are depicted. B. Immobility time measured during a forced swim test in mice 3 hours after 
administration of the indicated concentrations of ketamine. Both 3 and 10 mg/kg of ketamine 
significantly reduced immobility time (N=20). C. Norketamine significantly reduced immobility time 
at 3 and 10mg/kg (N=16-17). D. A-NK (10 mg/kg) also significantly reduced immobility time 
alongside norketamine (N=32-34). E. A-NK amide (10 mg/kg) has no effect on immobility time 
(N=24-25). F-G. Ketamine (3 and 10 mg/kg) did not alter general ambulation (F) or rearing frequency 
(G) compared to vehicle controls 3 hours after administration (N=13, two-way ANOVA). P values in 
figure represent level of significance between indicated groups, calculated using ANOVA and student-
t-tests.  Note: Data collected and analyzed by David Wozniak 
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 Norketamine and A-NK retain voltage dependent block of NMDAR function.  
Scant work has evaluated the effect of norketamine on NMDAR function (Ebert et al., 
1997; Dravid et al., 2007). No work has assessed activity of chemical biology analogues of 
ketamine/norketamine at NMDARs. In dissociated cultures of hippocampal neurons, we 
explored properties of the analogues on NMDAR function.  We found that norketamine (10 μM) 
had reduced potency and stronger voltage sensitivity than ketamine when measured at -70 mV 
and at +50 mV (Figure 5.2A-B).  A-NK also was a voltage dependent NMDAR antagonist 
(Figure 5.2C). Interestingly, when we tested the efficacy of the amide derivative, it was 
completely inert at 10 µM (Figure 5.2D). A-NK displayed similar potency to norketamine, but 
retained voltage dependence more similar to ketamine (Figure 5.2E-F). Both norketamine and 
A-NK displayed significantly slower onset kinetics than ketamine, with A-NK exhibiting 
especially slow onset and offset kinetics during continuous agonist exposure (Figure 5.2G). In 
summary, both norketamine and A-NK retained voltage dependence similar to ketamine, with 
subtle differences in kinetics, suggesting that both mimic the actions of the parent compound.  
We next compared the potency of ketamine, norketamine, and A-NK in dissociated 
hippocampal neurons. We found that norketamine is roughly 4-fold less potent than ketamine 
(IC50 ketamine: 0.43 μM, IC50 norketamine: 2.0 μM, N=9-10, Figure 5.3 A-B, D) and we found 
that A-NK was equipotent to norketamine (IC50: 1.8 μM, N=9. Figure 5.3 C-D). However, again 
we observed that it displayed particularly slow kinetics compared to the others. This may have 
led to a slight over-estimation of the IC50 concentration for this molecule. There are two possible 
explanations to explain its slow kinetics which our subsequent experiment addressed.   
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Figure 5.2: Ketamine, norketamine and A-NK are neuroactive at the NMDA receptor. A-D. 
Representative traces depicting block and washoff at -70 mV and +50 mV for 10 μM ketamine (A), 10 
µM norketamine (B), 10 µM A-NK (C), and 10 µM A-NK amide (D). Scale bar values in A 
correspond to all 4 panels. All the compounds, save A-NK-amide, were neuroactive. E. % Block 
achieved near steady-state for the active compounds was calculated. At -70 mV and at +50 mV, both 
norketamine and A-NK were significantly different than ketamine, but at +50 mV, norketamine 
achieved significantly less block than the either two (N=4-5, *p<0.05, t-test Bonferroni correction for 
multiple comparisons). F. The % block at +50mV was divided into the block achieved at -70mV to 
calculate a “block ratio” for all active compounds.  This measurement, which inversely correlates to 
the voltage-sensitivity of a compound, was significantly lower with norketamine compared to the two 
other compounds (N=4-5 *p<0.05, t-test Bonferroni correction for multiple comparisons). G. The rate 
of block onset at -70 mV was measured for all three active compounds. Norketamine exhibited 
significantly slower kinetics than ketamine, and A-NK displayed slower kinetics than both ketamine 
and norketamine (N=4-5, *p<0.05, t-test with Bonferroni correction for multiple comparisons).  
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Figure 5.3: Norketamine and A-NK 
are four-fold less potent than 
ketamine. A-C Representative traces 
depict block by increasing 
concentrations (0.3, 1, 3, 30 μM) of 
ketamine (A), norketamine (B) and A-
NK (C). Concentrations are depicted 
below each trace. Not shown are traces 
obtained in different cells with 0.1, 1, 3, 
10 μM blockers. Steady-state block 
achieved in the shared concentrations (1 
and 3 μM) were consistent across cells 
so data was pooled in D. D. 
Concentration-response curves for 
ketamine, norketamine, and A-NK are 
depicted (N=9-10). Solid lines represents 
fits to the Hill equation of the form I = 
Imax * C
n
 / (IC50
n 
+ C
n
), where Imax is 
maximum current in the absence of 
agonist, C is antagonist concentration, n 
is the Hill coefficient, and IC50 is the 
concentration inhibiting 50% of the 
response. The IC50 values for the 
compounds were calculated to be: 0.43 
μM (ketamine), 2.0 μM (norketamine) 
and 1.8 μM (A-NK). Ketamine was 
significantly more potent than 
norketamine and A-NK (p<0.05, 
unpaired t-tests). 
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A-NK has intrinsically slow kinetics 
Figures 5.2 and 5.3 suggest that A-NK has slower kinetics than the parent compounds when 
applied during continuous agonist presentation. We and others have previously shown that 
kinetics of trapping NMDAR channel blockers, including ketamine, is rate limited by low 
channel open probability (Gilling et al., 2009; Emnett et al., 2013).  The additional slowness of 
A-NK could result from intrinsically slow pharmacodynamics (kon, koff), or it could represent 
slow access to the NMDAR through mechanisms other than aqueous diffusion. For instance, 
previous work has shown that ketamine can reach a blocking site via a lipophilic pathway (Orser 
et al., 1997). Given the enhanced lipophilicity that a long hydrocarbon chain imparts to the 
molecule (LogP A-NK: 3.86 +/- 0.54 vs. ketamine: 2.75 +/- 0.33 vs. norketamine: 2.32 +/-0.33, 
see methods) we hypothesized that A-NK may be more prone to access a binding site through the 
membrane. If so, the slow kinetics we observed may be due to slow accumulation. Pre-applying 
the compound before agonist application would allow for membrane accumulation, speeding 
block upon agonist application. To test this, we employed a 60 s pre-application procedure 
(followed by agonist co-application) and compared kinetics of block onset with that observed in 
a co-application only protocol.  The rate of A-NK block upon NMDA co-application was 
unaffected by A-NK pre-application (Figure 5.4A-C). This suggests that A-NK 
pharmacodynamics accounts for the slow block during continuous agonist presentation, perhaps 
due to the steric-hindrance from the bulky side chain.  These data also support the concept of A-
NK as a use-dependent blocker because no block occurred before agonist was presented, again 
mimicking effects previously shown for the parent compound ketamine (MacDonald et al., 
1987).  
 
174 
 
 
Blocker effects during non-equilibrium voltage changes 
 Our earlier experiments suggest that norketamine exhibits stronger steady-state voltage 
dependence than A-NK or ketamine. However, neurons typically experience transient voltage 
perturbations. Therefore, rates of blocker re-equilibration are important to their physiological 
impact.  Furthermore, kinetic analyses can lend insight into the basis for steady-state differences.  
To test how these blockers behave during transient voltage steps, we measured the percentage of 
Figure 5.4: Preapplication of A-NK does not speed 
rate of block. A Representative trace depicting 
control current (black) in response to 30 μM NMDA 
or current recorded following a saline pre-application 
and immediate co-application of NMDA and 10 μM 
A-NK. B. Same as in A, except prior to the cyan 
trace, A-NK was preapplied for 60 seconds. C. The 
rate of onset of block (depicted by arrows in A, B) 
was calculated for both protocols. There was no 
significant difference between blocking rates during 
the different pre-application protocols (N=5 each, 
p>0.05, unpaired t-test). 
175 
 
baseline NMDA current (in the absence of blocker) before, during, and after a 10 second pulse 
from -70 mV to +50 mV. Steady-state differences among the blockers from Figure 5.2 were 
reproduced in this protocol (Figure 5.5A-C).  The rate at which blockers re-equilibrated to +50 
mV was indistinguishable. (Figure 5.5D, F). However, upon the return of Vm to -70 mV, 
blockers reached steady-state block with rates constants consistent with their different onset 
kinetics in Figure 2 (Figure 5.5E, F). We conclude that differences in rates of equilibration at -
70 mV, but not at +50 mV, contribute to differences in steady-state voltage dependence among 
the compounds.   We also conclude that during physiological activity the compounds will exhibit 
similar proportional relief from block during transient depolarization, but rates of block re-
establishment will differ.  
 Blocker effects during phasic endogenous agonist presentation 
 We tested whether the kinetic differences among compounds would be evident during 
brief exposure to high glutamate concentration that occurs at synapses.  In addition to transient 
voltage perturbations, open channel blockers in neuronal networks must block receptors during 
brief synaptic events. Synaptic agonist presentation can influence the rate and degree of block 
achieved (Chen and Lipton, 1997; Wroge et al., 2012; Emnett et al., 2013). We measured initial 
inhibition of the peak amplitude and acceleration of decay of autaptic EPSCs in hippocampal 
microcultures. Although norketamine (10 µM) strongly truncated EPSC decay kinetics 
(comparably to an equipotent concentration of ketamine, data not shown), A-NK (10 µM) had 
only a subtle, trend-level, effect on the kinetics (Figure 5.6A-C). Nevertheless, when we 
examined the ability of the compounds to progressively block EPSC currents, norketamine and 
A-NK reached maximum block at comparable rates (Figure 5.6D-G). Therefore, while A-NK 
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may have a weaker effect on the EPSC decay of isolated EPSCs than norketamine, it exhibits 
progressive block of synaptic receptors at -70 mV similar to norketamine 
  Alkyne-norketamine and intracellular targets of ketamine  
 A new hypothesis suggests that ketamine may exert anti-depressant effects by triggering 
downstream signaling pathways, but initiates them by binding to nascent NMDA receptors 
intracellularly, such as in the ER or  Golgi (Lester et al., 2012). The alkyne moiety allowed us to, 
for the first time, label and track the accumulation of a ketamine/norketamine analogue in cells. 
After bath incubation with alkyne-norketamine or the amide derivative, we fixed cells and 
“clicked” AlexaFluor488 to residual compound (see Methods). We observed clear intracellular 
staining in neurons, but only in the presence of A-NK and not the inactive amide derivative 
(Figure 5.7A-B).   However, antibody co-labeling of A-NK with anti-PDI, an endoplasmic 
reticulum protein, failed to reveal significant specific overlap. Similar results were obtained with 
the Golgi marker, giantin, and the mitochondrial marker, COXIV (Figure 5.8).  We conclude 
that intracellular labeling characterizes an active, but not inactive, ketamine/norketamine 
analogue, but there appears to be no specific compartmentalization of labeling.     
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Figure 5.5: Ketamine, norketamine, and A-NK show subtle differences during rapid membrane 
depolarization. Neurons were subjected to a 10 second voltage pulse from -70 mV to +50 mV in the 
continuous presence of 300 μM NMDA with or without 10 μM of the given blockers (ketamine, 
norketamine, A-NK). All drugs were collected on the same cell with a full NMDA trace between 
blockers to ensure complete washout and limit cross-contamination. The order of blockers alternated 
between cells. A. Representative traces depicting the current in the presence of the three blockers as 
% of NMDA control before and immediately after the depolarizing step. Dotted lines indicate 0% 
and 100% NMDA current. B. Representative traces that depict blocker current as %NMDA control 
current immediately before, during, and after the return hyperpolarizing step to -70 mV.  C. %Block 
achieved at steady-state at -70 mV or +50 mV for all blockers. Norketamine blocked significantly 
less than either ketamine or A-NK at -70 mV (N=10, *p<0.05, paired test with Bonferroni correction 
for multiple comparisons).  At +50 mV, all three compounds achieved a significantly different level 
of block from each other (N=10, *p<0.05, paired-test with Bonferroni correction for multiple 
comparisons). D. The traces in A, scaled and fitted with a bi-exponential decay line indicating the 
similar rate of relaxation from -70mV to +50 mV for all three blockers. E. The traces in B scaled and 
fitted with a bi-exponential decay indicating the prominent difference in the rates of relaxation back 
to -70 mV. F. The relaxations in A and B were fit with bi-exponential fits and the weighted tau was 
calculated for each blocker. There was no significant difference between blockers at +50 mV, but a 
strong difference between blockers at -70 mV (N=10, *p<0.05, paired t-test, Bonferroni correction 
for multiple comparisons). 
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Figure 5.6: Alkyne norketamine blocks synaptic-EPSCs similarly to norketamine. A-B. 
Representative traces depicting autaptic NMDA-EPSCs in saline (black) and the initial sweep (5-15 
seconds preapplication) with 10 μM norketamine (A) or A-NK (B). Each recording was collected on 
separate cells. Traces collected with 5 second preapplication were indistinguishable from those with a 
longer preapplication and so were combined in the dataset. C. Bi-exponential fits of the decay of 
baseline EPSCs and the initial sweep with the indicated blocker were obtained and a weighted tau (w) 
was calculated. Norketamine significantly accelerated the rate of decay compared to saline controls 
(N=18, *p<0.05, paired t-test). Alkyne norketamine slightly reduced EPSC decay kinetics (p=0.045, 
N=20, paired t-test). D-E. Representative traces from a subset of cells in C where block was allowed 
to run to completion. Legends indicate the identity of the colored traces. F-G. Normalized plots 
demonstrating that norketamine and A-NK reached maximum block and were washed out with similar 
rates (N=6-7, p>0.05 unpaired t-test).  
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Figure 5.8: A-NK staining shows no specific intracellular staining. A-C Left panels depict con-focal 
imaging of staining of cells exposed to A-NK, permeablized and stained with azide-Fluor488 under 
copper-catalyzed “click” reaction conditions. Middle panels show immunofluorescence staining of the 
ER (anti-PDI, A), Golgi (Anti-Giantin, B) or mitochondria (Anti-COXIV, C). Right panels are merged 
images indicating that the A-NK staining did not overlay specifically with any of the organelle markers. 
Scale bar: 5 μm. 
Figure 5.7: A-NK but not A-NK amide can be visualized inside neurons A. Con-focal imaging 
depicting cells exposed to DMSO, A-NK amide or A-NK, permeabilized and stained with azide-
Fluor488 under copper-catalyzed “click” reaction conditions. Indistinct staining is only observed in the 
A-NK treated dish. Scale bar: 5 μm. B. The amount of fluorescence in each condition was quantified. 
Significantly more staining/fluorescence was observed in the A-NK dish (N=15 neurons from 3 
separate experiments, *p<0.05, paired t-test).  
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DISCUSSION 
 Ketamine is a novel rapidly acting antidepressant whose mechanism of action is still 
unclear. This paper addressed two questions regarding its actions. First, we examined the 
pharmacology of norketamine, the major primary metabolite of ketamine, in a rodent behavioral 
screen for antidepressant actions and in cellular assays of NMDAR function.  At the cellular 
level, we stressed comparisons with ketamine during dynamic conditions that mimic 
physiological activity.  Second, we introduce a novel chemical biology tool that has similar 
actions as ketamine and norketamine.  Because of its similar effects, it and subsequent 
generations of similar compounds can be used to track novel targets for ketamine’s actions in 
neurons. Our work suggests that norketamine is subtly different than ketamine in its actions at 
the NMDA receptor but could participate in the anti-depressant actions of ketamine in vivo. In 
addition, we provide a bi-functional and pharmacologically similar tool that can be used in future 
studies to track ketamine accumulation in vitro and in vivo.   
Previous work examining norketamine at NMDA receptors confirmed that it is 
neuroactive, but the work did little to characterize its mechanism of action. Here, we provide 
evidence that norketamine, and the synthetic A-NK, both mimic ketamine’s actions at the 
NMDA receptor. Both norketamine and A-NK displayed characteristics consistent with open 
channel blockers. They are voltage dependent and slow to re-equilibrate at positive potentials 
following membrane depolarization, suggesting slow relief of channel block (Figures 5.2 and 
5.5). Additionally, each altered synaptic EPSCs in a manner consistent with other channel 
blockers (Emnett et al., 2013). They truncated synaptic decay, reached maximum block over 
many stimuli, and slowly washed out following blocker removal. Therefore, norketamine and A-
NK behave like ketamine at NMDARs, as use-dependent open channel blockers. We did find 
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that the addition of the alkyne chain to the norketamine backbone considerably slowed its rate of 
block during exogenous agonist application (Figures 5.2-5.3).  This may be caused by steric 
hindrance imparted by the bulky alkyne side-chain.  It is interesting that slow kinetics during 
exogenous application did not translate to slower cumulative EPSC block. One possible 
explanation is that higher local glutamate concentration (1 mM) (Clements et al., 1992) in the 
synapse encourages rapid block compared to the relatively lower concentrations employed 
during exogenous application.  
Interestingly, we found that conversion of the central amine to an amide in the A-NK 
structure abolishes activity at NMDARs, behavioral effects in FST, and intracellular 
retention/labeling.  Our inability to label neurons with the A-NK amide could be due to an 
inability of the compound to permeate the plasma membrane, or an inability to be retained by 
intracellular targets during processing. Computed pKa values for A-NK vs. A-NK amide reveal 
that at pH 7 virtually all of the A-NK amide is uncharged while A-NK retains a similar ratio of 
charged: uncharged molecules as norketamine (pKa A-NK: 6.88 vs. A-NK amide: -4.74, 
compared to norketamine: 6.78 and ketamine: 7.18) (Cohen and Trevor, 1974). This supports 
previous work suggesting that ketamine protonation is essential for its NMDAR block 
(MacDonald et al., 1991). At the same time, their logP values, which should correspond to 
lipophilicity, although higher than ketamine or norketamine, were similar (logPs A-NK: 3.86 ± 
0.54 vs. A-NK amide: 3.26 ± 0.43 vs. ketamine: 2.75 ± 0.33 vs. norketamine: 2.32 ± 0.33). 
Therefore A-NK amide retains a high lipophilicity and is neutral at physiological pH – 
characteristics that should favor membrane permeability. If protonation is required for membrane 
permeation, it is possible that some active transporter is required to shuttle protonated 
compounds across the membrane. However, the structural changes in A-NK amide also make it 
182 
 
possible that it no longer can interact with the same targets inside the cell that A-NK does. If A-
NK amide does permeate membranes, it is promising that we did not observe nonspecific 
membrane binding for A-NK amide, supporting the conclusion that A-NK associates with valid 
targets intracellularly.  
 Labeling with A-NK revealed that the compound permeates the membrane and binds 
indistinct targets in the intracellular space. As discussed above, it is unlikely that enhanced 
lipophilicity artificially biased towards intracellular staining by A-NK, since the A-NK amide 
could not be retained and visualized despite retaining a similar logP value. Another caveat to the 
lack of specific intracellular targets is that A-NK was not fixed in place before imaging, so 
significant diffusion beyond preferential sites of accumulation could have occurred during 
processing.  This issue has been dealt with in other contexts by introducing a photolabel (Chen et 
al., 2012).  For instance, a diazarine could be attached allowing for UV-catalyzed covalent 
attachment to associated lipids and proteins (Mackinnon and Taunton, 2009). Our results fail to 
refute the hypothesis that compound activity may be related to intracellular targets (Lester et al., 
2012), since the amide derivative failed to show intracellular labeling and also failed to have 
NMDAR or behavioral activity (preliminary results). 
Our results also suggest that if membrane partitioning of A-NK is important for its 
actions at NMDARs, partitioning or intracellular accumulation does not rate limit its actions 
(Figure 4). Additional insight might be gained by fluorescently tagging A-NK for use in time-
resolved imaging studies that correlate the partitioning/accumulation of the blocker with the time 
course of biological effects. Preliminary experiments with such a compound reveal that it retains 
inhibitory activity at NMDARs but loses the trapping block and voltage dependence 
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characteristic of ketamine (data not shown).  It is possible that other fluorophores might better 
retain ketamine-like behavior.   
 We show here that norketamine, ketamine, and A-NK each reduce immobility time in the 
FST assay with the same dose-response profile. This is surprising given their different potencies 
at NMDARs. It is possible that the 4-fold difference in IC50 in culture may not translate into a 
noticeable functional difference in vivo. The behavioral effects could be mediated by α-7 
acetylcholine antagonism (Paul et al., 2014); however, given the different potencies of ketamine 
and norketamine at these receptors, this is less likely (Moaddel et al., 2013). Another possibility 
is that a common downstream metabolite mediates the effect. It should be noted that a common 
metabolite for both ketamine and norketamine is 6-hydroxynorketamine, a neuroactive but much 
weaker NMDAR antagonist (Moaddel et al., 2013). The cyclohexane ring, which is modified in 
both ketamine and norketamine to form various hydroxyketamine and hydroxynorketamines, can 
also be modified in A-NK. However alkyne moieties are generally inert in vivo.  This should 
prevent the backward conversion to norketamine or ketamine in vivo. Since A-NK administration 
also decreased immobility in FST it seems remote that a common downstream molecule from 
ketamine, norketamine and A-NK exists. Thus, the common in vivo target, if it exists could be 
either the NMDA receptor, targeted by the common protonated central amine in all three 
structures or an unknown receptor targeted by the cyclohexane group.   Our preliminary evidence 
that the A-NK amide does not alter immobility in the FST seems consistent with a primary target 
of NMDARs for antidepressant effects, but our results do not exclude other common targets of 
ketamine/norketamine that A-NK but not A-NK amide affects.  
 When administered in humans, ketamine induces psychotomimetic disturbances which 
peak around 40 minutes post-administration and dissipate before the anti-depressant effect is 
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seen. A recent study showed that norketamine has no effect on cognitive disturbances during 
ketamine administration, suggesting that it’s rising levels dilute ketamine’s effects (Olofsen et 
al., 2012). Why does norketamine lack the ability to cause psychotomimetic effects? Comparison 
with memantine, another similar compound to ketamine that also shows no dissociative actions, 
could be illuminating here.  
Memantine is nearly identical to ketamine in many circumstances except that it more 
rapidly dissociates from the channel during depolarization. This characteristic underlies 
differences in blocker effects in networks in vitro and is unmasked in the presence of positive 
modulators of the NMDAR (Emnett et al., 2013; Emnett et al., 2014). There are two major 
differences between memantine and norketamine. Memantine re-equilibrates faster than 
ketamine, and only reaches a slightly reduced level of block compared to ketamine at +50 mV 
(Emnett et al., 2013). Norketamine re-equilibrates with an equivalent time course to ketamine, 
but exhibits almost no steady-state block at +50 mV (Figure 5.5). Meanwhile, at -70 mV, 
ketamine and memantine re-equilibrate with equivalent onset kinetics while norketamine re-
equilibrates more slowly than ketamine. 
Despite clear voltage dependent and kinetic differences, the voltage step protocol does 
not have the sensitivity to distinguish ketamine from norketamine in the same way it 
distinguished between memantine and ketamine. The rate of relaxation that occurs following a 
voltage step is inversely proportional to the sum of the two rate constants (kon and koff) at the new 
potential (Jin et al., 2009). Any nonproportional shift in kon or koff for either norketamine or 
ketamine (relative to the other blocker) could result in relaxation time courses that are 
experimentally indistinguishable. Classical voltage dependent block would demand a 
proportional decrease in the rate of block, and corresponding increase in the rate of unblock at 
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each incrementing voltage step (Woodhull, 1973). An alternative explanation for voltage 
dependence suggests that the direction and force of permeant ions also influences blocker 
potency (Antonov and Johnson, 1999). Ketamine’s potency is, in fact, altered by manipulating 
driving force of ion influx through the channel (Mennerick et al., 1998). Our data suggest that 
the voltage dependence of norketamine behaves similarly to this new definition, further 
supporting nonproportional changes in kon or koff following voltage jumps.  Norketamine rate of 
block accelerates after depolarization, contrary to what is expected of a classic voltage dependent 
blocker. A classic blocker is voltage dependent because it directly experiences changes in the 
electric field across the membrane, leading to its extrusion from the channel due to its positive 
charge. In contrast, norketamine will be mostly neutral at physiological pH, providing support 
for an alternative explanation for voltage dependence.  It is possible that norketamine and 
ketamine experience permeant ion flow differently, resulting in unexpected changes in their rate 
constants after depolarization. This hypothesis will be further discussed in the next chapter, but it 
remains a plausible explanation for the surprising similarities we observed between ketamine and 
norketamine during the voltage step protocol.  
 In sum, our experiments here and in earlier work point to two ways drugs can differ 
during transient voltage steps in ways consistent with their behavioral actions. As membrane 
depolarization summates during repetitive synaptic activity, both memantine and norketamine 
will be less effective at maintaining synaptic block than ketamine: the former because of its 
faster relief of block during even brief depolarizations, the latter because of its reduced potency 
at positive potentials, accentuated during long depolarizations. In addition, norketamine will be 
hindered in restoring block because of its slower kinetics even at negative potentials; a 
disadvantage memantine does not have. Together, this suggests that ketamine’s ability to impair 
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physiological synaptic activity may participate in its cognitive effects. Future work examining 
memantine or norketamine unblock during pulse trains of various durations to mimic synaptic 
summation could provide more insight.  
The temporal delay in anti-depressant effects relative to psychotomimetic effects suggests 
the involvement of persistent signaling pathways rather than just acute NMDAR block (Kavalali 
and Monteggia, 2012). Anti-depressant effects may not even require NMDA block if they are 
mediated by intracellular targets. Our work here has begun to identify these intracellular targets 
visually. Future work with second generation compounds will important for further refinement.   
 The results laid out in this study clarify and define norketamine’s actions at the NMDA 
receptor and introduce a novel agent that can be used to visually track ketamine/norketamine’s 
actions intracellularly. The field of psychiatry has largely failed to respond to the need for rapid 
acting, effective, anti-depressants. The work in this study and further work with A-NK 
compounds could be used to discover novel targets for effective therapeutics. 
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Chapter 6 
“Discussion and Future Directions” 
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Summary of Dissertation 
 Through this dissertation, I’ve explored properties of N-methyl-D-aspartate receptors 
(NMDARs) pertaining to their function in excitotoxic paradigms and models of psychiatric 
disorders. Chapter 2 demonstrated that synaptic NMDARs contribute to neuronal death during 
hypoxia.  It also showed that the putative “extrasynaptic NMDAR blocker”, memantine, 
possessed no exclusive selectivity for different receptor populations, and could strongly block 
synaptic NMDARs at neuroprotective concentrations. I then directly compared memantine with a 
closely related open channel blocker, ketamine (Chapter 3). These drugs have similar 
pharmacodynamic properties in vitro, despite their very different clinical uses. My work 
demonstrated that part of this discrepancy could be explained by the low open-channel 
probability of the NMDAR. By subjecting NMDARs to positive allosteric modulation I 
demonstrated that the blockers exhibit pharmacodynamic differences in physiological paradigms 
of network activity and excitotoxicity (Chapter 4). Positive modulation selectively accelerated 
relaxation/re-equilibration at depolarized potentials to a time course relevant for synaptic 
activity. This allowed differences between memantine and ketamine to emerge during network 
activity when synapses/terminals are transiently depolarized. I found that the more voltage 
sensitive drug (memantine) was most affected by changes in open probability compared to 
ketamine. The ability of ketamine to remain trapped in synaptic receptors, even during synaptic 
voltage perturbations, could underlie its stronger physiological effects. Another characteristic of 
ketamine is its rapid metabolism into a variety of neuroactive derivatives, notably, norketamine. 
In Chapter 5, I characterized norketamine alongside ketamine, revealing that it was slightly less 
potent, but retained qualitatively similar properties. I further showed that an analogue that can be 
conjugated to a fluorophore for visualization/localization was also neuroactive. In summary, the 
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breadth of my thesis substantially increased our current understanding of NMDARs: their role in 
excitotoxicity, and their modulation by clinically relevant blockers.  
 Because there has been time for my first paper to be received in the literature, it has 
generated substantial debate and response. Here, I will discuss the supporting and contradicting 
studies in the literature that have been published in the past few years and offer suggestions for 
future directions. For my remaining chapters, (Chapter 3-5), I will place the work inside the 
context of NMDAR pharmacology, in general, and discuss future directions for these studies.  
NMDARs and toxicity: revising the “toxic” extrasynaptic receptor hypothesis.  
 In Chapter 2, I demonstrated that during hypoxic excitotoxic insults, when glutamate 
release is endogenous, synaptic NMDARs mediate cell death. I also substantially weakened the 
claim that the open channel blocker, memantine, is a “selective extrasynaptic NMDAR blocker”. 
I found instead that when receptors in both locations are activated equivalently (by tonic 
application of glutamate) memantine was equally effective at blocking both populations of 
receptors. Moreover, memantine showed strong synaptic block during repetitive synaptic 
activity, which can occur when the network is overexcited during excitotoxicity. Thus, I 
provided strong evidence against two legs of the “toxic” extrasynaptic NMDAR hypothesis. 
There is still a great deal of debate in the literature regarding how different NMDAR populations 
contribute to excitotoxic cell death. Although the original strong dichotomy between synaptic 
and extrasynaptic receptors has been softened somewhat, the idea that distinct populations of 
NMDARs are uniquely toxic is still pervasive.  To put our study into context I will first describe 
recent work that supports our conclusions before delving into critiques or alternative hypotheses.  
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 One paper also describes neuroprotection during excitotoxic insults by synaptic block 
(Papouin et al., 2012). The authors showed that the endogenous NMDAR co-agonists, D-serine 
and glycine, have different functional domains inside and outside the synapse, respectively 
(Papouin et al., 2012).  They then used selective depletion of D-serine or glycine to probe the 
role of synaptic/extrasynaptic receptors in toxicity. Consistent with our results, eliminating 
synaptic receptor signaling by degrading D-serine was neuroprotective against excitotoxic injury 
(Papouin et al., 2012). Importantly, this work was done in acute hippocampal slices, extending 
the relevance of our finding to an in situ preparation. A major issue with interpretation is whether 
the divide between D-serine/synaptic receptors and glycine/extrasynaptic receptors is as strong 
as they argue. An important next experiment to be done would be to see if excitotoxic conditions 
promote D-serine production and release. If so, D-serine degradation would be neuroprotective 
solely because it is the necessary/abundant co-agonist at all receptors. Many other studies have 
also argued for a prominent role for D-serine in NMDAR-mediated synaptic neurotransmission, 
strengthening their conclusions (Panatier et al., 2006; Henneberger et al., 2010; Fossat et al., 
2012). 
  It is also possible that in some situations activation of a larger receptor population is 
required to evoke an excitotoxic response. For instance, a recent study showed significant 
protection from an excitotoxic insult after synaptic receptor block, but they also saw increasing 
levels of cell death as more and more synaptic and extrasynaptic receptors were recruited. They 
reasoned that the necessary level of NMDAR activation extends beyond the synaptic or 
extrasynaptic space; both synaptic and extrasynaptic receptors are required to trigger cell death 
(Zhou et al., 2013b).  They also extended the critique of the location hypothesis to downstream 
transcription and signaling factors. One of the more compelling arguments made in favor of 
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selective extrasynaptic activation during excitotoxicity was that selective activation of 
extrasynaptic receptors up-regulated only death-promoting genes, whereas synaptic activation 
up-regulated survival genes (Hardingham et al., 2002; Hardingham and Bading, 2003; Papadia et 
al., 2008). Zhou and colleagues instead demonstrate that synaptic and extrasynaptic populations 
actually activate similar transcriptional pathways downstream (Zhou et al., 2013b). Since 
synaptic receptors comprise a large percentage of total receptors in our experimental system 
(70%), it is possible that we saw protection simply because we blocked a majority of receptors 
(~70%). The remaining receptors could not be activated sufficiently enough to reach the 
threshold to trigger cell death. 
 A recent study from McKay and colleagues offers two criticisms to the techniques used 
and conclusions we drew in our study (McKay et al., 2013). First, they argue that MK-801 is not 
a true irreversible blocker. Early work found that MK-801 unblock, with agonist present, is 
extremely slow,  offset= 15 minutes or more (Huettner and Bean, 1988). McKay and colleagues 
show that magnesium drastically accelerates this process. They warn that the combination of 
elevated glutamate and the presence of magnesium in our cultures exposed to hypoxia would 
lead to dramatic MK-801 unblock and lack of neuroprotection. If that were true, I would assume 
that we also would have seen no protection, or limited protection, in our cultures. On the 
contrary, we observed equivalent protection in synaptic pre-blocked cultures as we saw in 
cultures continuously exposed to saturating MK-801 (Figure 2.6). Thus, it is unlikely that we 
achieved the degree of unblock that these authors argue should have been seen. Moreover, we 
never claimed that MK-801 is truly irreversible, instead testing the amount of unblock that 
occurs in our cultures during a 150 min hypoxic insult. We saw minimum unblock, even in the 
setting of rising glutamate and magnesium (Figure 2.6). The second objection claims that we did 
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not achieve complete wash-out of MK-801 between the preblock protocol and hypoxic injury. 
Residual MK-801 could prevent unblock and provide additional protection. We took a 
conservative approach: washing three times with saline containing only calcium and glucose 
before the original culture media was restored. This washing protocol preserved the receptor 
block proportion we were striving for (70% block, corresponding to the 70% of total receptors 
that are synaptic), as measured by electrophysiology experiments. This was similar to approaches 
taken by other groups (Hardingham et al., 2002; Papadia et al., 2008).  In addition, the alternative 
washing protocol described in the McKay paper involves physical transfer of neuron coated 
cover-slips from one well to another (McKay et al., 2013). This exposure to air could lead to 
contamination and/or cell death unrelated to toxicity. Thus, our washing protocol is conservative 
and consistent with the goal of measuring death 24 hours after injury.  
Another group of NMDARs linked to excitotoxic cell death are GluN2B containing 
receptors. The GluN2B-specific hypothesis has garnered support by the understanding that 
GluN2B receptors are generally located extrasynaptically, although this is controversial (Tovar 
and Westbrook, 1999; Harris and Pettit, 2007). This hypothesis has many molecular advantages 
over the “location” hypothesis. First, the primary structural difference between the different 
GluN2 subunits resides in their C-terminus (Monyer et al., 1992). Therefore, different subunits 
are expected to, and indeed do, interact with different intracellular signaling pathways. Some key 
“death-signaling” pathways activated by GluN2B-containing NMDARs include: calpains, PTEN 
and DAPK whereas GluN2A receptors trigger pro-survival pathways mediated by Akt, CREB 
and ERK (Lai et al., 2014). However, the idea that over-activation of NR2B receptors 
specifically causes cell death is still disputed. Papouin and colleagues also show that selective 
GluN2B blockade does not protect against an excitotoxic insult (Papouin et al., 2012).  In 
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moderate agreement, another study suggests that both GluN2A and GluN2B containing receptors 
can contribute to cell death, and both receptor populations are capable of increasing pro-death or 
pro-survival signaling pathways (Zhou et al., 2013a). The tenor in the literature has led to 
enthusiastic marketing and profiling of various GluN2B-selective antagonists for the treatment of 
various neurodegenerative diseases (Mony et al., 2009). A recent study, however, provides 
sobering evidence against this idea. Tonic administration of a selective GluN2B receptor 
antagonist in vivo elicited severe circuit disruptions and had no protective effect in an animal 
model of Alzheimer’s disease (Hanson et al., 2014). This study was limited by the use of only 
one antagonist, which may have had undesirable off-target effects. Therefore, despite the appeal 
of this alternative hypothesis, NMDARs continue to elude parsimonious sorting into “toxic” vs. 
“protective” populations.  
Another possible explanation for the discrepancy across studies could be the absolute 
number and proportion of synaptic/extrasynaptic receptors across these different experiments. 
Variability in culture techniques, age of neurons, or other factors could influence the number of 
receptors blocked by selective “synaptic” or “extrasynaptic” protocols. In addition, since the 
preferred “blocking” protocol involves the use-dependent channel blocker, MK-801, any 
synaptic blocking protocol is highly dependent on factors that would influence glutamate release 
and/or receptor activation (Harris and Pettit, 2008). Alterations in probability of release (Pr), 
quantal content, receptor number, receptor open probability, or glutamate transport, could all 
result in different populations of receptors activated during the blocking protocol. To illustrate 
this point, I examined the number of receptors blocked by MK-801 during synaptic stimulation 
in low (reduced Ca
2+
) and high (high Ca
2+
) Pr conditions. Even by counteracting the reduced Pr 
by stimulating longer in reduced calcium, I still saw consistently less block proportional to that 
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seen in normal calcium (Figure 6.1).  I propose that future work could probe this discrepancy in 
more detail by examining the level of “synaptic” block under a variety of conditions (glutamate 
uptake block, presence/absence of NMDAR potentiators, and asynchronous conditions). The 
need for rigorous studies such as these has been encouraged by others in the field (Papouin and 
Oliet, 2014).  
 
Excitotoxicity, and the NMDAR populations involved, continues to underlie much of the 
literature of neurodegenerative disease etiology. Up to now, the predominant approach has been 
to use memantine as a “selective” extrasynaptic antagonist to discern the role separate 
populations assume in vivo. However, as demonstrated, memantine cannot be reliably used as a 
selective extrasynaptic blocker in all circumstances. Therefore, to address this, a more selective 
Figure 6.1. Synaptic NMDAR block by MK-
801 is reduced in low Pr conditions. A. 
Representative traces of NMDA-mediated eEPSC 
currents in hippocampal autapses in different 
external [Ca
2+
] in mM (black: 2, grey: 1, purple: 
0.75, and light grey: 0.5). B. Amplitudes for 
EPSC responses normalized to the 2 mM Ca 
condition. 0.75 mM calcium evoked responses 
1/5
th
 the size of controls. C1, D1. eEPSCs were 
evoked in the presence of 10 μM MK-801 for 4 
stimuli (2 mM Ca
2+
, high Pr, C1) or 20 stimuli 
(0.75 mM Ca
2+
, low Pr, D1). C2, D2. Responses 
to 30 uM exogenous NMDA before or after 
synaptic NMDAR block in high Pr (C2) or low 
Pr (D2) conditions. E. EPSCs were reduced 
equivalently by MK-801 block in low and high Pr 
conditions. F. Exogenous NMDA responses were 
blocked significantly less in low Pr conditions 
than in high Pr (p<0.05, unpaired t-test, N=15-
20). Grey line indicates 70% block which 
corresponds to “total” synaptic receptor block 
(Harris and Pettit, 2007).  
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antagonist must be designed. In chapter 5 of this dissertation, I revealed that steric hindrance 
may slow down a blocker’s kinetics and limit its ability to block rapid and transient synaptic 
events. This could suggest that if a functional compound could be designed with sufficient steric 
hindrance to occlude its accumulation in the synapse or in synaptic receptors, it could be used as 
a true “extrasynaptic” blocker. Technical hurdles involving administration and crossing the blood 
brain barrier in vivo would have to be overcome for this to be useful.  
  In all, my work, alongside these studies, indicates the complexity involved in NMDAR 
mediated cell death. While there is still evidence suggesting that extrasynaptic receptors play a 
privileged role in excitotoxicity, other notable studies including my own have provided strong 
evidence in favor of synaptic receptor involvement or bulk over-activation. Nevertheless, 
NMDARs continue to play a major role in excitotoxicity, supporting the use of NMDAR 
antagonists for viable therapeutic purposes.  But to successfully employ them, it is important that 
their actions at the NMDAR be well understood. The next part of my thesis explored a 
fundamental property of the NMDAR that plays a greater role in dictating therapeutic drug 
actions then previously realized.  
Memantine and Ketamine: Two drugs that illustrate the importance of NMDAR open 
probability in drug effects 
 Memantine and ketamine are two widely used and, importantly, clinically tolerated 
NMDAR antagonists. They operate as open channel blockers, binding within the channel pore of 
an open/activated receptor while still allowing the receptor to close and/or re-open around them 
(Johnson and Kotermanski, 2006). Ketamine has more therapeutic potential as an anesthetic, 
analgesic, and now as a novel antidepressant (Berman et al., 2000; Zarate et al., 2006b; Marland 
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et al., 2013). However, it also leads to strong psychotropic side-effects (Krystal et al., 1994). In 
contrast, memantine is largely used for treating cognitive decline during Alzheimer’s disease 
(Orgogozo et al., 2002; Lipton, 2006). Its antidepressant potential is unclear as the few studies 
that have investigated it have mixed results (Zarate et al., 2006a; Smith et al., 2013).  Since 
memantine and ketamine act at the same receptor, with equivalent potency, the explanation for 
their different effects was still unexplained.   
 Prior work had largely compared memantine to ketamine in the context of steady-state 
agonist conditions, when the receptor, blocker and agonist had time to reach equilibrium (Chen 
et al., 1992; Gilling et al., 2009). In contrast, my approach investigated the pharmacodynamics of 
these blockers while dynamically changing agonist concentrations and/or membrane voltage.  
Memantine and ketamine were virtually indistinguishable during both phasic and steady-state 
agonist presentation at a constant voltage. However, when subjected to voltage perturbations an 
interesting difference emerged.  Both drugs experienced slow relaxation kinetics to steady state 
block following a voltage jump to positive potentials. Their rates of relaxation/re-equilibration 
were so slow, in fact, that it is possible that both drugs are relatively voltage independent during 
rapid synaptic events. However, since memantine equilibrated faster especially at the onset of the 
depolarization, we found that it can unblock the receptor during sufficiently long phasic 
depolarizations. Notably, though, this difference did not translate into a noticeable difference 
between the blockers during network activity or mild excitotoxic insults. The blockers also were 
indistinguishable in their ability to modulate synaptic plasticity (both inhibited LTD but not 
LTP).  
 Why were differences observed at the cellular level not seen during network activity? We 
reasoned that one or two scenarios could explain this discrepancy. First, the depolarization 
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needed to distinguish the blockers in vitro was fairly severe; it is possible that the transient 
depolarization achieved during network activity was neither strong nor severe enough to 
differentiate the blockers. Secondly, we found that by increasing the basal open probability of the 
NMDAR we could significantly accelerate the rate both drugs equilibrated to a depolarized 
voltage. Thus, both prolonged depolarization and/or increased receptor open probability could 
potentially differentiate the blockers. We found, in fact, that this was the case. By increasing 
open probability and/or increasing strength of depolarization, we could differentiate the blockers 
in both excitotoxic and physiological paradigms.   
 Thus memantine and ketamine cannot be distinguished unless the NMDAR is potentiated 
or the neuron experiences extreme levels of depolarization (brought about by robust activity or 
excitotoxic insults). This has major implications for how these blockers may behave in vivo. For 
the remainder of this section of the discussion, I will delve into a deeper analysis on how 
NMDARs may be modulated in vivo and how I propose extending these findings into an in vivo 
preparation.  
 NMDARs are unusual in their low basal open probability. This allows them to be altered 
by numerous endogenous, and exogenous, modulators that increase or decrease open probability 
in turn. In addition, the various subtypes, defined by the GluN2 subunit (GluN2A-D) all possess 
different open probabilities and affinity for glutamate (Chen et al., 1999; Erreger et al., 2007). 
Thus, regional areas of the brain could conceivably have widely different acting NMDA 
receptors depending on the subtype expressed and the local concentration of modulators. Even 
this would be subject to change during ischemic injury or other situations when glutamate release 
becomes more sustained and tonic compared to the phasic, synaptic transmission that normally 
occurs.  
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 Several published modulators — zinc, protons, arachidonic acid, neurosteroids – were 
inappropriate to use in our study of memantine/ketamine’s network effects because none were 
selective/targeted enough to work only at NMDAR population in our preparation (heterogenous 
GluN1-N2A and GluN1-N2B population in dissociated hippocampal cultures). Instead, we 
turned to a newly characterized and physiologically relevant positive allosteric modulator, 24-S 
hydroxycholesterol (24S-HC), and its analogue, SGE-201. Recent work in our lab has 
demonstrated that 24S-HC and its analogues possess potent and selective allosteric effects at the 
NMDAR (Paul et al., 2013). My work employed the synthetic analogue, SGE-201, to provide 
proof-of-principle that potentiation of the NMDAR can differentiate the blockers during network 
activity. I propose that future experiments could directly investigate the role endogenous 24S-HC 
may play in the blockers actions in vivo. 
 24S-HC is produced by the mitochondrial enzyme: cholesterol 24-S hydroxylase, 
encoded by the CYP46 gene (Lund et al., 1999). David Russell has generated CYP46A1 
-/-
 mice 
that have little to no 24S-HC production, but are viable and usable for behavioral experiments 
(Lund et al., 2003). I propose using these animals to test the effect reduced 24S-HC production 
will have on the actions of memantine and/or ketamine in vivo. 24S-HC reduction should reduce 
NMDAR open probability. Our studies in vitro suggest that ketamine remains a strong blocker 
even in the presence of positive modulaton and that memantine’s actions in neural networks may 
be weakened with high open probability. One experiment could measure memantine 
neuroprotection from medial cerebral artery occlusion (MCAO). I hypothesize that memantine 
neuroprotection will be strengthened in CYP46A1 
-/- 
animals compared to that seen in control 
animals. A second experiment could test how ketamine’s ability to reduce immobility time in the 
FST is altered in mice without 24S-HC. Based on our assays in vitro, I would actually expect 
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little or no change in ketamine’s actions here. These experiments can help to reveal which 
blocker will be most impacted by the switch to 24S-HC negative animals. A necessary caveat, of 
course, is that different readouts from these experiments may make direct comparisons difficult 
should the effects of each drug be affected by loss of 24S-HC. Another important question in 
both of these experiments would be how baseline MCAO damage or immobility time is altered 
in 24S-HC knockout animals. If they are altered, follow-up experiments could then link these 
changes to loss of NMDAR function specifically due to loss of 24S-HC potentiation.  Regardless 
of the outcome, these experiments would be the first to demonstrate whether 24S-HC, and 
possibly basal open probability, has any effect on channel blockers in behavioral assays.  Results 
from these studies could be used to develop targeted neuroprotective or antidepressant therapies.   
 Our conclusion that channel open probability is important for memantine’s and 
ketamine’s behavioral effects does not exclude other possible explanations. For instance, a recent 
study shows that ketamine, but not memantine, can block spontaneous events (mEPSCs) in the 
presence of physiological magnesium (Gideons et al., 2014). We were unable to discern a 
difference between memantine and ketamine during MEA assays, despite the presence of 
physiological magnesium. It is possible that evoked activity in our MEA system masks subtle 
differences that occur at the level of spontaneous release.   In vivo, where evoked vs. 
spontaneous transmission may serve separate or even opposing functions on synaptic 
modulation, our two explanations could converge to explain how memantine and ketamine may 
behave during both spontaneous and evoked transmission (Sutton et al., 2007). Continuous 
suppression of large, action-potential driven, events by ketamine may predominately explain its 
psychotomimetic properties, while its suppression of smaller, quantal events may trigger 
downstream synaptogenesis important for its antidepressant qualities (Autry et al., 2011).  It 
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would be interesting to determine how well ketamine blocks spontaneous events and/or triggers 
downstream effectors in the presence of positive modulation. Ketamine’s specific role as an 
antidepressant and how it may trigger synaptic modulation will be explored in more detail later 
in this chapter.  
My work highlighted that NMDAR low open probability (Po), even with saturating 
agonist, is important to the actions of clinically relevant blockers. Why does the NMDAR exhibit 
such low Po? Most other receptors have a Po closer to 1 when saturated with agonist (including 
AMPA, glycine and GABAA receptors) (Jin et al., 2003; Akk et al., 2004; Jin et al., 2009). If the 
concern is for neurotoxicity, why couldn’t a cell just reduce the level of expression of high 
efficacy NMDA receptors?  Expressing fewer highly efficacious channels should be equivalent 
to increasing the levels of one with reduced efficacy, while lowering the energetic cost of 
transcription, translation, and trafficking many receptors. This approach could help mitigate 
uncontrolled NMDAR activation in pathological conditions. However, it prevents rapid changes 
in NMDAR function.  Altering protein expression by regulating transcription, translation, and 
trafficking is a long term synaptic change and not one that can occur on the time scale of 
synaptic transmission. Providing a receptor with a dynamic range to be manipulated allows 
neurons to manipulate NMDAR function and activity on a synaptic time scale. A number of 
modulators like zinc ions and protons can accompany vesicular release of classical 
neurotransmitters like glutamate at synapses (Erreger and Traynelis, 2008; Ketterman and Li, 
2008). Neurosteroids, oxysterols, and other lipophilic molecules like pregnenolone sulfate (PS), 
24S-HC, and arachidonic acid accumulate in membranes and could increase efficacy depending 
on their regional levels. If NMDARs were only necessary for synaptic transmission and toxic 
when over stimulated, an evolutionary protective mechanism could tightly control expression. 
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The fact that they are necessary for a host of other functions including neuronal survival and 
synaptic modulation, demonstrates that it is experimentally advantageous for the neuron to 
regulate NMDAR activity via rapid allosteric modulation.  
 Potential role of metabolites on ketamine effects in vivo. 
 Ketamine is a dissociative anesthetic and analgesic that was recently discovered to be a 
rapid acting antidepressant. However its clinical utility is constrained by the strong psychotropic 
and dissociative symptoms that accompany its administration. Therefore, it is imperative to 
understand how it mediates its rapid effects to develop therapies without similar side effects. To 
address this, we characterized its major active metabolite, norketamine, to determine what 
characteristics it shares with ketamine. We also addressed a novel hypothesis, recently raised, 
that ketamine could mediate downstream effects by binding intracellular targets (Lester et al., 
2012). Future work in this area should probe details of norketamine pharmacology related to 
ketamine, and employ second generation compounds to clearly identify novel intracellular 
targets of ketamine in vivo.  
While ketamine itself has been extensively investigated by our group and others, little 
attention has been paid to its active metabolite, norketamine. Norketamine concentrations rise 
and persist long after ketamine is cleared from the system but it does not contribute to ketamine’s 
psychotomimetic activity (Olofsen et al., 2012; Zarate et al., 2012). Earlier studies found that it 
also antagonizes NMDARs (Ebert et al., 1997). However, its pharmacodynamics compared to 
ketamine was unknown. Investigation into norketamine’s pharmacodynamics showed that it is a 
weaker blocker (measured by IC50 concentrations) and more voltage dependent than ketamine. It 
can block synaptic transmission effectively but when exposed to prolonged depolarization it 
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effectively escapes from the channel, at least at the concentration tested. This provides a partial 
resolution for its different behavioral effects. During strong synaptic activity, when the 
postsynaptic membrane potential summates, norketamine will have a reduced effect on synaptic 
responses.  
The relaxation of a voltage dependent current following a voltage jump is approximated 
by the equation: = 1/(kon+koff), where kon and koff are activation/deactivation of the channel or, 
in the case of blockers, association/dissociation rate constants for that voltage (Jin et al., 2009). I 
provide evidence in this thesis that low channel open probability can severely hinder calculation 
of accurate rate constants of open channel blockers. Nevertheless, when basal open probability is 
assumed to remain constant across blockers, voltage step protocols can generate some 
provocative hypotheses about the blockers in question.   As described in Chapter 3, detailed 
analysis of memantine and ketamine behavior during these voltage steps lead to the idea that 
NMDAR open probability could influence the actions of these drugs in vivo.  Importantly, 
memantine and ketamine showed different relaxation kinetics from the outset that accelerated to 
a more physiological time-frame in the presence of positive modulation (Figure 4.5). 
Interestingly, despite strong differences in voltage sensitivity and kinetics between norketamine 
and alkyne-norketamine, we were unable to resolve differences in their relaxations during 
depolarizing voltage-steps.  I can conclude that norketamine will show less steady-state block 
during prolonged depolarizations, but the voltage step protocol lacked sensitivity to discern 
differences between these blockers. Here I will offer a few hypotheses as to why open channel 
blockers that show different steady-state voltage dependence could nevertheless re-equilibrate at 
the same rate. These, in turn, offer promising next steps in researching the pharmacodynamics of 
ketamine and norketamine.  
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Classically, there have been two explanations for voltage dependence. One is that a 
(positively charged) blocker binds deep within the channel pore, experiencing the electric field 
across the membrane and is expelled as the membrane is depolarized (Woodhull, 1973). The 
macroscopic rates of onset and offset of such a blocker will slow and accelerate, respectively, 
upon depolarization. This mechanism best describes sodium channel blockade, and originally, 
magnesium blockade (Woodhull, 1973; MacDonald and Nowak, 1990). However, magnesium’s 
binding site near the Q/R/N “selectivity filter” on the M2 transmembrane loop is too shallow to 
correlate with magnesium’s strong voltage dependence (Antonov and Johnson, 1999).  An 
alternative explanation suggests that ion efflux through the channel pore can “knock-off” or 
displace a blocker positioned near the lip or opening of the channel. This explanation reconciles 
physiological data with mutational analysis very well for ketamine and MK-801, both of which 
are too bulky to traverse the pore deeply enough to match their voltage dependence as described 
by Woodhull’s model. Thus, it is likely that voltage dependence, at least for ketamine and 
norketamine, is governed by an interaction with the voltage field and with interactions with 
permeant ions. I hypothesize that norketamine is displaced more readily by permeant ions than 
its parent compound, ketamine at positive potentials.  
The idea that norketamine is displaced more effectively than ketamine by current efflux 
has not been explored. To test this, I propose measuring ketamine and norketamine block with 
either a permeant (sodium) or impermeant (choline) extracellular ion. Extracellular choline will 
increase the driving force for current efflux from the cell. Both ketamine and norketamine block 
of positive current (at the same positive potential) should be reduced in the presence of choline. 
If norketamine is more displaced by permeant ions, then its level of block with choline should 
decrease significantly more than ketamine’s. The experimental advantage for this protocol is the 
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ability to isolate differences in ion permeance from membrane potential (Mennerick et al., 1998).  
Demonstration that increased current efflux, due to an increased driving force and not just 
depolarization, reduces the potency of norketamine would help explain two results. Norketamine 
is less protonated at physiological pH than ketamine (pKa=6.8 vs. 7.5), yet is more voltage 
dependent, contrary to the classical assumption that positive charge governs voltage sensitivity.  
Second, despite this strong voltage sensitivity its apparent rate of block accelerates at depolarized 
potentials, contrary to what is expected in the Woodhull model (Figure 5.2). MK-801 also 
exhibits acceleration of block at positive potentials, suggesting that this result is applicable to 
many channel blockers (MacDonald et al., 1991). Additional experiments could investigate how 
norketamine’s structure (for instance, the loss of a methyl group) may permit easier displacement 
by permeant ions. 
The fact that norketamine and ketamine do not behave like “prototypical” channel 
blockers as described by Woodhull, gives additional credence to the idea that their kinetic rate 
constants at different voltages will not be easily predicted. At -70 mV, norketamine blocks with a 
significantly slower rate than ketamine, which equates to different onset and offset rates. A 
Woodhull channel blocker would experience a deceleration in its blocking rate and an 
acceleration of its unblocking rate at positive potentials. However, as discussed, norketamine 
shows noticeably faster blocking kinetics at +50 mV than ketamine. Thus, the changes in onset 
and offset rates from -70 to +50 mV for both blockers are not proportional and it is possible that 
the sum of these altered rate constants (1/(kon+koff)) at +50 mV are, in fact, experimentally 
indiscernible.    
A recent study exploring the effect pH has on channel blockers revealed that acidification 
of the extracellular solution can strongly increase the potency (decrease the IC50) for MK-801, 
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ketamine and norketamine (Dravid et al., 2007).  For ketamine and norketamine, which have pKa 
values close to physiological pH, this is consistent with the idea that a more protonated blocker 
will block more. However, the authors also show that MK-801, which has a pKa too high to be 
strongly influenced by variations in physiological pH, shows increased potency because of 
receptor protonation – MK-801 has a higher affinity for the protonated receptor channel pore. In 
addition, receptor protonation also strongly reduces the voltage dependence of MK-801. Thus, 
external acidification, by altering blocker protonation and/or receptor protonation, can lead to 
changes in blocker potency and voltage dependence. Acidification strongly reduces receptor Po 
(Tang et al., 1990), but my data in Chapter 4 shows that blocker potency is not significantly 
affected by shifts of Po, suggesting that pH driven potency changes are a result of blocker and/or 
receptor protonation.  An unanswered question is how receptor acidification, specifically, affects 
the potency and voltage dependence of ketamine and norketamine. To address this, I would 
propose testing the potency and voltage dependence of the two blockers at a receptor lacking the 
proton sensitive residue (Low et al., 2003). Additional experiments could then use this receptor 
to test how changes in external pH, which should specifically alter blocker protonation, affect 
their potency and voltage dependence. Together these experiments will deepen our 
understanding of pH driven changes in blocker actions, and may provide insights to drive 
pharmaceutical development.  
The second question addressed by this last section of the thesis was whether ketamine 
facilitates its behavioral effects by binding intracellular targets. To this end, we developed a 
version of ketamine that could be visualized. Attaching an alkyne group to the 
ketamine/norketamine backbone allows for cycloaddition of a fluorescent tag and visualization. I 
showed that addition of the alkyne group slowed kinetics of block, but retained general voltage 
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dependence and potency of norketamine/ketamine. Importantly, alkyne-norketamine retained the 
behavioral activity of ketamine and norketamine as measured by the forced swim test. 
Interestingly, when the alkyne was attached with an amide linkage, the resulting compound lost 
all potency at NMDARs, lacked behavioral activity and could not be retained intracellularly.  
Using these two compounds in future studies could be instructive to test for specific targets for 
ketamine in the cell.  
The single most advantageous quality of alkyne-norketamine, compared to ketamine 
alone, is its ability to be visualized inside the cell. However we were unable to discern specific 
labeling in the ER, Golgi or mitochondria. This likely was due to lack of an attachment that 
could permanently link A-NK to its substrate, resulting in significant diffusion away from 
preferential sites of accumulation during processing. To mitigate this, future generations of these 
compounds should incorporate a diazarine ring to allow for UV-catalyzed covalent linkage with 
nearby structures (Mennerick et al., 2010; Chen et al., 2012).  Once the compounds are stabilized 
and visualized in the cell, specific hypotheses could be tested.  
The first question is whether alkyne-norketamine preferentially accumulates in a given 
organelle. Lester hypothesizes that ketamine binds to nascent NMDARs in the ER or Golgi 
(Lester et al., 2012). However other targets such as mitochondria are also possible (Korde and 
Maragos, 2012). Whether A-NK simply accumulates nonspecifically in cellular membranes 
should also be addressed using a general lipid marker such as Nile Red. Secondly, is Lester right 
when he suggests that ketamine binds to intracellular NMDARs? If A-NK accumulation is 
NMDAR dependent, I would expect no accumulation in non-transfected HEK cells or in neurons 
lacking NMDARs or where NMDAR translation has been disrupted. We were unable to discern 
clear intracellular labeling with the inert A-NK amide compound. If the ability to bind to the 
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NMDAR is critical for all cellular/behavioral activity of A-NK, then this would provide a 
resolution behind this result. If NMDARs prove to not be the intracellular target, additional cell-
biology experiments could be used to isolate relevant targets. Eventually, further experiments 
could then test how relevant downstream modulators are recruited and activated by intracellular 
accumulation.  
Conclusions  
These studies reveal important insights into how NMDA receptors function in 
physiological and pathophysiological conditions. Important advances were made regarding the 
pharmacology and pharmacodynamics of memantine and ketamine and its metabolites. Finally, a 
chemical biological tool was developed to aid in future studies investigating ketamine’s long-
term effects on synaptic function, relevant towards its antidepressant actions. It is my hope that 
these studies will allow for advances to be made in pharmaceutical development and psychiatric 
disease treatment.  
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